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Abbrevations 
 
Aβ    Amyloid beta 
CAN    Acetonitrile 
Aib     Aminoisobutyric acid 
AMBER    Assisted Model Building with Energy Refinement 
Boc   tert-Butoxycarbonyl 
Bzl    Benzyl 
Cbz      Carboxybenzyl 
chGly     Cyclohexylglycine  
COMU      1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium-         
                hexafluorophosphat 
CuAAC     Copper catalyzed azide alkyne cycloaddition 
DBU     1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC       N,N’-dicyclohexylcarbodiimide 
DCM    Dichlormethane 
DIBALH   Diisobutylaluminium hydride 
DIC      N,N’-diisopropylcarbodiimide 
DIPEA    N,N-diisopropylethylamine 
DMF     dimethylformamide 
DOP     Dimethyl 2-oxopropylphoshponate 
EDC      N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
ELISA     Enzyme-linked Immunosorbent Assay 
Fmoc     Fluorenylmethoxycarbonyl 
HOAt    1-Hydroxy-7-azabenzotriazole 
HPLC     High performance liquid chromatography 
NMR    Nuclear Magnetic Resonance 
Oxyma     Ethyl cyano(hydroxyimino)acetate 
p-ABSA     4-Acetamidobenzenesulfonyl azide 
PG      Protecting Group 
pKa     Acid dissociation constant 
Pmc     2,2,5,7,8-pentamethylchromane-6-sulfonyl 
PyBOP     (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
ROESY      Rotating frame nuclear Overhauser effect spectroscopy 
rt    room temperature 
RuAAC    Ruthenium catalyzed Azide Alkyne Cycloaddition 
SPPS     Solid Phase Peptide Synthesis 
T3P    1-Propanephosphonic anhydride 
TBAF    Tetrabutylammonium fluoride 
TEA     Triethylamine 
Tf     Trifluoromethanesulfonyl 
TFA     Trifluoroacetic acid 
THF     Tetrahydrofurane 
ThT    Thioflavin T 
TMS     Trimethylsilyl 
Trt     Triphenylmethyl 
Tz    Triazole 
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1. Abstract 
 
In the course of this dissertation, three major topics were elaborated.  Initially, the focus 
was placed on the synthesis and conformational analysis of 1,5-disubstituted 1H-1,2,3-
triazole containing peptidomimetics, in which the triazole units replace every second 
amide bond. Such oligomers were addressed as peptidotriazolamers and might comprise of 
a homochiral or heterochiral alignment of residues. This topic involved the synthesis of 
enantiomerically pure propargylamines and α-azido acids, the ruthenium catalysed alkyne 
azide cycloaddition (RuAAC) and the peptide coupling of triazoles which are conversantly 
prone to epimerization. The conformational analysis was done utilizing X-ray crystal 
structure analysis and molecular modelling, taking ROESY-NMR constraints into 
account. The homochiral oligomer Boc-Ala[5Tz]Phe-Val[5Tz]Ala-Leu[5Tz]Val-OBzl 
turned out to closely resemble a βVIa1 turn, while the sequence related heterochiral 
peptidotriazolamer Boc-D-Ala[5Tz]Phe-D-Val[5Tz]Ala-D-Leu[5Tz]Val-OBzl adopts a 
polyproline-like helical structure.  
The second topic covered the synthesis and biological evaluation of Amyloid-β aggregation 
inhibitors, based on the peptide sequence KLVFF. This work included the Bestmann-Ohira 
reaction of trityl protected amino aldehydes and the application of deprotected triazoles, 
as dipeptide isosters, on solid phase peptide synthesis. The synthesized peptidomimetics 
were evaluated as inhibitors of Amyloid-β fibrillization by a Thioflavin-T assay. As a result, 
the triazole does not serve as a generic substitute for an amide bond in complex biological 
interactions and replacement positions ought to be be carefully selected. However, the 
SEN304-based peptidotriazolamer H-D-[chGly[4Tz]chGly-chGly[4Tz]Tyr-(NMe)Leu]-NH2 
lead to complete inhibition of Amyloid-β oligomerization.  
Lastly, the synthesis of cyclic peptidomimetics, containing one or two 1,5-disubstituted 
triazoles, based on cilengitide (cyclo-[RGDf(NMe)V]) was studied. Thus, the N-methylated 
peptide bond was replaced by a 1,5-disubstituted triazole. This included the synthesis of a 
versatile, functionalizable peptidomimetic, in which the non-essential valine was 
exchanged with an azidobutyl residue for a possible prodrug application. The 
peptidomimetic was shown to exhibit a nanomolar antagonistic activity towards the αvβ3 
receptor. 
Keywords: Peptidomimetics, Foldamers, Triazoles, Amyloid-β, RGD peptides. 
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2. Introduction 
 
2.1. Amino acids, peptides and proteins 
 
Proteins and peptides are constructed by the organism from amino acids as building blocks. 
While there are more than ~500 different amino acids conversant, only 20 of them are 
encoded as triplet nucleotides (codons) in the genetic code of a cell (Figure 1).1 Although 
few bacteria incorporate D-amino acids in their cell wall, most of the amino acids 
exclusively occur in their L-configuration. 
 
Figure 1. The 20 genetically encoded amino acids (full name, three and one letter code), 
grouped by their side chain functionality. 
 
For the human body, nine of these amino acids (H, I, L, K, M, F, T, W and V) are refered to 
as essential amino acids, implying that they cannot be produced by its own and must be 
delivered via nutrition.2 While some single amino acids display crucial functions in the 
human body in isolated form (e. g. glutamic acid and γ-aminobutyric acid (GABA) which 
work as neurotransmitters, therefore influencing the function of neurons by modulating 
trans-membrane ion flux)3, they are mainly used as structural units for the linear build-up 
of proteins and peptides. The biological process of protein synthesis is called translation 
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and is a part of gene expression. The proteins are therefore gene products, which are 
encoded by different triplet codons on the DNA. The translation follows transcription of 
the DNA into single stranded m-RNA and is performed by the ribosomes in the cytoplasm 
of the cell. The ribosome consists of two subunits, a smaller subunit, which reads out the 
information on the m-RNA and a larger ribosomal subunit, which connects the related 
amino acids by condensation into a growing polypeptide chain.4  
While a protein comprises only of a single-stranded, non-branched polypeptide chain, it 
folds, in a reproducible manner, into a distinct biologically active three-dimensional 
arrangement. This is predetermined by the linear sequence of the amino acid side-chains 
(Anfinsen’s dogma),5 which can undergo a myriad of intramolecular correlations (H-bonds, 
hydrophobic and hydrophylic interactions, salt-bridges, disulphide bonds etc.) ultimately 
leading to a thermodynamic and entropic favoured global minimum. Although this process 
is considered a physical process, it is often aided by so called chaperons, a class of proteins 
which aid in the correct folding of proteins, or more precise, prevent the aggregation of 
several proteins during the folding stage.6  
The structural evolvement of a protein during its translation and folding is divided and 
defined by four structures, the primary, secondary, tertiary and quaternary structure.7 The 
growing peptide chain is already folding during the translation process at the ribosome. 
The linear random coil peptide chain is considered as the primary structure but contains 
the information of the native protein structure in the sequence of its amino acid residues. 
The development of a periodic secondary structure is the first step during the folding 
process, its driving force is the formation of H-bonds, between the amide proton and the 
carbonyl oxygen, along the backbone of the peptide. Two common examples of secondary 
structure motifs are the α-helix and β-sheet, first correctly proposed by Pauling et al. in 
1951, considering the idea of a planar amide bond (Figure 2).8, 9  
 
Figure 2. The resonance structure of an amide bond explains the planarity of a peptide bond. 
Thus, the atoms Cα-CO-NH-Cα’ are located on the same plain. The oscillation between its 
constitutional isomers, where the amide proton migrates to the carbonyl oxygen is described 
by amide / imidic acid tautomerism. 
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The α-helix represents the most common secondary structure motif in peptides and 
proteins, it is a right-handed helix, often termed as 3.613-helix, which signifies the average 
number of amino acid side chains per helix turn, involving 13 atoms in the ring formed by 
the hydrogen bond (Figure 3).7 
 
Figure 3. Schematic depiction of an α-helix. Every carbonyl oxygen of an amino acid, forms 
a hydrogen bond with the amide proton four amino acids further in direction of the C-
terminus, forming a loop consisting of 13 atoms. This leads to the formation of a right-
handed helix, where the hydrogen bonds are parallel to the helix axis. The carbonyl oxygen 
atoms orientate towards the C-terminus, the amino acid residues are pointing outside the 
helix, each repetitive turn is 3.6 amino acids long, which translates into a distance of 0.54 nm 
between loops. 
 
The β-sheet on the other hand consists of so called β-strands, these are peptide chains in 
linear extended “zig-zag” conformation, which are aligned laterally and connected by 
backbone hydrogen bonds, forming a pleated peptide sheet (Figure 4).9 
 
Figure 4. Two extended peptide chains form a β-sheet by connecting the parallel strands by 
hydrogen bonds. This is possible in antiparallel fashion (left) or parallel fashion (right), intra 
and intermolecularly, resulting in planar or nonplanar inter-strand hydrogen bonds, where 
the antiparallel alignment is the more stable form. 
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These sheets may expand into a network of hydrogen bonds, between several antiparallel 
aligned β-strands, where each turn frequently consists of adjustable and or turn-inducing 
amino acids (Gly, Pro), which result in a flexible loop (Figure 5 A).  
Turn motifs usually consist of two to five amide bonds, classified as followed: δ-turn (one 
bond, sterically unlikely); γ-turn (two bonds); β-turn (three bonds, most common); α-turn 
(four bonds), π-turn (five bonds) and ω-loop (longer, extended disordered loop), with 
diverse categories in each type, dependent on their dihedral angles.10 A β-turn between 
two interacting, antiparallel β-strands is defined as a β-hairpin, including all different types 
of turns (Figure 5 B).11 
 
Figure 5. A) Antiparallel β-strands are connected by flexible turns, forming a β-sheet 
network. B) Example of a β-hairpin: a β-turn (Type II) connects two antiparallel β-strands. 
 
Although β-sheets are common secondary structure elements in proteins and necessary 
for proper function, they are also related to age dependent amyloidosis diseases such as 
Alzheimer, resulting of off uncontrolled aggregation of β-sheets leading to insoluble fibrils 
and plaques, finally damaging tissue and compromising proper organ function.12  
Despite the planarity of the peptide bond explained by its resonance structure (Figure 2), 
the polypeptide chain is quite flexible, resulting in secondary structure motifs discussed 
above. The flexibility is enabled by backbone rotations and thereby, a change of the 
dihedral angles between the amide N and Cα, as well as Cα and the carbonyl C. The dihedral 
angles are termed ϕ and ψ (Figure 6A)7 which describe the angles between two intersecting 
planes spanned by four different atoms (ϕ: CO-NH-Cα-C’O, ψ: NH-Cα-CO-N’H). The 
defined angle ω, which describes the rotation of the amide bond (ω: Cα-CO-NH-C’α), is 
either 0° or 180° due to the planarity discussed above, where ω=180° corresponds to a trans 
peptide bond and is favoured by 8 kJmol-1 over its cis isomer.13  The assignment of the 
dihedral angle can be illustrated by a view alongside the central bond of the four 
contributing atoms (Figure 6 B, C)7. 
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Figure 6. A) Defined dihedral angles of a peptide backbone next to the alpha carbon.  
B, C) Determination of both dihedral angles by a view alongside the rotating bond.7 
 
Although the dihedral angles offer a free rotation along both backbone bonds, due to steric 
hindrance, depending on the nature of side chain residues, not all angles are equally 
favoured. Many dihedral angle combinations would lead to the collision of atoms and are 
therefore, considered as not allowed. As a consequence, the remaining possible angle 
combinations lead to different secondary structures discussed above.  
The combinations of dihedral angles, in relation to the conformation of the peptide, were 
studied by Ramachandran et al.14 who proposed a convenient notation for this kind of 
peptide backbone organization principle. They came up with the idea of displaying 
combinations of all dihedral angles of the peptide or protein by a two-dimensional graph, 
highlighting possible and or favoured combinations through coloured surfaces, the 
Ramachandran-plot (Figure 7).7  
 
Figure 7. The Ramachandran-diagram displays allowed combinations of ψ (y-axis) and ϕ (x-
axis), green surfaces. Angle combinations corresponding to the white surface are unfavoured 
for the particular peptide due to steric hindrance.7 For example around -135/135 lies a typical 
basin for β-sheets and around -60/-60 for α-helices. 
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With knowledge about the structure of a peptide (e.g. by X-ray structure analysis or 
molecular modelling) the Ramachandran plot can be used to verify the quality of the 
crystallographic refinement or homology models, as it would expose disallowed torsion 
angle combinations or some uncommon wide distribution around secondary structure 
regions. 
The tertiary structure is a characteristic of proteins, necessary for proper function and 
describes the three-dimensional shape and folding of the protein. For example, a water-
soluble protein will have a polar surface around a lipophilic centre.7 It describes the 
alignment of independent secondary structure regions, within a given protein domain. The 
human β-tryptase for example, a serine protease expressed and released by mastcells, 
comprises four closely related protein subunits.15 The arrangement of this tetramer-
subunit complex is defined as the quaternary structure, where the single protein domains 
are defined as a tertiary structure (Figure 8). 
 
 
 
 
 
 
 
 
Figure 8. The quaternary structure of the human β-Tryptase is a ringlike tetramer, with 
active sites facing towards a central pore. It consists of four tertiary structure protein 
domains (blue, orange, green and red).15 (PDB 1A0L). 
 
 
2.2. Peptide Synthesis 
 
The condensation reaction between a carboxylic acid and a free amine is seemingly a 
simple process, which results in the formation of the peptide bond and one molecule of 
water. However, at room temperature the starting materials result in a deprotection of the 
carboxylic acid and formation of a stable salt. Laboratory strategies involve the activation 
of the carboxylic acid, following a nucleophilic attack of the amine moiety, resulting in 
elimination of the activation group and formation of the peptide bond (Scheme 1).13  
2. Introduction 
 
 
- 9 - 
 
 
Scheme 1. Formation of a peptide bond, starting by activation of the carboxylic acid, 
followed by nucleophilic attack of the amine. 
 
Although the peptide bond is one of the most abundant chemical connections in natural 
and biologically active compounds and despite being an object of high interest of 
comprehensive studies for decades, the laboratory synthesis is quite tedious. Compared to 
nature and its ribosomal synthesis (expressing complicated proteins and peptides starting 
from unprotected amino acids in minutes up to a few hours), the synthesis requires 
protecting groups for all functional moieties, different coupling reagents for specific 
couplings and, therefore, results in long reaction times and an unfavourable atom 
economy.  
Beside the old activation methods of carboxylic acids (namely the formation of mixed 
anhydrides and acid chlorides), a more convenient method was published by Sheehan et 
al.16 in 1955, using N,N’-dicyclohexylcarbodiimide as an activation reagent, which exploits 
the formation of stable and precipitating dicyclohexylurea as a driving force for the 
reaction (Scheme 2). DCC reacts with carboxylic acids to form a highly reactive O-
acylisourea, which readily reacts with free amines to form amide bonds. This highly 
reactive intermediate may also react with another acid molecule to form a symmetric 
anhydride, which delivers the amide by reaction with the amine. The main undesired side 
reaction observed is the O, N-acylshift, which results in a stable substituted urea derivative 
which is inaccessible to further peptide coupling.13 
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Scheme 2. The reaction between a carboxylic acid and a carbodiimide leads to the formation 
of an O-acylisourea as a highly reactive species which reacts with amines to form an amide 
bond. A possible side reaction (especially during preactivation): the O-acylisourea may react 
with a second acid molecule to form a symmetric anhydride. Another option is the O, N-
acylshift, which leads to the formation of a stable N-acylurea. The side reactions can be 
suppressed with the addition of a hydroxybenzotriazole, which captures the O-acylisourea 
and leads to the formation of a less reactive HOBt active ester. 
 
In 1970, König and Geiger published a modified procedure of carbodiimide mediated 
peptide couplings, utilizing acidic alcohols (e.g. 1-hydroxybenzotriazoles) as additives.17 
These alcohols act as nucleophiles which trap the reactive O-acylisourea and form less 
reactive active esters, therefore suppressing the side reactions mentioned above, 
consequently resulting in decreased racemization and improved yields. 
Other frequently used carbodiimides are N,N’-diisopropylcarbodiimide (DIC), which forms 
soluble diisopropylurea suitable for solid phase peptide synthesis and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) which forms a water soluble urea, removed by 
an acidic aqueous wash of the organic phase (Figure 9). 
 
 
 
Figure 9. Commonly used carbodiimides. 
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In 1993, Carpino introduced 1-hydroxy-7-azabenzotriazol (HOAt) as a more efficient 
additive than the widely used HOBt at this time.18 HOAt has been shown to decrease 
reaction times and racemization compared to other additives, this has been explained with 
a neighbouring group effect of the aromatic nitrogen, which pre-organizes the amine for 
the subsequent nucleophilic attack (Figure 10). Another reason for the increased activity 
is the slightly decreased pKa value (3.28 for HOAt compared to 4.60 of HOBt)19 which 
results in a more stable alcoholate anion and therefore a better leaving group. 
 
Figure 10. The H-bond between the aromatic nitrogen atom and a proton of the free amine 
pre-organizes the amine for the subsequent nucleophilic attack, by close spatial orientation. 
Additionally, the H-bond leads to increased nucleophilicity of the amine. 
 
For a more practical usage, especially for automatized applications, stand-alone coupling 
reagents have been developed (Figure 11), the most successful based on uronium-
/guanidinium salts and phosphonium salts, containing different additives introduced above 
and a non-nucleophilic anion as a counterion.20 
 
Figure 11. Stand-alone coupling reagents based on phosphonium- and iminium-salts. 
 
In contrast to carbodiimides, these require a base to activate the carboxylic acid (Scheme 3). 
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Scheme 3. The stand-alone coupling reagents require a base for the initial preactivation of 
the carboxcylic acid. The coupling itself is also facilitated by the HOBt ester as for the 
carbodiimide facilitated peptide coupling. 
 
To enable a selective coupling between amines and carboxylic acids, chemists use a 
combination of temporary and semi-permanent protective groups, which have to be 
orthogonally cleaved. The temporary protecting groups, usually the amine protecting 
group of the activated carboxylic acid or C-terminal protecting group, depending on the 
direction of synthesis, is cleaved after each single coupling step. The permanent protecting 
groups are reserved for the sidechains. These protecting groups are cleaved when the 
peptide is completed. 
Frequently used protecting groups for amine functions are urethane based, with Boc, Fmoc 
and Cbz being most widely used (Scheme 4). 
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Scheme 4. The Boc, Fmoc and Cbz group are cleaved under orthogonal conditions. (I) The 
Boc group is cleaved under acidic conditions, resulting in the elimination of isobutene and 
CO2. (II) the Fmoc group is generally cleaved with secondary amines such as piperidine. The 
elimination of dibenzofulven is initiated by a deprotonation of the double benzylic proton, 
resulting in elimination of CO2. The electrophilic dibenzofulven may be trapped by an 
addition of secondary amine. (III) The Cbz group is cleaved hydrogenolytically, starting with 
an oxidative addition to the Pd(0) catalyst and coordination of H2 by a three centered σ-
complex. The coordination to the Pd(II) center facilitates the deprotonation of hydrogen by 
the carboxylate, resulting in elimination of carbamic acid which releases the free amine by 
CO2 elimination, the Pd(0) is regenerated through reductive elimination of toluene. 
 
Common protecting group combinations are Fmoc/tBu and Boc/Bzl, were the latter ones 
are the semi-permanent (ether and ester type) protecting groups for the sidechains, whose 
cleavage conditions are orthogonal towards the amine protecting group.  
Urethane based protecting groups and the N-terminal synthesis direction offer the 
advantage, that possible epimerization is minimized, which is predominantly caused by 
5(4H)-oxazolone formation after activation of the carboxylic acid. This oxazolone is readily 
deprotonated to form an aromatic enolate while losing its stereo information (Scheme 5). 
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Scheme 5. Strongly activated peptides (e.g. acid chlorides, O-acylisoureas) may undergo a 
cyclization to a 5(4H)-oxazolones, strong acylation agents which get readily deprotonated to 
form aromatic enolates. In contrast, the urethane group offers enough electron donor 
capacity to prevent enolate formation and loss of its stereo information. 
 
In 1963, Merrifield revolutionized the synthesis of peptides with his approach of solid 
phase peptide synthesis, 21 for which he received the Nobel Prize for chemistry in 1984. He 
developed a solid phase resin, a chloromethylated copolymer based on styrene and 
divinylbenzene, which showed suitable swelling properties in organic solvents to allow 
access for reagents. The chloromethylene moiety allowed the anchoring of N-protected 
amino acids in combination with triethylamine to the solid phase, by forming a covalent 
benzylester bond. Continuous cycles of N-terminal deprotection on resin and coupling of 
an amino acid active ester in combination with washing steps in between, allow the 
formation of a polypeptide chain in N-terminal direction on solid phase (Scheme 6). The 
finished peptide is obtained through cleavage from the resin. 
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Scheme 6. General schematic work-flow of the SPPS. 
 
In 1966, Merrifield and co-workers demonstrated the advantages of this method with the 
complete synthesis of the peptide hormone insulin in a matter of days and in high yields.22 
In the last decades, the SPPS found widespread application and has evolved a lot as its own 
industrial field and towards easier automatized handling. The Fmoc/tBu SPPS evolved to 
be the method of choice for most applications, utilizing different acid labile protecting 
groups for the sidechains, mainly: Pbf, Trt, OtBu, tBu and Boc.23 Different and versatile 
linkers attached to the resin material allow for modified and mild cleavage conditions. 
Cleavage of side-chain protected peptides or cleavage of the peptide as carboxamides is 
possible. Some established linkers are presented in Table 1 as an example. 
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Table 1. Exemplary representation of resins (among others), which enable the synthesis of 
either fully protected/ deprotected peptides with a free carboxylic acid or carboxamide 
terminus. 
 Cleavage  Cleavage  Product 
 
90–95% TFA 
for 1-2 h. 
 
1–5% TFA 
in DCM for 
1 min. 
acid 
 
90–95% TFA 
for 1-2 h. 
 
1–5% TFA 
in DCM for 
1 min. 
amide 
 
The mild cleavage conditions of the Barlos and Sieber resin allow the synthesis of fully 
protected acids or carboxamides bearing peptides, where the Wang and Rink amide resins 
deliver a complete deprotected peptide upon cleavage, which can be precipitated from 
ether to increase its purity. 
Additionally, several new resin materials have been developed (e.g. PEG based 
ChemMatrix® resin),24 which showed improved swelling properties in more polar and 
greener solvents.25 De Marco et al. even demonstrated SPPS in water without conventional 
protecting groups, which were simultaneously protected and activated by the formation of 
N-carboxyanhydrides (Leuchs anhydrides).26 
 
 
2.3. Peptidomimetics  
 
Proteins and peptides are playing an essential role in complex living organisms. While 
proteins are mostly constituents of tissues or engaged in biocatalytic tasks in the form of 
enzymes, the smaller peptides operate as hormones, neurotransmitters and regulators in 
signal transduction pathways.7 Many pathologic conditions, caused by a disorder in the 
interplay between enzymes and receptors with their substrates or ligands, are treated by 
medicinal chemists with peptides and their chemical analogues.27 However, due to their 
pharmacologic properties, the use of peptides as therapeutic tools is often limited by low 
bioavailability and digestion by proteases.  
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In the last decades, peptidomimetics, which mimic biological effects of peptides (agonists), 
obtained an increased meaning in the medicinal and chemical research. In comparison to 
biologically active peptides, peptidomimetics possess a range of interesting benefits, which 
feature them as suitable candidates for drug development and for medicinal treatment. 
Increased potency by stabilization of active conformations and therefore decreased side 
effects, generation of oral bioavailability and prolonged duration of effect and prevention 
of metabolic degradation are objects of present research.27 Progress is accompanied by 
improvement and development of computational methods and programs, which aid in the 
rational de novo design of novel peptidomimetics. Spectroscopic methods (NMR), X-ray 
crystal structure analysis and molecular modelling play a vital role to solve the bioactive 
conformation of peptides, for example in an enzyme-substrate complex.28  
The design of functional peptidomimetics should be built upon two key attributes, a 
favourable conformation through the installation of a rigid structure-element, and the 
placement of functional groups in space to enable specific interactions (hydrophobic, 
hydrogen-bonds, electrostatic, salt bridges). A synthetic approach, to access new 
peptidomimetics, is to start from the native peptide as a lead structure and to apply one or 
several modifications (N-alkylation, Cα-alkylation, incorporation of D-amino acids) to the 
backbone, finally leading to improved pharmaco-kinetic properties in SAR-studies 
(Figure 12).29  
 
Figure 12. Backbone modification of a native peptide segment. 29 
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Modification of the peptide backbone not only increases metabolic stability but has also a 
substantial influence on the secondary structure and folding properties of the peptide, by 
changing H-bond patterns or through steric demands.  
 
 
2.4. Triazoles as amide bond isosters 
 
Pursuing the idea of replacing amide bonds by proteolytically stable and planar chemical 
groups, the triazole, which shares electronic and topologic characteristics with natural 
peptide bonds, emerged in the focus of peptidomimetic chemists.30 The 1,2,3-triazoles 
represent a class of aromatic heterocycles, whose characteristics make them promising 
candidates for the development of bioactive peptidomimetics with improved 
pharmacologic properties.31 Like amide bonds, 1,2,3-triazoles are planar, have a strong 
dipole moment and are capable of accepting and donating hydrogen bonds. While the 
distance between the α-carbons of 1,5-disubstituted triazoles matches quite well for the cis 
amide bond (3.0 compared to 3.2 Å), the distances for the trans amide bond does not comply 
well (3.7 compared to 4.9 Å) with the 1,4-disubstituted  triazole (Figure 13 ).31 
 
Figure 13. Comparison of trans- and cis amide bonds and their resembling 1,4- and 1,5-
disubstituted triazole surrogates. 
 
The synthesis of triazoles by a cycloaddition between mono-substituted alkynes (as 
dipolarophiles) and azides (as 1,3-dipolar components) was first described by Michael et al. 
in 1893 and reviewed by Huisgen.32 The thermal reaction between phenylazide and 
phenylacetylide gave a nearly 1:1 regioisomer-mixture of the 1,4- and 1,5-disubstituted 
diphenyltriazole. 
Since the independent discovery of the copper(I) catalysed azide alkyne cycloaddition 
(CuAAC) by the groups of Meldal and Sharpless in 2002 (Scheme 7),33, 34 which leads 
exclusively to 1,4-disubstituted 1,2,3-triazoles, the CuAAC has found wide spread use by 
the chemical community.35  
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Scheme 7. CuAAC between Propargyl phenyl ether and benzylazide in aqueous media 
without the exclusion of oxygen. The reductive “CuSO4/sodium ascorbate”-system serves as 
a regenerative CuI source; a) CuSO4.5H2O (1 mol%), sodium ascorbate (5 mol%), H2O/tBu 
(2:1), RT, 8 h.34 
 
Several key features account for the popularity of this versatile reaction. It proceeds very 
selectively and without side products also in aqueous media and is orthogonal towards 
biologically relevant functional groups. Due to its perfect atom economy and 
straightforward workup, Sharpless and co-workers defined the CuAAC as a prototype of 
a “click-reaction”.36 Because the reaction mechanism is initiated by a formation of a copper 
acetylide derivative, the CuAAC can be only performed with terminal alkynes.34 
In 2005, the groups of Fokin and Jia published its counterpart, the ruthenium(II) catalysed 
azide alkyne cycloaddition (RuAAC) based on the complex Cp*RuCl(L2), which enabled the 
selective synthesis of the 1,5-disubstituted 1,2,3-triazole regioisomer (Scheme 8).37  
 
Scheme 8. RuAAC between 2-ethynylnaphthalene and benzylazide under elevated 
temperatures; a) Cp*RuCl(PPh3)2 (1 mol%), benzene, 80 °C, 4 h.37 
 
Although the reaction does not tolerate water or protic solvents, it is quite tolerable 
towards functional groups like alcohols, aldehydes, alkenes, amides, amines, boronic 
esters, ketones and halides.38 Since the reaction is initiated by a π-complex between the 
acetylide and the Ru(II) center, the reaction also tolerates internal alkynes as substrates, 
which would lead to trisubstituted triazoles with another possible regioisomeric 
combination. 
A recent publication from Kim et al. in 2017 describes the nickel(II) catalysed [3+2] alkyne 
azide cycloaddition to obtain 1,5-disubstitued triazoles in aqueous media under oxygen 
atmosphere, thereby addressing the disadvantages of the RuAAC (Scheme 9).39  
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Scheme 9. Optimized reaction condition example of a NiAAC between benzylazide and 
phenylacetylide. The regioisomers 1,5-disubstitued and 1,4-disubstituted triazole were 
isolated in a ratio of 94% to 6%; a) Cp2Ni (10 mol%), Xantphos (10 mol%), Cs2CO3 (1 eq), 
toluene, rt, air, 12 h. 
 
However, the reaction conditions seem to be critical for the regioselectivity. A deviation 
from the standard conditions, considering temperature, amount of base and ligand, leads 
to varying formation of undesired 1,4-disubstituted triazole, which might be challenging 
to separate from its regioisomer. Even the optimized protocol leads to the formation of 6% 
1,4-disubstituted triazole, and to 94% of the 1,5-disubstituted in toluene (for the specific 
reaction example between benzylazide and phenylacetylide), whereas a change of solvent 
using water as a reaction solvent leads to a 91% to 6% ratio in isolated yield. Although the 
authors claimed a broad substrate scope similar to the CuAAC, biocompatibility could not 
be proven, since the NiAAC failed with unprotected sugars as substrates, further 
experiments with amino acids were done with fully protected starting materials.  
An interesting, alternative approach for the synthesis of 1,5-disubstituted triazoles, 
without the use of alkynes, was published in 2011 by Dey et al.40 They described a metal-
free and regioselective formation of 1,5-disubstituted triazoles in water under reflux 
conditions, utilizing vinyl sulfones and azides (Scheme 10). 
 
Scheme 10. Metal-free formation of 1,5-disubstituted triazoles between vinylsulfones and 
azides in water, both aromatic or aliphatic substrates are tolerated; a) Ph-N3, water or 
toluene, reflux, 12 h. 
 
This approach works for either aromatic or aliphatic substrates. Furthermore, the substrate 
scope included several ethers, free alcohols, mesylated amines and ketals. Although, vinyl 
sulfones are readily available from alkenes, 1,2-diols, epoxides and aldehydes,41 to the best 
of our knowledge, a synthesis of 3-tosyl-prop-2-en-1-amines, starting from chiral amino 
aldehydes under preservation of the chiral integrity, has not been described in the 
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literature yet (which would be suitable starting materials for peptide-based building 
blocks). 
If “click chemistry” is supposed to be used in living organisms and in vivo applications, the 
toxic nature of transition metals may pose a problem, this could be circumvented 
employing electron withdrawing substituents and by ring-strain activated alkynes, which 
readily react selectively with azides to form the desired disubstitued triazoles within 
minutes, without transition metal catalysts. The group of Bertozzi published a 
bioorthogonal in vivo ligation employing difluorinated cyclooctyne as an activated alkyne 
for the copper-free click chemistry,42 therefore combining the rate-enhancing features of 
ring-strain and electron-withdrawing substituents (Scheme 11). 
 
Scheme 11. Difluorinated strained alkynes react readily with azides in a biological 
environment to form trisubstituted triazoles as “click”-product. 
 
However, the formation of both regioisomers might impose a problem for the synthesis of 
smaller ligation products but is generally not considered an issue in the labelling or 
immobilization of larger biomolecules. 
With these tools in hand, chemists started to come up with applications for both, 1,4- and 
1,5-disubstitued triazoles.43 A successful replacment of a backbone amide bond by a 1,4-
disubstituted triazole was demonstrated by Nahrwold et al. in Cryptophycin-52, while 
preserving its bioactivity (Figure 14).44 
 
Figure 14. Schematic depiction of the cryptophycin-52 and its peptidomimetic, which 
contains a 1,4-disubstituted triazole between the 3-chloro-4-methoxy-phenylalanine and β-
Aib moieties. 
 
Cryptophycin-52 is a cyclic depsipeptide, which shows high in vitro cytotoxicity against 
multidrug resistant human cancer cell lines (KB-V1), after the incorporation of the 1,4-
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disubstituted triazole, reproducting the trans configured amide bond (in this position), the 
bioactivity was only slightly reduced (IC50= 3.2 nM compared to 0.7 nM).44 
The 1,5-disubstituted triazole was demonstrated to be a cis amide bond surrogate by Tam 
et al. in 2007.45 In this work, the dipeptide surrogate -Xaa[5Tz]Ala- was shown to be a 
general substitute for -Xaa-cis-Pro- (Figure 15), built into the turn region of RNase A by an 
expressed protein ligation (Asn113-Pro114 were replaced). The semisynthetic folded 
enzymes where compared to their wild-types, resulting in thoroughly retained catalytic 
activity and similar CD-spectra.45 
 
Figure 15. Comparison of the turn region -Gly-Asn-cis-Pro-Tyr- and its 
mimic -Gly-Asn[5Tz]Ala-Tyr-.45 
 
 
2.5. Chiral propargylamines and α-azido acids 
 
Chiral propargylamines are important building blocks for the synthesis of 
conformationally restricted amide-bond isosters. Beside their use as precursors for dipolar 
cycloadditions, e.g. the 1,2,3-triazole formation in peptidomimetics30 or the  Diels-Alder 
reaction,46 they serve as valuable starting materials for several transition metal catalysed 
additions, for example the Sonogashira cross-coupling,47 allyl-transformation followed by 
Stille-coupling48 and other versatile transformations49 (Figure 16).  
 
Figure 16. Several selected transformation and extension reactions of propargylamines in 
organic chemistry. 
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Besides the possible route to obtain chiral propargylamines by an asymmetric alkynylation 
of imines, or enzymatic racemic resolution, alkynes are commonly obtained from 
homologation reactions starting from aldehydes.50 The synthesis of chiral 
propargylamines has been described starting from protected -amino aldehydes converted 
in a Corey-Fuchs or Bestmann-Ohira reaction (Scheme 12).48, 51,   
The -amino aldehydes are accessible by either reduction of the corresponding Weinreb 
amide with LiAlH4/DIBAL-H, or oxidation of the amino alcohol by Swern oxidation.53, 54 
However, these α-amino aldehydes are prone to epimerization during prolonged storage 
or upon contact with silica and are advised to be used immediately.55 
 
Scheme 12. After conversion of the amino acid into an α-amino aldehyde it can be 
transformed, by two Wittig related homologation reactions, into chiral propargylamines. 
 
Both methods have the advantage that the chiral pool of naturally occurring amino acids 
(Figure 1) is commercially available, with orthogonal protecting group combinations. 
The group of Ellman engaged themselves in the asymmetric synthesis of chiral amines.56 
They applied tert-butanesulfinamide as a chiral auxiliary. Together with aldehydes or 
ketones, the sulfinamide forms chiral N-sulfinimines which are further susceptible towards 
nucleophilic attacks by metal organyls. They postulated a cyclic hexagonal transition state, 
formed by coordination of the oxygen to the metal ion, which explains the 
diastestereoselective induction.56 After the nucleophilic addition, the N-sulfinyl group can 
be cleaved under acidic conditions to release the free amine as a salt (Scheme 13). 
 
Scheme 13. Synthesis of chiral amines utilizing Ellman’s auxiliary. 
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Hence, it was argued that the N-sulfinyl group may be used as an alternative to the Boc-
group. Moreover, after acidic cleavage it was shown that the Ellman-auxiliary can be 
recovered from the reaction.57, 58 In 2010, Chen et al. published an extensive report about 
the addition of different alkynylmagnesium chlorides to N-sulfinylimines. In this 
publication, the Grignard-addition of trimethylsilylacetylide provided several chiral 
propargylamines with unnatural amino acid side chains.59 
The groups of Ellman and Qing published the addition of in situ generated 
((trimethylsilyl)ethynyl)lithium to sulfinketimines. In the presence of a Lewis acid high 
yields and diastereomeric excesses were afforded (Scheme 14).60,  61 Addition of a Lewis 
acid drastically improved the diastereomeric excess of the addition to the sulfinimine. Both 
groups showed that the reaction could be either performed in toluene, with AlMe3 as a 
Lewis acid, or in THF, with Ti(OiPr)4, with excellent diastereomeric purity and yields. It 
was furthermore demonstrated that the TMS group can be cleaved off in quantitative yields 
with TBAF, giving access to synthetic versatile terminal alkynes. The procedures are also 
appliable to sulfinylaldimines (R1= H). 
 
Scheme 14. Diastereofacial addition of in situ generated ((trimethylsilyl)ethynyl)lithium to 
chiral N-sulfinylketimines lead to α,α-dibranched propargylamines in high purity. The TMS 
group could be cleaved off by the addition of TBAF in organic solvents, affording versatile 
terminal alkynes. 
 
During the fluoride mediated deprotection of the TMS-group, under certain circumstances 
where the residue at the alkyne homologues allylic position is either electron withdrawing 
or aromatic, a deprotonation of the proton at the stereogenic center is observed, which 
results in the formation of an allene which further rearranges into an α,β-unsatured 
imine.62 This was shown to be prevented by protodesilylation of the TMS-group catalysed 
by Ag(I)-salts.63 The principles and scope of this method, towards the asymmetric synthesis 
of natural and non-natural propargylamines, were further explored in our group by 
Wünsch et al.62  
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The synthesis of chiral α-azido acids is well established since a decade ago. Starting from 
the pool of 20 natural amino acids (Figure 1), the complementary chiral azides can be 
obtained by a Cu(II)-catalysed diazotransfer employing triflyl azide (Scheme 15).64, 65 
 
Scheme 15. Chiral α-azido acids can be obtained by a diazotransfer reaction using Tf-N3 as 
a transfer reagent under basic conditions.  
 
The mechanism was postulated by Wong and coworkers in 200266 and later confirmed by 
Pandiakumar et al.67 in 2014 by isotopic 15N labelling of the diazotransferreagent. With or 
without the addition of copper(II) ions, the two outer nitrogen atoms of the diazo-transfer 
reagent are transmitted to the amine.  
Regarding the safety issues of toxic NaN3, which is used to prepare TfN3 out of triflyl 
anhydride in big excess and the potential explosive nature of TfN3, an improved method 
has been published by Yan et al. in 2005 which significantly reduces its amount.68  
The HCl-salt of imidazole sulfonyl azide was described 2007 as inexpensive and shelf-stable 
diazotransfer reagent,69 which was later corrected by the authors, as safety concerns 
arised.70 The hydrogen sulfate salt on the other hand, can be considered safe to handle as 
a solid.71, 72 
 
 
2.6. Foldamers 
 
A chain-like oligomer which folds itself into a discrete conformation in solution can be 
applied to mimic structure features of peptides and proteins. The noncovalent interaction 
properties, between nonadjacent monomers of these synthetic compounds are explored in 
studying of molecular self-assembly and host-guest complexes. Gellman used and defined 
the word “foldamer” to describe any polymer which strives to adopt a specific compact 
conformation.73 Control over polymer folding might lead to molecules with useful 
biological or material properties. In recent years, several foldamers have been designed, 
targeting protein surfaces and antagonizing protein-protein interaction binding tightly in 
a specific manner.74 Protein-protein interaction is an elementary event of signal 
transduction pathways, the manipulation of those pathways has become a promising 
strategy for the treatment of several diseases and reducing of cancer growth.  
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In the field of nonpeptidic foldamers which mimic secondary structure motifs of native 
peptides, the group of Arora published in 2010 a set of oligooxopiperazines as α-helix 
mimetics,75 which are derived from α-amino acids and feature a chiral backbone 
(Figure 17 A). These mimics imitate the binding surface of an alpha helix in protein-protein 
interactions, therefore reproducing the arrangement of the i, i+4 and i+7 residue of a helix. 
Since only the arrangement of the key side chains is reproduced, those synthetic scaffolds 
are thought to have an increased selectivity over their natural counterpart. These 
oxopiperazine helix mimics were shown by Lao et al. in 2014 to be suitable small-molecule 
inhibitors of the transcriptional protein-protein interaction of HIF-p300/CBP76 which 
results in modulation of gene expression and reduction of tumor growth in mice model.  
In the research field of peptidomimetics for enzymatic inhibition, the extended β-sheet 
structure as well as its H-bonding capabilities are crucial parameters for the search of 
convenient non-peptidic scaffolds. In 1992 the group of Hirschmann published a 
peptidomimetic framework based on pyrrolinone, which mimics the conformation of a β-
sheet with the residues in axial orientation to the heteroaromatic rings. The 
heteroaromatic ring itself was shown to fix the angles analogue to ψ and ω in a peptide, 
where the ϕ-angle is defined by steric interactions of a side-chain with its neighbouring 
heteroaromate (Figure 17 B).77 
 
Figure 17. A) Example of an oligomer build up by oxopiperazines which mimics a section 
of an α-helix.76 B) A framework based on pyrrolinone effectively mimics a β-sheet.77 
 
By an overlay comparison with the X-ray crystal structure of a β-sheet forming peptide 
the group of Hirschmann could show that the carbonyl functions of the pyrrolinone-
moieties closely match the orientation of the amide-carbonyl functions of the peptide. 
Consequently, the peptidomimetic maintains the crucial H-bond acceptor capability which 
would be necessary for protease recognition. 
In 2005 the group of Arora published the synthesis and conformational analysis of 1,4-
disubstituted 1,2,3-triazole containing oligomers, which they termed triazolamers. In these, 
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every amide bond is substitued by a triazole as amide-bond isoster, but the chiral main-
chain, which contains the amino-acid residues, remains preserved.78 This distinctly folded 
new class of nonpeptidic oligomers adopts a zig-zag conformation reminiscent of peptide 
β-strands through the large dipole moment of single triazole moieties of ~5 D (Figure 18).  
 
Figure 18. Comparison of both sets of syn- and anti-conformations. The dipole moment of 
each single triazolering is represented by an arrow. The anti-conformations are favoured by 
4 kcal/mol over their syn-conformations. 
 
The triazolamers where shown to be obtainable by solid phase or solution phase synthesis, 
through iterative diazotransfer of the free amine function followed by copper catalysed 
dipolar cycloaddition with a chiral propargylamine and a final deprotection of the amine 
protective group.79  
Due to their extended conformation and capability to contribute to H-bonding, these 
oligomers where examined as possible protease inhibitors. Jochim et al. evaluated the 
potential of these triazolamers as HIV-1 protease inhibitors in 2009,80 by designing 
triazolamers which mimic the residual orientation of the known peptidic HIV-1 protease 
inhibitors (L-700,417 and A74704), which have been co-crystallized with the enzyme in 
their biological active conformation.81 Although docking experiments suggest that the 
triazolamer superimposes in good agreement with the established inhibitors, the inhibitory 
concentrations were only in µM range (IC50= 25 µM for the most active triazolamer), 
compared to the low nanomolar inhibition constants of the leading inhibitors 
(IC50=  0.67 nM for L-700,417) (Figure 19). 
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Figure 19. Structural comparison between triazolamer-1 and the known inhibitor L-700,417.  
 
 
2.7. Amyloid-β related diseases 
 
The term amyloid originally referred to protein deposits resembling those of starch, with 
amyloid meaning starch-like.82 It is nowadays specifically associated with the fibrillization 
process of peptides and proteins, by aggregation of β-sheet structured monomers. The 
aggregation of the amyloid-β peptide (Aβ) plays a role in Alzheimer’s disease, an age 
dependent, neurodegenerative disease, which was first described by Alois Alzheimer in 
1906.83 Due to the aging society and increasing lifespan which goes along with a rising 
incidence of this condition, a lot of effort is performed to investigate the causes and 
treatment of Alzheimer’s disease (AD), which is responsible for 50-80% of all dementia 
cases.82 An estimated amount of 18 million people is currently affected by AD, a number 
which is predicted to double within the next 20 years, causing billions of US-$ annual 
medical-cost for society. Aggravatingly is the fact, that a single genetic risk-factor does not 
exist, but several genes associated with susceptibility to the condition are known, as well 
as lifestyle comprising of unfavourable diet (leading to increased IGF-1 levels), lack in 
exercise and mental activity.82 AD is usually diagnosed by cognitive testing methods 
supported by MRI scanning, which does not consider the fact, that the pathogenic process 
leading to AD, often times, start a period of one decade before obvious symptoms are 
observed. Until now, the progression of AD is not reversible or curable, however, several 
existing treatments can decelerate the progression of the disease.  
The Aβ-hypothesis implies Amyloid-β (Aβ) as a central causative of AD, which is 
supported by the fact, that levels of soluble Aβ correlate better with the extent of cognitive 
degradation than simple plaque counts.84 The two predominant variants of Aβ in human 
have been identified as Aβ40 and Aβ42, with 40 or 42 residues. Although Aβ40 is ~10 times 
more abundant, the more hydrophobic Aβ42 has been shown to form fibrils more rapidly, 
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the early oligomers formed in the initial self-assembly process are thought to be the 
neurotoxic agents.82 Aβ is formed by proteolytic cleavage of the transmembrane precursor-
protein APP (amyloid precursor protein), which is expressed in many tissues but 
concentrated in synapses of neurons, by the endoproteases β- and γ-secretase. Therefore, 
the β- and γ-secretase are considered to be prime targets for the development of protease 
inhibitors, to treat the disease at an initial stage, preventing the formation of Aβ and as a 
consequence the development of neurotoxic oligomers.85 The role of APP in the human 
body is not entirely understood, it is an ancient gene encoded on chromosome-21 and has 
been linked as a modulator in the formation-process of synapses,86 or in apoptosis 
processes by releasing a cytotoxic C-terminal fragment.87 Consequently, low levels of 
soluble Aβ can be also detected in the plasma of healthy individuals. The accumulation and 
aggregation in brain tissue, however, is prevented by different clearance pathways, which 
allow Aβ to cross the blood-brain-barrier followed by subsequent degradation by 
proteases.88 Hence, Alzheimer’s disease is further characterized by an imbalance between 
production and clearance of Aβ. 
Beside the approach to hinder the pathogenesis of Alzheimer’s disease at an early stage in 
the cascade, by inhibiting the secretase enzymes, a physicochemical path is imaginable to 
prevent the aggregation of Aβ. The idea behind this approach is to utilize a small peptide 
with a specific recognition sequence for Aβ, which binds Aβ and meanwhile prevents the 
ability of the affected strand to form neurotoxic oligomers. Searching such a recognition 
sequence, chemists focused on the peptide sequence of Aβ itself, since it is able to 
selectively bind and interact intermolecularly with other Aβ-strands to form oligomers. 
This self-recognition element was discovered and limited to the Aβ fragment 16-20, which 
corresponds to the truncated amino acid sequence KLVFF. Tjernberg et al. showed in 1996, 
that the core motif KLVFF is indeed able to bind full length Aβ and to interrupt its 
polymerization, therefore envisioning KLVFF as a lead-structure for the discovery and 
development of novel potent aggregation inhibitors in vivo.89 
 
 
2.8. Monitoring of the Aβ aggregation and fibrillization process 
 
Fluorescence dye binding assays are used to investigate the self-assembly process of 
amyloid proteins and to study the nature of early stage soluble oligomers. The fluorescence 
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probe should exhibit distinct spectral properties, for instance a shift in emission 
wavelength upon binding compared to its unbound state. Thioflavin T (ThT) (Figure 20), a 
benzothiazole derivative, is widely used as a histochemical dye to quantify the amount of 
misfolded protein aggregates.90 It is able to recognize and noncovalently bind β-sheet rich 
structures, which is accompanied by a red shift in its fluorescence spectrum.  
 
Figure 20. Structure of Thioflavin T, which is synthesized by methylation of 6-methyl-2-
benzothiazolyl-4-aminophenyl with methanol in the presence of hydrochloric acid. 
 
In presence of amyloid, ThT becomes highly fluorescent with an emission maximum at 
480 nm arising from a new absorption peak at 450 nm, indicating an impact of interactions 
between ThT and amyloid on fluorescence. A study in 2005 by Krebs et al.91 examined the 
localisation of binding between ThT and amyloid proteins, discovering a regular and 
specific binding pattern of ThT, which leads to increased quantum yields during the 
fluorescence assay. This is explained by a 6.5 to 6.9 Å wide binding channel, typical for the 
extended β-sheets of amyloid fibrils, stabilizing the excited state conformation of ThT. This 
explains the inability of some β-sheet rich structures to increase fluorescence (e.g. 
transthyretin).90 As a direct implication, Krebs et al. proclaimed ThT as a dye more suitable 
for the probing of amyloid fibrils.  
Small molecular dyes, which selectively bind secondary structure motifs of Aβ, are of great 
interest in today’s investigation in the formation of smaller, soluble neurotoxic oligomers, 
representative for the early stage of Alzheimer’s disease development. 2010, Smith et al. 
published two triazole containing BODIPY dyes, which show an improved sensitivity in 
the recognition towards unordered soluble oligomers of Aβ1-42 (Figure 21).92 
 
Figure 21. BODIPY derivatives, extended by a N1-benzyl triazole. 
 
Whereas an excess of dye, relative to Aβ, is required for ThT fluorescence to receive an 
enhanced signal, this is not the case for the BODIPY dye, which is, therefore, not disrupting 
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the integrity of Aβ self-assembly.92, 93 Smith et al. demonstrated that small concentrations 
of BODIPY (2-4% compared to Aβ) already provide a significant enhancement of 
fluorescence. Additionally, the characteristic “lag-phase” of ThT assays, arising from the 
fact that ThT is unable to detect smaller soluble oligomers at the early stage of aggregation 
(which results in diminished fluorescence), is not observed for BODIPY assays. This 
supports the evidence that BODIPY is able to recognize smaller soluble aggregates of Aβ1-
42. 
  
2.9. Integrins and RGD-peptides 
 
RGD refers to the peptide sequence Arg-Gly-Asp which is located predominantly in the 
extracellular matrix (a protein-network in which the cells reside) and on certain plasma 
proteins. The sequence is able to bind cell surface receptors, the integrins, a class of 
transmembrane proteins which are important for the signal transduction between cells and 
their environment.94 Integrins play a critical role in cell adhesion processes and the 
angiogenesis of tumor cells by regulating the activities of cytoplasmic kinases.95 They are 
heterodimeric receptors, composed of noncovalently associated α- and β-subunits, the fact 
that they are linked with pathologic conditions have turned them into potential therapeutic 
targets.96 Several types of integrins exist, composed of 18 α and eight β units giving 24 αβ 
heterodimers in mammals. Eight of them are able to recognize the RGD sequence in their 
native ligands (five αv, two β1 (α5, α8) and aIIbβ3).97, 98 All members of the integrin family 
adopt a large extracellular “head on two legs” resembling shape, with the head containing 
the ligand-binding domain, and the legs traversing the membrane and terminating in a 
short cytoplasmic domain. They connect the ECM with the intracellular cytoskeleton 
(Figure 22).96,99  
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Figure 22. Schematic depiction of the bent and upright conformation of an integrin.96  
 
The 24 different integrins in mammals can be separated into two groups, one containing, 
and the other one lacking an αI domain inserted into the α subunit, which serves as a 
divalent cation binding site for extracellular ligands.100 The binding of a ligand to a specific 
integrin is accompanied by a significant conformational change of the integrin, 
subsequently mediating the signal transduction into the cell. This is shown in Figure 22, 
where the integrin changes from an extended conformation on the left, to a bent 
conformation closer to the membrane in its ligand-occupied stage. 
In the group of RGD binding integrins the integrins αvβ3, αvβ5, α5β1 have been shown to 
be involved in angiogenesis and metastasis of solid tumors and were, therefore, considered 
as promising drug targets for cancer treatment, further supported by the fact that these 
integrins are overexpressed in tumor-cells.101 The group of Kessler was interested in 
finding ligands for the integrin αvβ3. Due to missing X-ray crystal structure of the integrin 
bound ligand at this time and, therefore, unknown biologically active conformation of the 
RGD sequence, the group focused their initial efforts on a “ligand-oriented design”. In these 
the RGD-sequence was optimized to develop suitable ligands. By a combinational strategy 
of cyclizing different peptides to restrict the conformation and a N-methylation scan of 
amide bonds, the group discovered the cyclic peptide cyclo-[RGDf(NMe)V] in 1995, which 
shows a sub-nanomolar antagonistic activity towards αvβ3.101 The peptide was called 
“cilengitide” and patented in collaboration with Merck, entering phase III clinical study for 
threatening glioblastoma in human. However, in recent years it has been shown that 
inhibitors targeting αvβ3 and αvβ5, although entering clinical trials, were ineffective in 
showing significant benefit for concerned test groups.102 Reynolds et al. have shown that 
low concentrations of RGD-mimetic integrin inhibitors paradoxically have a 
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proangiogenic effect, by stimulating VEGF (vascular endothelial growth factor) dependent 
angiogenesis in nanomolar concentrations, and therefore may increase cancer-growth, 
which limits their application in human.102 Cilengitide has been declined to be further 
developed as a single-agent anticancer drug, after failing to show significant efficiency 
compared to conventional chemoradiotherapy.103  
The reason for this lack of efficiency in human compared to preclinical tests is not yet 
resolved. Since cilengitide shows a high in vitro affinity towards integrin expressing 
glioblastoma cells, there should be a high interest to address the inefficiency towards the 
majority of human cancers.102 However, in the field of drug-conjugates, RGD-mimetics are 
still a viable option as a targeting device, combined with a potent cytotoxic drug. 
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3. Research Objective 
 
The aim of this dissertation has been to develop general and convenient synthesis methods 
for peptidomimetics, containing 1,5-disubstituted 1,2,3-triazoles as rigid amide-bond 
isosters. The substitution of amide bonds should lead to increased metabolic stability and 
potentially to conserved defined conformations, eventually mimicking secondary structure 
motifs of naturally occurring peptides. The knowledge about the conformation inducing 
effects of nonpeptidic scaffolds would contribute to the objective to design novel 
peptidomimetics, which might target protein surfaces in biological systems, or mimic 
bioactive conformations of receptor ligands and enzymatic inhibitors.   
The project was inspired by the triazolamers of the Arora workgroup,78 which showed 
encouraging potential as lead structure for the development of protease inhibitors. 
Differently to the work of the Arora group, the effort was focused on linear compounds 
with an alternating sequence of amide-bonds and 1,5-disubstituted triazoles, which were 
termed as peptidotriazolamers in previous works of our group (Figure 23).104 
 
Figure 23. Two examples of peptidomimetic oligomers with an alternating sequence of 
amide-bonds and 1,5-disubstituted triazoles. Additionally, the compounds comprise of a 
homo- or heterochiral setup of proteinogenic residues. 
 
The previous master thesis105 covered the synthesis of aliphatic propargylamines  from 
aldehydes via Ellman’s auxiliary based on Xiao et al.,61 and later described more in depth 
by Wünsch et al.,62 the synthesis of benzylester protected α-azido acids by diazotransfer 
based on Lundquist et al.65 and the microwave assisted synthesis of 1,5-disubstituted 
triazoles. The RuAAC utilized Boc protected propargylamines, since the sulfinyl group 
proved itself incompatible with the microwave conditions of the RuAAC (Scheme 16). 
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Scheme 16. A) formation of chiral propargylamines via Ellman’s auxiliary; B) diazotransfer 
to form benzylester protected azido acids in high yields and C) microwave assisted RuAAC 
to obtain triazoles, utilizing the previously obtained starting materials. 
 
For this dissertation and future coupling scenarios a “building block” approach would be 
desirable, consisting of orthogonal deprotection procedures and coupling of single triazole 
dipeptide isosters, instead of the “submonomer” approach applied by Fröhr.104 Therefore, 
a suitable and epimerization free coupling procedure ought to be explored.  
This research objective was likewise covered by Johansson et al. in 2014, who synthesized 
several peptidotriazolamers of various lengths, comprised of 1,5-disubstituted triazoles and 
peptide bonds in an alternating pattern.106 Johansson et al. had focussed on the synthesis 
of achiral oligomers, comprised of glycine moieties, thus avoiding the intricate synthesis 
of chiral propargylamines, and the coupling of racemization prone triazole dipeptide 
surrogates. To prevent the issue of overlapping signals in the 1H-NMR-spectra Johansson 
et al. had to deal with, a variety of different side chain residues should be utilized to obtain 
a preferable number of ROESY-NMR constraints for the following conformational analysis. 
Furthermore, we were interested in the influence of stereochemistry on the adopted 
conformations, to understand if preferred orientations are navigated by backbone 
influences or the different orientation of the residues. The conformational analysis of 
synthesized oligomers ought to be explored by X-ray crystallography and molecular 
modelling. With knowledge about the foldameric properties of different 
peptidotriazolamers, suitable biological applications depending on protein peptide 
interactions should be explored. 
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4. Results and Discussion 
 
4.1. Synthesis of 1,5-disubstituted triazole containing peptidotriazolamers 
 
(Part of this work was already published in “Chemistry A European Journal”:  
Oliver Kracker, Jerzy Góra, Joanna Krzciuk-Gula, Antoine Marion, Beate Neumann, Hans-
Georg, Stammler, Anke Nieß, Iris Antes, Rafał Latajka, Norbert Sewald. (2017). 1,5-
Disubstituted 1,2,3-Triazole-Containing Peptidotriazolamers: Design Principles for a Class 
of Versatile Peptidomimetics. Chemistry - A European Journal. 10.1002/ 
chem.201704583.)107 
  
A possible synthesis route, describing the course of a “building block” approach towards 
peptidotriazolamers, is illustrated in Scheme 17.  
 
Scheme 17. Starting with the RuAAC, the Boc/Bzl strategy allows the solution phase 
synthesis of peptidotriazolamers, using 1,5-disubstituted triazoles as building blocks. 
 
The synthesis strategy comprises of a RuAAC between Boc protected alkynes and 
benzelester protected azides, leading to 1,5-disubstituted triazoles in high yields without 
the formation of side products. Subsequent elongation of these triazoles is enabled by the 
orthogonal Boc/Bzl protecting group combination, which is cleavable under acidic or 
hydrogenolytic conditions, leading to selectively deprotected triazoles. By-products of the 
cleavage are removed under vacuum.  
Since we were interested in peptidotriazolamers of various lengths, an oligomer synthesis 
in solution proved to be convenient, because each step allowed for a full characterization 
of the product, followed by subsequent further elongation. Previous work from our work-
group104 reported the elongation in a step-wise fashion in N-terminal direction. Coupling 
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of a free α-azido acid to a triazole, or peptidotriazolamer, followed by a cycloaddition with 
a propargylamine. A “building-block” approach (Scheme 17) offers the advantage, that 
single triazoles, which are valuable and interesting compounds by their own, are isolated 
and analysed. 
Chiral α-azido acid benzylesters 4a-c were synthesized based on the procedure of Alper 
and Lundquist.64, 65 The azide equivalents of Val, Ala and Phe were obtained in very good 
yields of >87% starting with commercially available amino acid benzylesters 1 by a 
copper(II) catalysed diazotransfer reaction with triflyl azide 2 (Scheme 18). 
 
Scheme 18. The α-azido acids as analogues of Val, Ala and Phe were successfully 
synthesized by diazotransfer with Tf-N3. 
 
In contrast to the group of Pelletier, which established an aqueous workup to separate the 
trifluoromethanesulfonamide (3) from their free azido-acids by exploiting their different 
pKa-values, a column chromatography was used to obtain the azido acid benzylesters. 
Moreover, a transesterification reaction from the benzylester to the methylester was 
noticed, facilitated by methanol under basic conditions. This could be prevented by using 
the less acidic and less nucleophilic tBuOH as a co-solvent. 
The synthesis of (R)- and (S)-configured propargylamines was realized with Ellman’s 
auxiliary as described by Wünsch et al. (Scheme 19 and Table 2).62 Both enantiomers of 
Ellman’s auxiliary were synthesized in enantiomerically pure form according to the group 
of Ellman, with a yield of 36% for (R)-5 and 23% for the (S)-5 enantiomer.108  
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Scheme 19. Aliphatic aldehydes react with Ellman’s auxiliary 5 to generate chiral 
sulfinaldimines 6a-h. Nucleophilic addition of ((trimethylsilyl)ethynyl)lithium followed by 
deprotection with TBAF affords the propargylamines 7a-h. Acidic methanolysis of the Bus- 
group, followed by Boc protection lead to Boc- protected propargylamines 8a-h in acceptable 
to high yields over two steps.  
 
Table 2. Yields during the propargylamine synthesis. The synthesis of Bus protected 
propargylamines entails two steps (acetylide addition and TMS cleavage). As well for the 
Boc protected propargylamines (Bus deprotection and Boc introduction). 
 
   
R =  (R)  (S)  (R, R)  (S, S)  (R)  (S)  
Methyl 6a (81%) 6b (80%) 7a (49%) 7b (46%) 8a (85%) 8b (61%) 
Isopropyl 6c (90%) 6d (71%) 7c (45%) 7d (67%) 8c (90%) 8d (56%) 
Isobutyl 6e (79%) 6f (93%) 7e (46%) 7f (52%) 8e (94%) 8f (82%) 
Cyclohexyl 6g (93%) 6h (46%) 7g (71%) 7h (60%) 8g (84%) 8h (86%) 
 
Utilizing different aldehydes (acetaldehyde, isovaleraldehyde, methylbutyraldehyde and 
formylcyclohexane), the sulfinimines 6a-h were synthesized in high yields, employing 
MgSO4 or CuSO4 as Lewis acids, as described by Liu et al.109 The nucleophilic addition of 
((trimethylsilyl)ethynyl)lithium was performed according to Xiao et al.61, utilizing 
Ti(OiPr)4 as a lewis acid in THF, deprotection with TBAF lead to Bus protected 
propargylamines 7a-h in diastereomerically pure form after column chromarography. 
Although the Bus group was mentioned to be a feasible substitute for the Boc group in 
peptide synthesis, we found it to be partially unstable towards the microwave conditions 
during the RuAAC. Moreover, it decomposes upon standing in polar solvents. The initial 
low yields of the RuAAC are reasoned with a thermal rearrangement mechanism for 
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Ellman’s auxiliary,110 which can be applied on N-sulfinyl protected propargylamines and 
triazoles.  In this proposed mechanism, N-sulfinyl protected propargylamines react 
intermolecularly to form a deprotected and N-(tert-butylthio)-tert-butylsulfonamide linked 
alkyne, as the more stable forms (Scheme 20).105  
 
Scheme 20. The Mechanism which describes the rearrangement reaction of e.g. N-sulfinyl 
protected propargylamines, leading to an unprotected species and N-(tert-butylthio)-tert-
butylsulfonamide linked amine.110  
 
Therefore, the Bus- protected propargylamines were deprotected and the protecting group 
exchanged to the more stable Boc group. Based on a publication of Basel et al., imidazole 
was used to scavenge the slight excess of (Boc)2O, which can successively be removed by 
washing with diluted acid, avoiding the necessity of a column chromatography in most 
cases (Scheme 19).111 Using this procedure, the Boc- protected (R)- and (S)-configurated 
alkyne analogues of Ala, Val, Leu and chGly 8a-h were successfully synthesized in 
enantiomerically pure form.  
The RuAAC was performed under microwave conditions, where THF turned out to be a 
suitable solvent, regarding solubility of the starting material, boiling temperature and 
stability of the catalyst. In addition, degassing of the freshly destilled THF was not required. 
Using a slight excess of azide, the RuAAC was completed in 1-2 h in excellent yields of 77-
94%, leading to different homo- and heterochiral triazoles 9a-i, representing dipeptide 
isosteres (Scheme 21). 
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Scheme 21. The MW-assisted RuAAC lead to several aliphatic and aromatic 1,5-
disubstituted triazoles in high to excellent yields. 
 
The obtained triazoles proved to be highly stable, even on storing them at RT for several 
months. Most of them readily crystallized out of ethylacetate, methanol or isopropanol, by 
slow evaporation of the solvent at room temperature overnight. The obtained crystals were 
suitable for X-ray crystallography, once again proving the regioselectivity of the RuAAC 
and the configuration of the formerly propargylamines chiral centre.  
The obtained crystal structures are shown in Figure 24, highlighting the similarity of the 
1,5-disubstituted triazole with a cis-peptide bond, recognizable by the turn inducing 
properties of the triazole and distance between both α-carbons. 
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A)  B) C) 
 
 
D)                                                    E)                                                  F)     
 
 
Notably, in case of homochirality, the 1,5-disubstituted triazole moiety seems to result in 
a turn induction and reversal in direction of the peptide chain, which is not the case for 
both heterochiral dipeptide isosters, where the peptide chain may continue growing in the 
same direction, possibly leading to a more extended structure. 
With the homo- and hetero-chiral triazole building blocks available, Boc/Bzl solution phase 
peptide synthesis was used for the assembly of larger oligomeric peptidotriazolamers. The 
acidic cleavage of the Boc- group and hydrogenolysis of the benzylester were quantitative. 
The deprotected derivatives were used without further purification for the peptide 
coupling. With TBTU or HATU as coupling reagents in DMF, either without or in 
combination with HOBt/HOAt and DIPEA as a base, the products were obtained in high 
yields, but suffered from epimerization. In contrast, a base-free carbodiimide mediated 
Figure 24. Obtained crystal structures of Boc protected triazoles (distance of α-carbons in Å): 
A) Boc-D-Val[5Tz]Ala-OBzl (9f) (3.206); B) Boc-D-Leu[5Tz]Val-OBzl (9d) (3.175); C) Boc-
chGly[5Tz]Phe-OBzl (9h) (3.162); D) Boc-Ala[5Tz]Ala-OBzl (9g) (3.169); E) Boc-Leu[5Tz]Val-
OBzl (9e) (3.207); F) Boc-Val[5Tz]Ala-OBzl (9c) (3.174). 
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preactivation of the carboxylic acid in DCM, in combination with OxymaPure or HOAt as 
an additive, followed by a sym-collidine facilitated coupling step, did not suffer from this 
shortcoming.19 A publication of Carpino and El-Faham,112 which demonstrates the 
influence of solvent and base on the DIC/HOAt preactivation rate of amino acids, 
suggested to use a base-free preactivation in DCM, instead of DMF. Sym-collidine was used 
as a base for the successive coupling step, to release the free amine from the hydrochloride 
salt, obtained upon the Boc-cleavage and to enhance coupling efficiency.  
Under these conditions, coupling proceeded in DCM without any epimerization and with 
high yields (Scheme 22 and Scheme 23).  
 
Scheme 22. The synthesis of the homochiral peptidotriazole tetramer 10 and hexamer 11 
was performed in N-terminal direction, using DIC/Oxyma as coupling reagents in excellent 
yields. 
 
Scheme 23. The synthesis of the heterochiral peptidotriazole tetramer 12 and hexamer 13 
was performed in C-terminal direction, employing DCC/HOAt as coupling reagents. 
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The peptidotriazolamers could be purified by either column chromatography or 
preparative HPLC. In contrast to Johansson et al.,106 a drastic decrease in coupling yields 
between the tetramer and hexamer units was not observed. Furthermore, the carbodiimide 
mediated coupling seems to lead to increased coupling yields, compared to the T3P/DIPEA 
system Johansson et al. used for their achiral oligomers. If solubility of the hydrochloride 
salt in DCM becomes a problem it can be dissolved in DMF and added dropwise to the 
preactivated acid, which is dissolved in DCM, for a final DCM/DMF ratio of 1:1 without 
any epimerization.  
The problem of possible epimerization during the coupling of triazole dipeptide isosters 
was reported for 1,4-disubstituted triazoles.113,114 Horne et al. overcame this problem, by 
coupling with a five-fold excess of triazole/DIC/HOAt to a free amine on solid phase, 
without the use of any base for the coupling step. During this dissertation, a 0.1 eq excess 
of activated acid, in combination with sym-collidine as a base, proved to lead to full 
conversion of the amine. As a further advantage, the use of a base enables the use of 
synthesized and commercially available amine salts. 
In addition to the homo- and heterochiral hexamer oligomers described above, which were 
published recently,107 additional oligomers were synthesized. The peptidotriazolamer Boc-
Val[5Tz]Ala-Leu[5Tz]Val-OBzl (10), which showed to be crystalline (CCDC 1561608) and 
was considered as our lead-structure for further modifications, was elongated by a simple 
alanine in C-terminal direction, however, the pentapeptide 14 failed to give any crystals 
(Scheme 24). 
 
Scheme 24. Elongation of the tetramer by an alanine moiety. 
 
Further, the possibility to analyse a simpler system, by synthesizing triazoles and 
oligomers based on polyalanine, was explored (Scheme 25). 
In the case of the tetra-alanine peptidomimetic 15, the NMR comprised off overlapping 
signals, therefore the synthesis of the analogue hexamer unit was omitted. The issue of 
overlapping signals was also observed by Johannson et al. for their achiral polyglycine 
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oligomers, which hampers the possibility to compare calculated structures with the 
measured conformation in solution, by taking ROESY restraints into account. Likewise, the 
tetra-alanine peptidotriazolamer failed to give suitable crystals.  
 
Scheme 25. Synthesis route, describing the synthesis of the tetra-alanine peptidotriazolamer 
15. 
 
An additional hexameric peptidotriazolamer 17 was synthesized by solution phase peptide 
synthesis, however, this comprises of non-natural amino acid residues and was not 
addressed with comparable priority for further study (Scheme 26).  
 
 
Scheme 26. The tetramer 16 and hexamer 17 were synthesized in C-terminal direction. 
 
Noticable, some of the latter presented peptide couplings represent early modification 
attempts of the coupling procedure. In these, the new generation stand alone reagent 
COMU,115 in combination with Oxyma as an additive and sym-collidine was used in pure 
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DCM, which performed without partial epimerization. However, the DIC mediated 
reaction, compared with stand-alone coupling reagents, scores in terms of atom economy 
and practical handling and proved to be highly efficient. These findings are in agreement 
with Fara et al.116 who demonstrated the efficiency of the DIC/HOBt system under 
microwave conditions for the synthesis of challenging peptide sequences on solid phase, 
openly questioning the necessity of more exotic coupling reagents.  
In summary, a chain elongation in N-terminal direction, employing a slight excess of 
activated acid (amino acid or triazole-dipeptide in 0.1 eq excess), proved to be ideal for the 
synthesis of peptidotriazolamers in solution and was therefore used as a standard 
procedure. 
 
 
4.2. Synthesis of 1,4-disubstituted triazole containing peptidotriazolamers 
 
In addition to the peptidotriazolamers described above, featuring 1,5-disubstituted 
triazoles, two additional peptidotriazolamers were synthesized. These contain 1,4-
disubstituted triazoles, to round up the set of peptidotriazolamers synthesized by Dr. Tanja 
Fröhr.104 In contrast to the step wise synthesis strategy used by Fröhr, coupling a free azido 
acid in N-terminal direction onto the growing chain, followed by a click reaction with a 
Bus protected propargylamine and using the Bus/OAll protecting group pair, the synthesis 
strategy discussed in Scheme 17 and demonstrated in Scheme 22 was used.  
To retain the C-terminal allylester of the oligomers, H-Val-OAll.TosH was converted into 
the α-azido acid 4e by diazotransfer. For the oligomers with alternating stereocenter and 
methylene moiety, the achiral Boc protected propargylamine 8i, was synthesized out of 
commercially available prop-2-yn-1-amine (Scheme 27). 
 
Scheme 27. One step Synthesis of N3-Val-OAll (4e) and Boc-Gly≡ (8i). 
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The triazoles were synthesized via CuAAC in a mixture of DMF and water, stochiometric 
amounts of catalyst were required to drive the reaction to completion (Scheme 28). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28. The CuAAC at room temperature lead to several aliphatic and aromatic 1,4-
disubstituted triazoles as benzyl- and allylesters 18a-e in acceptable to good yields. 
 
The triazoles obtained above were selectively deprotected with either HCl in dioxane or 
hydrogenolytically, the oligomer synthesis was performed with carbodiimides as described 
for the 1,5-disubstituted triazole containing peptidotriazolamers (Scheme 29 and 
Scheme 30). 
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Scheme 29. Boc/Bzl solution phase synthesis of peptidotriazolamer heptamer 21. 
 
Scheme 30. Boc/Bzl solution phase synthesis of peptidotriazolamer heptamer 24. 
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4.3. Conformational analysis 
 
The conformational analysis of the peptidotriazolamers was done in collaboration together 
with the groups of Prof. Rafał Latajka and Prof. Iris Antes, by Dr. Jerzy Góra, Dr. Antoine 
Marión and Dr. Joanna Krzciuk-Gula,107 who recently developed an AMBER based force 
field parametrization for 1,4- and 1,5-disubstituted triazole containing peptides, based on 
the triazoles and peptidotriazoles we contributed.117 
The conformational analysis started with the tetra-peptidotriazolamer Boc-Val[5Tz]Ala-
Leu[5Tz]Val-OBzl (10) and its conformation in solid state, derived from its crystal structure 
(Figure 25). Obtained by dissolving the compound in EtOAc (1 mg/100 µL) and slow 
evaporation of the solvent overnight (CCDC 1561608).107 
 
Figure 25. Solid phase conformation of Boc-Val[5Tz]Ala-Leu[5Tz]Val-OBzl (10). 
 
The structure resembles a turn, induced by the 1,5-disubstituted triazoles and stabilized by 
an intramolecular hydrogen bond between the Boc carbonyl oxygen and the proton of the 
leucine amide bond, with a length of 2.08 Å.  
The crystal structure offered the possibility to validate the accuracy of the developed 
methodology, based on the specific TZLff molecular mechanics force-field 
parameterization of the 1,5-disubstituted triazole based peptidomimetics. A non-restrained 
simulated annealing of the compound in gas phase, starting from a random conformation 
and performed by Dr. Antoine Marion, lead to a conformation with a nearly identical 
backbone orientation as the X-ray analysis (Figure 27 and Table 3). 
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Table 3. Torsion angles of the tetramer 10 according to X-ray analysis and molecular 
dynamics simulation. 
Residue 
φn/c 
(X-ray / MD) 
ψn/c 
(X-ray / MD) 
Val1 -66.4(2)° / -66.28° 132.8(1)° / 130.86° 
Ala2 -112.2(2)° / -111.38° 39.8(2)° / 30.42° 
Leu3 -128.6(1)° / -131.03° 57.7(2)° / 57.14° 
Val4 -93.2(2)° / -100.35° - 
 
The torsion angles for the peptidotriazolamers are defined as followed, as the backbone 
differs from standard polypeptides (Figure 26). 
 
Figure 26. Defined torsion angles for this section of a peptidotriazolamer:  
φn= CO-NH-Cα-C5; ψn= NH-Cα-C5-N1; φc= C5-N1-Cα-CO; ψc= N1-Cα-CO-NH. 
 
The similarity of both structures is expressed by the root-mean square deviation (RMSD) 
value, which is a measure for the average distance between atoms and was determined as 
RMSD= 0.37 Å for the conformational overlay (Figure 27). 
 
Figure 27. Overlay between the X-ray structure (green) and MD-structure (magenta) of 
compound 10. 
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After demonstrating close agreement between X-ray analysis and the modelled 
conformation for the tetrameric peptidotriazolamer 10, the methodology was used for the 
analysis of the hexameric structures 11 and 13. 
 
A comparison of torsion angles for the 
homochiral compound 11 between the SA 
calculation (gas phase) and the distance 
restrained MD calculation in DMSO revealed a 
limited number of conformations for the MD 
run, which oscillate around the values obtained 
by the simulated annealing (Figure 28). This 
confirms that the modelled structure is in close 
agreement to the experimental data by 
validating that the initial set of NMR restraints 
enables a similar conformational behavior. 
 
 
 
The dihedral angles show close analogy to a βVIa1-turn (Table 4),118 in which the triazole 
backbone forms the centre and the sidechains are directed towards the solvent, this is also 
the case for the unrestrained MD simulations in water.107 
 
 
Table 4. Torsion angles for the representative structure of 11 observed during distance-
restrained MD in DMSO. 
 Ala1 Phe2 Val3 Ala4 Leu5 Val6 
φn/c -112.9° -92.6° -61.1° -108.5° -91.3° -166.0° 
ψn/c 62.8° 83.1° 123.9° 52.1° 99.2° - 
Figure 28. ψ/φ distribution for 11 
during distance restrained MD in 
DMSO (values for SA represented 
by black dots). 
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The structure is stabilized by an intramolecular 
hydrogen bond between the carbonyl oxygen of Phe2 
and the amide proton of Leu5 and shows close 
resemblance with its tetrameric precursor 10 
(Figure 29). Interestingly, deviating from peptide 
chains, were the common feature between VIa1, VIa2 
and VIb β turns is always a proline in position i+3,118 
this is not a shared requirement for our homochiral 
peptidomimetics, enabling the possibility to form a 
βVI turn with an addressable functionality in 
position i+3 as a unique feature. 
 
 
 
For the heterochiral peptidotriazolamer 13 less 
distance restraints were found from the ROESY-
NMR data (22 compared to 55 for compound 11), 
indicating a more extended conformation. This 
is supported by the fact that the Boc group is not 
involved in any distance restraints.107 The 
decreased amount of restraints and extended 
orientation allow for a wider variety of 
conformations for the sidechains and the 
terminal backbone, resulting in two additional 
basins at -160°/160° and 160°/-160° in the 
Ramachandran plot compared to the simulated 
annealing (Figure 30). 
 
 
 
Figure 29. Representative 
structures for 11 derived from 
clustering over the last 100 ns 
of distance-restrained MD in 
DMSO. 
Figure 30. ψ/φ distribution for 13 
during distance restrained MD in 
DMSO (values for SA represented 
by black dots). 
4. Results and Discussion 
 
 
- 53 - 
 
 
The representative structure obtained from restrained 
MD calculations in DMSO has similarities to left-
handed polyproline-I like helix, where the triazole 
rings are stacked on one site, and the residues are 
pointing towards the opposite direction (Figure 31 
and Table 5). In contrast to the homochiral 
compound, no intramolecular hydrogen bond is 
involved. 
 
 
 
 
 
 
Table 5. Torsion angles for the representative structure of 13 observed during distance-
restrained MD in DMSO. 
 
 Ala1 Phe2 Val3 Ala4 Leu5 Val6 
φn/c 145.6° -135.3° 84.3° -106.2° 92.9° -71.9° 
ψn/c -140.9° 151.8° -92.3° 43.0° -103.3° - 
 
Additionally, unrestrained MD calculations in DMSO and water were performed for both 
compounds, to extrapolate the behaviour in a more natural environment. Although the 
release of the constraints resulted in more degree of freedom and the sampling of new 
regions in the dihedral plot, the effect was more distinct for the heterochiral compound 
due to its lack of intramolecular stabilization, resulting in a slightly pronounced helix in 
water. The overall backbone conformation for both compounds are very similar to those 
obtained by NMR restraint calculations.107 
The conformational analysis for the 1,4-disubstituted triazole containing 
peptidotriazolamers 21 and 24 has not been finished yet, because of encountered 
aggregation effects, which aggravate the ROESY-NMR assignment. 
 
 
 
Figure 31. Representative 
structures for 13 derived from 
clustering over the last 100 ns 
of distance-restrained MD in 
DMSO. 
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4.4. Synthesis of propargylamines with functional side chains 
 
The propargylamines described and synthesized so far comprised of aliphatic residues, 
which are synthesized conveniently utilizing Ellman’s auxiliary, as described in Scheme 19 
which utilizes highly reactive lithium or Grignard organyls. 
For a practical synthesis of chiral propargylamines with protected functional sidechains 
the Bestmann-Ohira variation of the Seyferth-Gilbert homologation would be suitable.119 
This reaction converts aldehydes into terminal alkynes by a Wittig/HWE- related reaction 
at mild basic conditions (Scheme 12). The reaction has been improved in the application 
by an in situ formation of the dimethyl 1-diazo-2-oxopropyl-phosphonate (25) and 
following addition of the aldehyde, to generate the terminal alkyne 8 (Scheme 31 A).120, 121 
In 2004, Dickson et al. published an efficient two step one pot procedure, starting from 
Boc- protected amino acid methylesters or Weinreb amides 26, followed by in situ 
reduction with DIBAL-H and subsequent Bestmann-Ohira reaction to deliver chiral 
progargylamines (Scheme 31 B).52  
 
Scheme 31. Two examples of the Bestmann-Ohira reaction, where either the Bestmann-
Ohira reagent 25 or the aldehyde 27 is generated in situ. 
 
Although they claim that the reaction proceeds under mild conditions without loss of 
stereo information, if enolizable aldehydes are used, they are merely comparing the optical 
rotation values with former publications, which doesn’t account very precisely for partial 
epimerization.  
Applying the procedure of Dickson et al. starting with Boc-Phe-OMe and controlling the 
enantiomeric excess by chiral HPLC, Fröhr encountered partial epimerization to a 
changeable degree of ee= 16% and 52% after replication.104 Furthermore, after triazole 
formation by a cycloaddition with an α-azido acid, the obtained diastereomers were not 
separable from each other.  
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A recent publication from 2017 by the group of Evans describes partial epimerization as a 
general feature of the Bestmann-Ohira reaction.122 The chiral lability of urethane protected 
α-amino aldehydes in aldol or Wittig reactions is further documented in the literature.123  
Aliphatic protecting groups, which offer a positive inductive effect, might be used as a 
substitute for carbamates to decrease the acidity of the alpha proton. This issue was 
addressed by the group of Reetz124, 125 with the usage of N, N-dibenzyl aminoaldehydes, 
which are accessible and isolable aldehydes and configurationally stable at room 
temperature (Scheme 32).  
 
Scheme 32. Synthesis of dibenzyl protected α-amino aldehydes. Starting with the 
benzylation of free amino acids to N, N-dibenzyl amino benzylesters, which are reduced with 
LiAlH4 to the respective dibenzylated amino alcohols, followed by a Swern oxidation to 
obtain the aldehydes. 
 
These have been shown to react without loss of stereoinformation in several electrophilic 
reactions with organometal species, as well as aldol- and Wittig reactions.124, 125 However, 
since the benzyl group is cleaved hydrogenolytically, it cannot be cleaved on the 
propargylamine stage, which would result in a reduction of the triple bond. Furthermore, 
it would not be orthogonal to a benzylester in solution phase peptide synthesis.  
The required properties are provided with the application of the acid labile N-trityl group, 
which has been successfully used by Dellaria Jr. et al. to add the anion of dimethyl 
methylphosphonate to N-trityl-phenylalaninal, without any racemization of the C3-atom 
of the product (Scheme 33).126  
 
Scheme 33. The trityl protected phenylalaninal proved to be configurationally stable during 
nucleophilic attacks at basic conditions. 
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In a further publication they mention the comparison of the configurational stability of 
highly epimerization prone Boc-phenylalaninal, with N-trityl phenylalaninal, in presence 
of TEA in chloroform. The optical rotation did not change after 19 h, for the trityl protected 
aldehyde.127  
Since the addition of a phosphonate anion represents the first reaction step in the Seyferth-
Gilbert reaction, the trityl-group was used for the Bestmann-Ohira reaction as N-
protecting group (Scheme 34).  
 
Scheme 34. Synthesis of the Boc- and Fmoc-protected propargylamine (S)-33 and 34; 
a) LiAlH4 (2.0 eq), THF, 0°C 2 h, reflux, overnight; b) Trt-Cl (1.0 eq), TEA (2.0 eq), DCM, rt, 
overnight; c) Swern‘s procedure;53 d) p-ABSA (1.2 eq), DOP (1.2 eq), K2CO3 (3 eq), 
ACN/MeOH (5:1), rt, overnight; e) DCM/MeOH/TFA (2:1:1), rt, 30 min; f) Fmoc-OSu (1.1 eq), 
NaHCO3 (4 eq), THF/H2O (1:1), rt, overnight; g) i) Boc2O (2 eq), THF/H2O (1:1), K2CO3 (4 eq), 
rt, overnight; ii) imidazole (3 eq), rt, 30 min. 
 
Starting from H-Phe-OH, the phenylalaninol ((S)-28) can be obtained on multiple gram 
scale in good yields of 88% after reduction with LiALH4 and a simple extraction. On bigger 
scale, if desired, the inflammable LiAlH4 can also be exchanged by the NaBH4/I2-system.128  
For the trityl protection step it is worthwhile to mention, that only the amino group reacts 
with Trt-Cl, when used in equimolar ration and the less nucleophilic alcohol moiety 
remains unprotected. The trityl protected amino alcohol (S)-29 can be obtained in sufficient 
crude purity for the following Swern reaction, which likewise proceeds without side 
products. However, caution is advised concerning the high acid lability of the trityl group. 
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For the aqueous workup, a 10% citric acid solution is tolerated to remove residual free basic 
compounds, whereas commonly used dilute HCl or KHSO4 solutions lead to a partial 
deprotection. If column chromatography becomes necessary, although most of the side 
products and remaining reagents can be removed by aqueous workup and the quantitative 
reaction process can be monitored by TLC, adding 1 vol% TEA into the eluent is 
recommended.  
The Bestmann-Ohira reaction using dimethyl diazomethylphosphonate (25) according to 
the original procedure119 works in a very clean manner. On a bigger scale, the one-pot 
procedure was performed successfully, where the dimethyl diazomethylphosphonate is 
formed in situ.120 P-ABSA (35), which is considered a safe diazo-transfer reagent, was 
utilized instead of Tos-N3.129 However, compared to Tos-N3 it reacts more slowly, generally 
requiring stirring overnight, compared to the stated 2 h of the original procedure. The 
storable p-ABSA was synthesized on multi-gram scale from inexpensive starting materials 
(Scheme 35).129, 130 
 
Scheme 35. Synthesis of p-ABSA (35), starting from the sulfonyl-chloride via addition-
elimination mechanism with NaN3, the tert-butyl ammonium chloride serves as a phase 
transfer reagent. 
 
The Bestmann-Ohira reagent 25 was obtained as a green oil after column chromatography, 
starting from dimethyl 2-oxopropylphosphonate and using shelf-stable p-ABSA as a 
diazotransfer reagent in high yields of 82% in acetonitrile, utilizing K2CO3 as a mild base 
by stirring overnight (Scheme 36). 
 
Scheme 36. Synthesis of the Bestmann-Ohira reagent (25), utilizing p-ABSA and K2CO3 in 
acetonitrile at rt. 
 
This method avoids the usage of sodium hydride in dry THF, which is commonly used for 
the deprotonation of the activated methylene moiety,131, 132 followed by reaction with p-
ABSA. Another advantage is the convenient nature of a one-pot process. 
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However, utilizing trityl protected propargylamines (S)-31 in the RuAAC resulted in 
lacking conversion of the starting materials, which could be recovered after the failed 
reaction attempts. Therefore, the trityl group was cleaved with dilute TFA and methanol 
as a scavenger, followed by Boc- or Fmoc-protection without prior purification of the free 
amine. The Fmoc or Boc protected propargylamines (S)-33 and 34 were purified by a final 
column chromatography and obtained in acceptable yields. Comparing the Boc-protected 
enantiomer via chiral HPLC with the data obtained by Fröhr,104 we found it to be 
enantiomerically pure. 
The synthesis of the D-Phenylalanine analogue propargylamine (R)-33 was performed with 
the same method (Scheme 37). 
 
Scheme 37. Synthesis of the Fmoc-D-Phe≡ ((R)-33); a) LiAlH4 (2.0 eq), THF, 0°C 2 h, reflux, 
overnight; b) Trt-Cl (1.0 eq), TEA (2.0 eq), DCM, RT, overnight; c) Swern‘s procedure;53 d) p-
ABSA (1.2 eq), DOP (1.2 eq), K2CO3 (3 eq), ACN/MeOH (5:1), rt, overnight; e) DCM/ 
/TFA/TES (95:2.5:2.5), rt, 30 min; f) Fmoc-OSu (1.2 eq), NaHCO3 (4 eq), ACN/H2O (1:1), 
overnight. 
 
In contrast to the L-configured propargylamine, the column chromatography of the Trt 
protected propargylamine (R)-33 was skipped, which resulted in an overall yield of 32% 
over four steps after Fmoc protection and only a single column chromatography in total 
(averaging 77% per step starting from D-phenylalanine). 
Additionally, the possibility to apply this route for amino acids with functional side chains 
was investigated. Regarding solid phase peptide synthesis, a general method would be 
desirable, which converts commercially available Fmoc protected amino acids (bearing 
orthogonal sidechain protecting groups) into Fmoc protected propargylamines.  
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This was addressed utilizing trityl protected aminoaldehydes for Fmoc-Lys(Boc)-OH 
(Scheme 38). 
 
Scheme 38. a) Carboxylic acid reduction.133 CDI (1.3 eq), THF, rt, 10 min, NaBH4 (1.7 eq), 
THF/H2O, 0°C->rt, 30 min; b)  Fmoc cleavage.134 1-octanethiol (10 eq), DBU (3 mol%), THF, 
rt, 4 h; c) Trt-Cl (1.0 eq), TEA (3.0 eq); d) Swern oxidation53; e) p-ABSA (1.2 eq), DOP (1.2 eq), 
K2CO3 (3.0 eq), ACN/MeOH (5:1), rt, overnight; f) DCM/TFA/MeOH (92.5:2.5:5); g) Fmoc-
OSu (1.2 eq), NaHCO3 (4.0 eq), H2O/THF (1:1), rt, overnight. 
 
Due to the N-terminal Fmoc group, or ester protecting groups for several sidechain 
functionalities, a reduction of the weinrebamide with DIBAL-H, as described by Dickson 
et al., is not feasible. Cleavage of the Fmoc-group followed by reduction of the carboxylic 
acid with LiAlH4 under reflux condition, as in the case of the phenylalanine, would also 
lead to cleavage of most sidechain protecting groups. A convenient protocol of Hwang et 
al.133 which converts the carboxylic acid with CDI into an activated acylimidazole and 
subsequently reduce it under mild conditions with NaBH4 into the Fmoc- protected 
aminoalcohol 36 was used. Alternatively, an activation with DCC and N-
hydroxysuccinimide, followed by NaBH4 reduction would be feasible, as demonstrated by 
Jadhav et al.135  
In terms of product isolation in solution phase the cleavage of the Fmoc group is not as 
straightforward as for its solid phase pendant, where the free amine is immobilized on solid 
phase and the dibenzofulvene-adduct can be simply washed off. A procedure from 
Sheppeck II et al.134 which cleaves the Fmoc group with catalytic amounts of DBU and uses 
thiols to trap the dibenzofulvene, followed by removing the dibenzofulvene-thiol adduct 
by trituration with petroleum ether, was used. The free amine remains as a colourless oil 
in sufficient crude purity.  
The subsequent trityl protection is performed utilizing equimolar ratios of Trt-Cl, leaving 
the remaining hydroxyl group unprotected 37. The propargylamine 38 is formed by a 
Bestmann-Ohira reaction of the trityl protected aminoaldehyde, which is obtained by a 
previous Swern oxidation.  
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Overall the Fmoc-protected propargylamine 39 was obtained in 13% yield, starting from 
Fmoc-Lys(Boc)-OH over seven steps (averaging 75% per step), utilizing just two column 
chromatographies. A possible improvement might be the application of polymer bound 
thiols, which would improve the execution of the Fmoc deprotection, by avoiding the 
trituration step and possibly, lead to improved yields at this step. 
A further development and alternative to the trityl group is the phenyl fluorenyl (Pf) group, 
introduced in the 1980s.136 The Pf group resembles the trityl group but is up to 6000 times 
more solvolytically stable towards acids and has been proven to effectively prevent 
racemization of α-amino acid derivatives in enantiospecific synthesis. However, 
stochiometric amounts of lead are required for the introduction of the Pf group 
(Scheme 39). 
 
Scheme 39. The Pf group can be introduced to amino acid esters and silylesters. The lead 
forms a salt with the bromide to enhance its leaving group capability. 
 
The Pf group is commonly cleaved hydrogenolytically or under strong acidic conditions. 
Depending on the situation, it could be used with benzyl or allyl type sidechain protecting 
groups. 
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4.5. KLVFF aggregation inhibitors 
 
After establishing reliable and convenient procedures for the synthesis of 
peptidotriazolamers, this concept of peptidomimetics should be investigated in a biological 
context.  
Based on the publication of Arai et al.,137  who synthesized several derivatives of the 
KLVFF-sequence and quantified their ability to inhibit Aβ aggregation by ThT-
fluorescence assay, several peptidotriazolamers were synthesized. The L[5Tz]V dipeptide 
isoster 18e was already synthesized during the conformational analysis part of this 
dissertation. The propargylamines based on Phe 33 and 34 were synthesized utilizing trityl 
protected phenylalaninal in the Bestmann-Ohira reaction, as described in Scheme 34 and 
Scheme 37. Additionally, the Fmoc protected propargylamine Fmoc-Leu≡ (8j) and Fmoc-
D-chGly≡ (8k) were synthesized, for a convenient application on solid phase, starting from 
the sulfinyl protected alkyne 7f and 7g (Scheme 40). 
 
Scheme 40. Sunfinyl cleavage and Fmoc introduction. a) 4 M HCl in dioxane (3.0 eq), MeOH, 
rt, 30 min; b) Fmoc-OSu (1.2 eq), NaHCO3 (4.0 eq), H2O/THF (1:1), overnight. 
 
With the azides and N-protected propargylamines available, CuAAC and RuAAC reactions 
were performed, which lead to additional different triazole dipeptide isosters in good yields 
(Figure 32). 
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Figure 32. Several 1,4- and 1,5 disubstituted triazoles, mimicking LV and FF dipeptides, 
where successfully synthesized by either CuAAC or RuAAC in good to excellent yields. 
 
The yield for the Fmoc-protected Fmoc-Phe[4Tz]Phe-OBzl (18g) turned out to be lower, 
which can be explained due to its poor solubility in the aqueous  reaction mixture and the 
(PE/EtOAc) eluent mixture utilized for the column chromatography. Interestingly, this was 
not the case for the 1,5-disubstituted triazole and seemed to be a unique feature of its 1,4-
disubstituted regioisomer. 
The connection between both dipeptide mimetics L[Tz]V and F[Tz]F and a commercially 
available lysine should be tied by a peptide bond, which would result in our desired 
repetitive pattern of peptide bonds and triazoles. The Boc protected triazoles were 
deprotected at the C-terminus, using the established hydrogenolysis procedure: dissolving 
the triazole in EtOH and cleaving the benzylester with 1 atm of hydrogen in presence of 
catalytic amounts of Pd/C. After a simple filtration through a short silica plug, the Boc 
protected free acids were obtained in analytically pure form. 
Although the Fmoc group is widely considered as orthogonal towards hydrogenolysis 
conditions,138 we encountered partial deprotection of the Fmoc group, applying this 
procedure to the Fmoc protected triazoles. Further examples of this undesired deprotection 
can be found in the literature.139 Maegawa et al. published the hydrogenolysis of the Fmoc 
group as a novel additional deprotection method,140 which is accelerated in the presence 
of acetonitrile. 
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A Pd/C catalysed transfer hydrogenation with triethylsilane, as published by Mandal et 
al.,141 proved as a suitable and mild method (Scheme 41), avoiding the necessity to change 
the protection group strategy to Fmoc/tBu. The reaction involves the in situ generation of 
H2, which results in reduction of multiple functional groups (azides, imines, nitro groups, 
benzyl groups, allyl groups, unsaturated carbon bonds) by explicitly leaving the Fmoc 
group intact. Notably, the reaction cleaves benzyl groups as well as allyl groups, implying 
the formation of molecular hydrogen, as well as highlighting the hydride donor capability 
of the silane. 
 
Scheme 41. The TES induced benzylester cleavage reaction consists of a Pd catalysed 
transfer hydrogenation, resulting in quantitative cleavage of a benzylester in presence of the 
N-terminal Fmoc group. 
 
Standard Fmoc-SPPS protocols on Rink-amide and Barlos resin, as well as solution phase 
Boc/Bzl peptide synthesis were used for the generation of the compound library, in which 
triazoles were used as dipeptide isosters.  
Oxyma was preferred as a coupling additive over the benzotriazoles, as it results in better 
solubility of the Fmoc protected active esters in DCM. 
The peptidotriazolamers H-Lys-Leu[5Tz]Val-chGly[5Tz]Phe-OH (42a) and H-Lys-
Leu[5Tz]Val-Phe[5Tz]Phe-OH (42b) were synthesized in solution, with minimal excess of 
activated carboxylic acid (Scheme 42 and Scheme 43). The cyclohexyl containing oligomer 
42a was synthesized as an alternative to the usual benzyl residue, as the propargylamine 
is readily available by the Elmman route. Cbz-Lys(Cbz)-OH was utilized for the 
peptidotriazolamer 42b on the last coupling step, which offers the convenient option to 
cleave all protecting groups at once by hydrogenolysis. 
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Scheme 42. Synthesis of H-Lys-Leu[5Tz]Val-chGly[5Tz]Phe-OH (42a) by solution phase 
peptide synthesis, employing COMU and using triazoles as dipeptide mimetics. 
 
Scheme 43. Synthesis of H-Lys-Leu[5Tz]Val-chGly[5Tz]Phe-OH (42b) by solution phase 
synthesis, using DIC/Oxyma mediated preactivation and successive coupling step with sym-
collidine as a base. 
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Based on the publication of Arai et al.137 we were also interested in a cyclic compound, 
which has generally additional proteolytic stability and potentially improved 
pharmacophoric properties. It should be composed of 1,5-disubstituted triazoles, which 
might facilitate the cyclisation through their turn inducing properties. 
The synthesis was once again performed by orthogonal Boc/Bzl chemistry, and based on 
the linear precursor Cbz-Lys(Boc)-Leu[5Tz]Val-Phe[5Tz]-OBzl (45) (Scheme 44). 
 
Scheme 44. Synthesis of a cyclic peptidotriazolamer 42c. PyBOP was utilized for the 
cyclization step, to prevent capping of the free N-terminus. 
 
The three-step reaction starting from the linear precursor 45 could be monitored by 
analytical HPLC and worked with full conversion for all steps (Figure 33).  
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Figure 33. Chromatogram section displaying the reaction process of Scheme 44. Starting 
with the purified protected linear precursor 45 (red), the debenzylated product (blue) is 
obtained in pure form after hydrogenolysis and lyophilization. Cyclization is performed with 
full conversion (green, the chromatogram represents the reaction control, also displaying 
the excess of sym-collidine). After evaporation and lyophilization, 46 is deprotected to yield 
42c (violett), which is finally purified by preparative HPLC. 
 
The cyclization under diluted conditions of 1 mM effectively prevented the formation of 
dimers or oligomers. PyBOP was utilized as a coupling reagent for the cyclization to 
prevent a common chain-termination reaction by guanidinylation of the free N-terminus, 
observed with uronium reagents.  
The peptidotriazolamers with a C-terminal primary amide function were synthesized on 
solid phase, utilizing a polystyrene based Rink amide resin (Figure 34). 
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Figure 34. The Peptides were assembled by Fmoc SPPS. The activated amino acids are 
obtained in a separate flask, by preactivation with DIC/Oxyma in DCM for 5-10 min. The 
final peptide can be obtained by cleavage through concentrated TFA. 
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This lead to the following additional peptides and peptidomimetics 42d-I, which were 
analysed in their ability to inhibit Aβ-fibrillization in a ThT fluorescence assay, by Dr. 
Kaffy from the group of Prof. Ongeri (Figure 35). 
 
Figure 35. Peptides and Peptidotriazolamers which were obtaind by SPPS, utilizing Rink 
amide and 2-CTC resins. 
 
The N-methylated peptide SEN304 with the sequence H-D-[chGly-Tyr-chGly-chGly-
(NMe)Leu]-NH2,142, 143 published by Kokkoni et al. in 2006 as a potent Aβ aggregation 
inhibitor, was chosen as a second lead structure. 
To stay as close to the original sequence as possible, the N-methylated amide bond between 
chGly and Leu was preserved, which leaves the positions one and three for a triazole 
replacement (Figure 36). Although, an exchange of the methylated amide bond with a 1,5-
disubstituted triazole would be feasible, since N-alkylated amide bonds populate the cis 
configuration more readily. 
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Figure 36. Comparison between SEN304 and its peptidomimetic H-D-[chGly[4Tz]Tyr-
chgGly[4Tz]chGly-(NMe)Leu]-NH2 (42j). 
 
Since 1,4-disubstituted triazoles were chosen for this peptidomimetic and the CuAAC is 
compatible with free carboxylic acids, the azides of N3-D-chGly-OH (4f) and N3-D-Tyr(tBu)-
OH (4g) were prepared in their unprotected forms with the original procedure of Lundquist 
et al..65 Insteadt of the column chromagraphy applied for the compounds 4a-e, the 
procedure consists of an aqueous workup (Scheme 45). 
 
Scheme 45. Synthesis of chiral azido acids. 
 
The aqueous slurry of the reaction mixture is diluted with phosphate buffer (pH 6.2) and 
extracted with EtOAc (4x). Since the carboxylic acid has a pKa between 4-5, it stays 
deprotonated and in theory, remains in the aqueous phase, while the sulfonamide 
(pKa~6.4)144 remains protonated and is removed by repeated organic washing steps. 
Afterwards the aqueous phase is acidified to pH 2 and the product extracted with EtOAc. 
The yields are significantly lower than for the benzylester protected azides 4a-e.  Reasons 
for this might be the loss of product during the organic washing steps at pH=6.2, arising 
from an increased organic solubility due to the large hydrophobic residues. A column 
chromatography might be an alternative leading to improved yields, utilizing an eluent 
with 1% of AcOH as for the following triazoles 18h and 18i. The azides were employed in 
CuAAC reactions to yield Fmoc protected 1,4-disubstituted triazoles with free C-termina 
for subsequent coupling reactions (Scheme 46). 
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Scheme 46. CuAAC with the free α-azido acids 4f and 4g lead to 1,4-disubstituted triazoles 
18h and 18i in good yields; a) Sodium ascorbate (1.0 eq), CuSO4.5H2O (0.5 eq), DMF/H2O 
(2:1), rt, 1-2 days. 
 
The solid phase synthesis was initiated with a quantitative loading of the Rink amide resin 
with Fmoc-D-Leucine and cleavage of the Fmoc group. The synthesis was continued with 
N-methylation according to the Chatterjee et al.145 and coupling of the triazoles 18h and 
18i with DIC/Oxyma/sym-collidine, followed by Fmoc deprotection and cleavage of the 
peptide with concentrated TFA. After precipitation with cold ether and purification by 
preparative HPLC the peptide was obtained in 14% yield (Scheme 47). 
 
Scheme 47. a) Fmoc-D-Leu-OH (1.5 eq), Oxyma (1.65 eq), DIC (1.65 eq), DCM/DMF (1:1), rt, 
overnight; b) 20% piperidine in DMF; c) Methylation according to Chatterjee et al.145; d) 
Fmoc-D-chGly[4Tz]-D-chGly-OH (1.5 eq), Oxyma (1.65 eq), DIC (1.65 eq), DCM/DMF (1:1), 
rt, overnight; e) Fmoc-D-chGly[4Tz]-D-Tyr(tBu)-OH (1.5 eq), Oxyma (1.65 eq), DIC (1.65 eq), 
DCM/DMF (1:1), rt, overnight; f) 20% piperidine in DMF; g) TFA/H2O/TIS (95:2.5:2.5). 
 
The synthesized KLVFF mimetics were evaluated in their ability to inhibit early stage 
aggregation and later stage fibrillization of Aβ, using a Thioflavin-T and BODIPY 
fluorescence assay. These were performed by Dr. Julia Kaffy and Dr. Nicolo Tonali. 
Since Aβ is self-aggregating over time, depending on purification and preparation 
protocols of the monomeric Aβ stock solution, the initial aggregation rate (lag phase) and 
kinetics may vary substantially, the comparison of fluorescence intensity values between 
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different publications is therefore problematic. A cautious comparison between 
fluorescence measurements can be achieved after identical preparations of the Aβ stock 
solution, however, it should include a control measurement with just Aβ and another one 
with the test compound to verify the integrity of the test.  
The results of the ThT-fluorescence assays are shown below (Figure 37a-j). 
 
 
 
H-KLVFF-OH (42d) H-klvff-OH (42h) 
 
 
 
 
H-KLVFF-NH2 (42e) 
 
 
 
 
H-klvff-NH2 (42f) 
4. Results and Discussion 
 
 
- 72 - 
 
 
 
 
H-KL[5Tz]V-chGly[5Tz]F-OH (42a) 
 
 
 
H-KL[5Tz]VF[5Tz]F-OH (42b) 
 
 
 
 
Ac-KL[5Tz]VF[5Tz]F-NH2 (42i) 
 
 
 
 
Ac-KL[4Tz]VF[4Tz]F-NH2 (42g) 
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cyclo-[KL[5Tz]VF[5Tz]F] (42c) 
 
 
H-D-[chGly[4Tz]Tyr-chGly[4Tz]chGly-
(NMe)Leu]-NH2 (42j) 
 
 
Figure 37a-j. Depicted is the ThT fluorescence progression over time, which is proportional 
to the amount of formed Aβ fibrils. Starting with a lag-phase, representing early stage 
oligomers which are not monitored by the ThT dye and ending in a plateau at which the 
fibillization process is finished. All graphs share the same color code. Legend: [black: Aβ 
(10 µM); red: compound (100 µM); blue: compound (10 µM)/Aβ (10 µM) (1:1); green: 
compound (100 µM)/Aβ (10 µM) (10:1)]. In case of multiple measurements, the arithmetic 
average curve is given, complemented with the standard error of the mean.  
 
The insignficant activity of H-KLVFF-OH (42d) to inhibit Aβ, although considered as a 
lead structure for development of novel Aβ inhibitors, is quite surprising but was also 
described by Arai et al..137 In agreement to their structure-activity relationship studies, the 
activity is greatly increased for the D-configurated peptide H-klvff-OH (42h), which 
decreases fibril formation by half after 40 h when applied in a tenfold excess, equimolar 
ratios compared to Aβ show a slight decrease of the slope during the aggregation phase. 
The activity for both peptides increases, when the carboxylic acid is exchanged with a 
terminal carboxamide, leading to a peptide which completely shuts down Aβ fibril 
formation in tenfold excess with H-klvff-NH2 (42f).  
The peptide Ac-KLVFF-NH2 (not synthesized in this work, but used as a comparison 
standard by the group Prof. Ongeri)146 is comparable in its activity to H-klvff-OH, leading 
to half the amount of fibrils after 40 h (plateau decrease of 46% after 40 h),146 if utilized in 
a tenfold excess. 
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From the studies with the native peptides, it can be concluded that the D-form is always 
more active then the L-form, this also applies for the terminal carboxamide in comparison 
to the carboxylic acid, also an acetylated N-terminus seems to be advanteous. 
Unfortunately, the exchange of amide positions two and four, with either 1,4- or 1,5 
disubstituted triazoles, generally decreases its activity. As can be seen most drastically by 
a comparison of Ac-KLVFF-NH2 with Ac-KL[4Tz]VF[4Tz]F-NH2 (42g) and Ac-
KL[5Tz]VF[5Tz]F-NH2 (42i), where the latter one even increases amyloid fibril formation 
at an equimolar ratio. This effect was also pronounced with two other 1,5-disubstituted 
triazole containing peptidomimetics, H-Lys-Leu[5Tz]Val-chGly[5Tz]Phe-OH (42b) and the 
cyclic derivative cyclo-[KL[5Tz]VF[5Tz]F] (42c).  
The SEN304 analogue H-D-[chGly[4Tz]Tyr-chGly[4Tz]chGly-(NMe)Leu]-NH2 (42j) on the 
other hand, which bears the 1,4-disubstituted triazoles at position one and four, showed a 
good activity. Considering the fluorescence increase arising from the compound by itself, 
a tenfold excess completely inhibits Aβ fibril formation, while an equimolar ratio 
approximately decreases it by half after 40 h. A comparison with SEN304 was not 
performed, however, the authors describe a ~85% decreased fluorescence intensity 
(compared to Aβ control) utilizing equimolar ratios in a ThT assay after 24 h,142, 143 which 
is comparable to our results for the peptidotriazolamer 42j.  
Figure 38 shows the results of the BODIPY measurements for 42j, confirming a good 
inhibition of Aβ early stage oligomerization in equimolar ratios and ten-fold excess. 
 
Figure 38. Representative curves of BODIPY fluorescence assays over time showing 10 μM 
Aβ42 oligomerization in the absence (black curve) and in the presence of compound 42j at 
compound/Aβ42 ratios 10/1 (green curve) and 1/1 (blue curve). 
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For this particular measurement, the control measurement with just the compound at 
100 µM was not performed. However, earlier BODIPY measurements have shown that 42j, 
in the absence of Aβ, does not increase fluorescence as it does during the ThT assay. 
So far, the results from the ThT fluorescence assay imply that the triazole does not serve 
as a generic substitute for amide bonds. Reasons for this could be deviations in space 
between 1,4-disubstituted triazoles and a trans-amide bonds, as well as the weak hydrogen 
bond donor capabilities of the triazole, which might pose a crucial factor for the interaction 
with Aβ at the given position.  
The 1,5-disubstituted regioisomer generally leads to a fixed turn in the peptide chain, 
which apparently disagrees with the concept of β-sheet recognition and binding sequence. 
However, Soto et al. reported about short synthetic peptides designed as beta sheet 
breakers (BSB) which purposely contain a proline moiety.147 In this approach the peptide 
contains a sequence alike or similar to the beta sheet rich abnormal region of the deposits, 
it is able to recognize this region and prevent pathologic conformational changes by 
destabilizing the Aβ oligomers.148 The BSB-peptide Soto developed with the sequence 
LPFFD was based on the hydrophobic L17VFF20 sequence of Aβ and contains, beside the 
proline, an aspartate to increase solubility. As it turned out, besides inhibition of Aβ 
fibrillogenesis, the peptide showed the ability to disassemble already formed fibrils in vitro 
and reduces Aβ deposition in a rat brain model. Therefore, the carefully selected 
substitution of an amide bond with a 1,5-disubstituted triazole may pose an interesting 
approach towards novel BSB-peptides.  
To address the unsatisfactory activity of the peptidotriazolamers in a methodical manner 
and to identify essential amide bonds, a triazole scan could be performed. In analogy to an 
alanine scan, which is widely used to identify essential residues in a peptide, the four amide 
bonds in the KLVFF sequence could be one by one replaced by a 1,4-disubstited triazole, 
giving four different peptides.  
The synthesis of the necessary propargylamine for lysine was successfully addressed in 
our working group by Wünsch et al. utilizing Ellman’s auxiliary.62 Also, the Bestmann-
Ohira reaction with trityl protected α-amino aldehydes yielded Fmoc-Lys(Boc)≡ (39) in 
good yields (Scheme 38).  
Considering the activity-relationship of the native KLVFF peptides discussed above, also 
the synthesis of Ac-kl[4Tz]vf[4Tz]f-NH2 and Ac-k[4Tz]lv[4Tz]ff-NH2 would be promising. 
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4.6. Cyclic RGD peptidomimetics 
 
Since the 1,5-disubstituted triazole, incorporated into a peptide sequence, effectively 
enables cyclization of pentapeptides (as demonstrated for the cyclic peptidotriazolamer 
42c), cyclic RGD peptidomimetics based on cilengitide (cyclo-[Arg-Asp-Gly-D-Phe-
(NMe)Val]) ought to developed. The N-methylated amide group should be replaced with a 
1,5-disubstituted triazole, although Marelli et al. have shown that no cis peptide bonds are 
observed in the NMR structures of cilengitide.149  
As for the synthesis of cilengitide, the linear precursor was synthesized on solid phase, 
followed by a cyclization in solution.150 The solid phase synthesis was done, utilizing 2-
chloro trityl resin, whose mild cleavage conditions allows the synthesis of side chain 
protected peptides.151 The loading was performed with Fmoc-Arg(Pmc)-OH, to avoid the 
necessity to perform the loading with a triazole, which might result in decreased loading 
yields and loss of triazole material. In case of the second cyclic peptide 48b, with just one 
triazole moiety, the loading could also begin with Fmoc-Gly-OH, to prevent racemization 
during the cyclization step, or side reactions between the guanidino group and the 
activated acid. But it was performed in analogy to the first peptide 48a (Scheme 48). 
 
Scheme 48. Synthesis of the protected linear precursors 47 and 49 was performed on solid 
phase, the cyclization was done in solution under diluted conditions, to prevent the 
formation of oligomers. 1) sym-collidine (10 eq), PyBOP (1.5 eq), DCM/DMF (1:1), 1 mM; 
2) Reagent “R”: TFA/thioanisole/1.2-ethanedithiol/anisole (90:5:3:2). 
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The synthesis of the D-Phenylalanine analogue propargylamine (R)-33 was performed as 
previously described, employing the Bestmann Ohira reaction with trityl protected α-
amino aldehydes (Scheme 37). 
The Fmoc protected glycine analogue propargylamine 8k was synthesized out of 
commercially available prop-2-yn-1-amine, through Fmoc protection with Fmoc-OSu 
(Scheme 49), providing Fmoc-Gly≡ (8k) in 71% yield. The benzylester protected azide of 
aspartate 4f was synthesized, starting from Fmoc-Asp(tBu)-OH, following esterification 
with Bzl-Cl (thus avoiding activation of the carboxylic acid and possible epimerization of 
the alpha carbon), Fmoc deprotection with piperidine and subsequent diazotransfer, to 
obtain N3-Asp(tBu)-OBzl (4f) in 23% over three steps. 
The RuAAC between both compounds yielded Fmoc-Gly[5Tz]Asp(tBu)-OBzl (9m)  in 74% 
(Scheme 49). 
 
Scheme 49. Synthesis scheme for the triazole Fmoc-Gly[5Tz]Asp(tBu)-OBzl, starting from 
Fmoc-Asp(tBu)-OH and prop-2-yn-1-amine. 
 
The RuACC between Fmoc-D-Phe≡ ((R)-33) and N3-Val-OBzl (4a) yielded Fmoc-D-
Phe[5Tz]Val-OBzl (9n) in 87% yield (Scheme 50). 
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Scheme 50. Synthesis of Fmoc-D-Phe[5Tz]Val-OBzl (9n) by RuAAC. 
 
After deprotection of the benzylester, using the procedure of Mandal et al.141 (Scheme 41), 
the Fmoc protected triazoles could be used for the solid phase peptide synthesis. 
Additionally, the synthesis of a functionalizable cyclic peptidomimetic would be 
interesting, which could be used in a prodrug application. Because the Val residue is not 
essential for the activity of cilengitide, it should be replaceable with an azidobutyl residue. 
Since the azide moiety would interfere with the N-terminal azido group during the RuAAC, 
the sidechain azido group must be introduced after the initial cycloaddition (Scheme 51). 
The synthesis was started with with H-Lys(Z)-OBzl.HCl, the analogue azide (4d) was 
synthesized in 87% yield by diazotransfer with Tf-N3. The RuAAC was performed with 79% 
yield, delivering triazole 9o. The combination of Cbz group and benzylester offers a 
convenient deprotection of both protecting groups in one step, using the TES mediated 
cleavage conditions of Mandal et al., which does not affect the Fmoc group. A final 
diazotransfer yielded the desired dipeptide-isoster 53, for the solid phase synthesis, in 58% 
yield. The conditions for the final diazotransfer were based on a publication of Yan et al.68 
which utilizes triethylamine as a base in acetonitrile in combination with triflyl azide, 
which was estimated to be more compatible with the Fmoc group. 
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Scheme 51. Synthesis of an azidobutyl containing triazole 53, suitable for solid-phase 
peptide synthesis. 
 
The triazole was utilized in SPPS to obtain the linear protected sequence in quantitative 
yields from a 2-chloro trityl resin in sufficient crude purity, after loading Fmoc-Arg(Pmc)-
OH with 70% yield to the resin (Scheme 52). 
 
Scheme 52. After cleavage of the linear precursor 54 from the resin, the peptide was 
cyclyzed in solution followed by a cleavage of acid labile protecting groups.  1) sym-collidine 
(10 eq), PyBOP (1.5 eq), DMF/DCM (1:1) 0.1 mM;  
2) Reagent “R”: TFA/thioanisole/1.2-ethanedithiol/anisole (90:5:3:2). 
 
Reagent “R” was chosen as a cleaving cocktail, which is specifically developed for peptides 
containing arginine with sulfonyl based protecting groups. Although the reaction progress 
could be monitored by HPLC and went with full conversion, the final peptide could be only 
isolated in 13% yield.  
The literature reveals substantial reduction of azide moieties during acidic cleavage, 
utilizing cleavage cocktails containing thiol scavengers.152 While cocktails lacking EDTE 
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have no influence on the artificial building block, this might explain the decreased yield 
compared to the cyclic peptides 48a and 48b. 
The cyclic peptidomimetics 48a-c were tested in their antagonistic properties towards 
αvβ3, compared to cilengitide as a standard, by Isabell Kemker from our workgroup. A cell 
adhesions assay, developed by Conradi et al.153 and an ELISA-based solid phase assay, 
developed by the group of Kessler, were used.154 The peptides 48a-b (48c not tested) 
showed no antagonistic activity towards αvβ3 in the cell adhesion assay (IC50>500 µM). 
However, the peptides 48b and 48c (48a not tested) showed a good activity in the cell free 
ELISA assay with an IC50 value of 19.7 and 18.6 nM, by comparison measurements with 
cilengitide (0.54 nM) against αVβ3 (Figure 39).  
 
Figure 39. Dose response curve of 48b and 48c, the IC50 is determined as molar concentration at 
50% inhibition. 
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5. Summary  
 
In the scientific field of peptidomimetics and medicinal chemistry, the disubstituted 1,2,3-
triazole evolved to be a promising surrogate for amide bonds, as they share 
physicochemical properties like a strong dipole moment, planarity, as well as hydrogen 
donor/acceptor ability. The popularity is supported by the circumstance, that both 
regioisomers of the triazole are selectively accessible by either copper(I) (CuAAC) or  
ruthenium(II) (RuAAC) catalysed azide alkyne cyloaddition, where the former leads to 1,4-
disubstituted and the latter to 1,5-disubstituted triazoles. 
We were interested in the synthesis and conformational behaviour of oligomeric 
peptidotriazolamers, consisting of amides and triazoles in an alternating fashion. 
Additionally, the influence of the configuration on the conformation of the oligomers was 
investigated by comparison of homochiral and heterochiral peptidotriazolamers. 
Oligopeptidotriazolamers were prepared by a building block approach in solution, 
exploiting the orthogonality of the Boc/Bzl protecting group pair (Scheme 53). In this 
approach, C-terminal deprotected triazoles are coupled onto the growing oligomeric chain 
in N-terminal direction, giving rise to different peptidotriazolamers in various lengths. 
 
Scheme 53. The peptide coupling of a triazole as a dipeptide isoster onto the growing 
oligomeric chain, leads to peptidotriazolamers in various lengths. 
 
For the synthesis of triazole building blocks, enantiomerically pure propargylamines and 
α-azido acids are required. The α-azido acids 4a-e, 4h were prepared by a diazotransfer 
employing Tf-N3 based on Luindquist et al.65 and benzyl-/allylester protected amino acids 
(Val, Ala, Phe, Lys(Boc) and Asp(tBu)) in excellent yields of 71-98% after column 
chromatography. When the procedure was performed with unprotected amino acids (H-
D-chGly-OH, H-D-Tyr(tBu)-OH), the aqueous workup lead to yields of 36% (4f) and 26% 
(4g). The chiral propargylamines were synthesized as described by Xiao et al. Ellman’s 
chiral auxiliary was condensated with aliphatic aldehydes bearing the desired sidechain 
(isobutyl, isopropyl, methyl, cyclohexyl) as a residue, to form N-sulfinylaldimines. They 
were reacted with in situ generated ((trimethylsilyl)ethynyl)lithium to give sulfinyl 
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protected propargylamines in high diastereomeric purity. The butylsulfinyl group was 
cleaved off under acidic conditions and exchanged by an urethane based protecting group 
to prevent disproportionation at elevated temperatures. The yields for the synthesis steps 
are given in Table 6. 
Table 6. Yields of intermediates in the synthesis of N-protected propargylamines. The yields 
for the Bus protected propargylamines entail two steps (acetylide addition and TMS 
cleavage), likewise the Boc and Fmoc protected species (Bus cleavage and urethane 
introduction). 
 
   
 
 
 
 
R = (R) (S) (R, R) (S, S) (R) (S) (R) (S) 
Methyl 6a (81%) 6b (80%) 7a (49%) 7b (46%) 8a (85%) 8b (61%) - - 
Isopropyl 6c (90%) 6d (71%) 7c (45%) 7d (67%) 8c (90%) 8d (56%) - - 
Isobutyl 6e (79%) 6f (93%) 7e (46%) 7f (52%) 8e (94%) 8f (82%) - 8j (71%) 
Cyclohexyl 6g (93%) 6h (46%) 7g (71%) 7h (60%) 8g (84%) 8h (86%) 8k (43%) - 
 
Additionally, the propargylamine analogues of phenylalanine and lysine were synthesized 
by the Bestmann-Ohira homologation. However, urethane protected α-amino aldehydes 
turned out to partially epimerise. Utilizing the electron donating trityl protecting group 
for α-amino aldehydes, the corresponding propargylamines were obtained in high 
enantiomeric purity (Scheme 54). Since they failed to give any conversion in the RuAAC 
they were reprotected with urethane groups like Boc or Fmoc. 
 
Scheme 54. The trityl protected α-amino aldehydes are obtained in high yields after 
oxidation of the corresponding α-amino alcohols and turned out to be enantiomerically 
stable under the basic reaction conditions of the Bestmann-Ohira homologation. 
 
The RuAAC was performed under MW conditions, giving rise to several 1,5-disubstituted 
triazoles in high yields after 1-2 h reaction times. The CuAAC was performed at room 
temperature overnight, providing 1,4-disubstituted triazoles (Table 7).  
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Table 7. 24 different triazoles were synthesized in good yields by RuAAC and CuAAC. 
 
Boc protected                                                                            Fmoc protected 
[5Tz] 
Boc-Val[5Tz]Ala-OBzl 
(9c) (84%) 
Boc-D-Val[5Tz]Ala-OBzl  
(9f) (88%) 
Fmoc-D-Phe[5Tz]Val-OBzl  
(9n) (87%) 
 
Boc-Leu[5Tz]Val-OBzl 
(9e) (81%) 
Boc-D-Leu[5Tz]Val-OBzl 
(9d) (87%) 
Fmoc-D-Phe[5Tz]Lys(Cbz)-OBzl 
(9o) (79%) 
 
Boc-Ala[5Tz]Phe-OBzl 
(9a) (87%) 
Boc-D-Ala[5Tz]Phe-OBzl 
(9b) (94%) 
Fmoc-Phe[5Tz]Phe-OBzl  
(9l) (92%) 
 
Boc-chGly[5Tz]Phe-OBzl 
(9h) (87%) 
Boc-D-chGly[5Tz]Phe-OBzl  
(9i) (86%) 
Fmoc-Leu[5Tz]Val-OBzl 
(9k) (75%) 
 
Boc-Phe[5Tz]Phe-OBzl 
(9j) (75%) 
Boc-Ala[5Tz]Ala-OBzl  
(9g) (77%) 
Fmoc-Gly[5Tz]Asp(tBu)-OBzl  
(9m) (74%) 
[4Tz] 
Boc-D-Val[4Tz]Phe-OBzl 
(18a) (67%) 
Boc-D-Leu[4Tz]Phe-OBzl 
(18b) (60%) 
Fmoc-D-[chGly[4Tz]chGly]-OH  
(18i) (72%) 
 
Boc-Gly[4Tz]Phe-OBzl 
(18d) (88%) 
Boc-Gly[4Tz]Val-OAll  
(18e) (81%) 
Fmoc-D-[chGly[4Tz]Tyr(tBu)]-OH 
(18h) (82%) 
 
Boc-D-Leu[4Tz]Val-OAll 
(18c) (81%) - 
Fmoc-Leu[4Tz]Val-OBzl  
(18f) (91%) 
  - - 
Fmoc-Phe[4Tz]Phe-OBzl  
(18g) (69%) 
 
The Boc/Bzl protected 1,5-disubstituted triazoles were selectively deprotected by either 
HCl in dioxane or by palladium catalysed hydrogenolysis. The deprotected triazoles were 
obtained in quantitative yields and sufficient crude purity for the successive peptide 
coupling steps. However, the triazole dipeptide isosteres proved themselves to be highly 
prone to epimerization. This issue could be prevented by performing the coupling reactions 
in DCM, or a mixture of DCM/DMF of (1:1), with sym-collidine as a base. A carbodiimide 
mediated preactivation in DCM, followed by a sym-collidine facilitated coupling step, was 
finally favoured (Figure 40). 
The X-ray crystal structure of the homochiral tetramer Boc-Val[5Tz]Ala-Leu[5Tz]Val-OBzl 
(10) displayed close resemblance to a βVIa1 turn, which is stabilized by an intramolecular 
hydrogen bond between the Boc carbonyl oxygen ((CH3)3C-CO) and the amide proton of 
the leucine (NH-Cα,i+3), with a length of 2.08 Å. Additionally, the solid state conformation 
was supported by comparison with the gas phase structure obtained by simulated 
annealing, which match closely with a RMSD of 0.37 Å.  
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Figure 40. Boc/Bzl protected 1,5-disubstituted triazole containing peptidotriazolamers were 
synthesized in solution. Yields are given for the final coupling step. 
 
The close analogy to a βVIa1 turn is preserved after elongation of the sequence to Boc-
Ala[5Tz]Phe-Val[5Tz]Ala-Leu[5Tz]Val-OBzl (11), demonstrated by molecular modelling 
implying ROESY restraints. On the other hand, the heterochiral compound Boc-D-
Ala[5Tz]Phe-D-Val[5Tz]Ala-D-Leu[5Tz]Val-OBzl (13) was shown to resemble a 
polyproline I reminiscent helix, where the triazoles show in the opposite direction than 
the residues.  
Additionally, peptidotriazolamers based on 1,4-disubstituted triazoles were synthesized. 
These oligomers comprise of a heterochiral residue alignment and an alternating pattern 
of a chiral residue and a methylene moiety (Figure 41). The conformational analysis was 
not finished for these peptidotriazolamers because of encountered aggregation effects in 
solution. 
 
Figure 41. Boc/All protected 1,4-disubstituted triazole containing peptidotriazolamers were 
synthesized in solution. Yields are given for the final coupling step. 
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To investigate the peptidotriazolamers in a biological application, different 1,5- and 1,4-
disubstituted triazole containing peptidotriazolamers were synthesized in solution and on 
solid phase, representing the KLVFF sequence (Figure 42). These novel lead compounds 
were investigated in their ability to inhibit neurotoxic Amyloid-β aggregation, which is 
responsible for neurodegenerative diseases, by ThT and BODIPY assays.  
 
Figure 42. Linear and cyclic peptidomimetics based on the sequence KLVFF. 
 
While the triazole containing KLVFF peptidomimetics lack the activity of their derived 
peptides, the SEN304 analogue 42j turned out to completely inhibit Aβ fibrillization and 
early stage oligomerization in an equimolar ratio and tenfold excess compared to Aβ.  
Based on the RGD-peptide cilengitide three cyclic peptidomimetics were successfully 
synthesized in which the N-methylated peptide bond was replaced by a 1,5-disubstituted 
triazole (Figure 43). Additionally, 48c contains an azidobutyl residue for additional 
functionalization, which makes it readily available for a prodrug application. While the 
peptidomimetics 48a and 48b failed to show any affinity (IC50>500 µM) in a cell adhesions 
assay, 48b and 48c showed a comparable nanomolar antagonistic activity against αVβ3 in 
an ELISA assay, with an IC50 of 19.7 and 18.6 nM. 
 
Figure 43. Cyclic peptidomimetics based on cilengitide containing one or two 1,5-
disubstituted triazoles. The yields refer to the cyclization and deprotection of the linear 
sequence after SPPS. 
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6. Outlook 
 
The results of the presented work may lay the principles and foundations for the design of 
future triazole containing peptidomimetics. The elaborated synthetic methods for the 
synthesis of enantiomerically pure propargylamines as valuable precursors for a wide 
variety of scaffolds, as well as solution and solid phase strategies for the obtainment of 
peptidotriazolamers, have been shown to be highly variable and robust.   
The ability of 1,5-disubstituted triazole containing peptidotriazolamers to mimic β-turns 
and polyproline like helices, might represent a starting point to discover further biological 
applications. The direction of rotation might be additionally changed by an inversion of all 
stereo centres. The conformations of the 1,4-disubstituted triazole containing 
peptidotriazolamers Boc-Ala-D-Val[4Tz]-Phe-D-Leu[4Tz]-Phe-D-Leu[4Tz]-Val-OAll (21) 
and Boc-Ala-Gly[4Tz]-Phe-Gly[4Tz]-Phe-Gly[4Tz]-Val-OAll (24) still need to be confirmed 
by molecular modelling. Additionally, the conformation of Boc-Ala[5Tz]Ala-Ala[5Tz]Ala-
OBzl (15), obtainable by molecular modelling, would give an insight if the conformational 
behaviour is controlled by the sequence of residues, or the combination of stereochemistry 
and triazole regioisomery. 
While a cis- amide bond in nature is mainly facilitated by a proline in the sequence, the 
1,5-disubstituted triazole enables the possibility to mimic a cis- peptide bond with the 
benefit of adding an extra residue in that position. That residue might contribute to 
important interactions with a protein backbone or enzymatic pocket. For clarification, Tam 
et al. identified Xaa-Pro to be efficiently mimicked by Xaa[5Tz]Ala.45 However, the alanine 
moiety in the triazole might be readily exchanged with an α-azido acid bearing a functional 
group and thereby, the triazole would still mimic a cis- peptide bond.  
Although it was shown that trityl protected α-aminoaldehydes are far less prone to 
racemization during the conditions of the Bestmann-Ohira reaction, starting from Fmoc- 
protected amino acids, the synthesis route contains a lot of steps resulting in overall low 
yields (Scheme 38). The Fmoc deprotection134 might be facilitated with the usage of 
polymer-bound thiol groups to conveniently scavenge the dibenzofulven followed by 
removal through filtration. Alternatively, starting with N-Cbz/tBu(side-chain) protected 
amino acids would be feasible, which would effectively give rise to free amino alcohols 
after two steps, without elaborate workup or purification procedures. 
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In the topic of Aβ aggregation inhibitors, a further peptide sequence which comes to mind 
is the modified Soto peptide Ac-LPFFD-NH2, which might be modified into Ac-
Leu[5Tz]Ala-Phe-Phe-Asp-NH2 as the closest analogue.147 Practically, the synthesis of the 
precursors Fmoc-Leu≡ (8j) and N3-Ala-OBzl (4a) was already presented in this dissertation. 
This would be an interesting model peptide for the incorporation of the 1,5-disubstituted 
triazole, since the other peptidomimetics synthesized so far, based on the KLVFF sequence 
containing 1,5-disubstituted triazoles, were inactive in inhibiting Aβ-fibrillization. The 
synthesis of Fmoc-Lys(Boc)≡ (39) in this work offers the possibility to perform a triazole 
scan of the Ac-KLVFF-NH2 sequence, or more promising, its enantiomer Ac-klvff-NH2, to 
spot crucial amide bonds. 
For the active RGD peptidmimetics 48b and 48c, it would be necessary to test them with 
other integrine receptors, for example αIIbβ3, to quantify the selectivity towards αvβ3. 
Further, the functionalizable peptide 48c might be conjugated by “click-chemistry” with a 
variable linker, bearing a fluorophore or cytotoxic agent, followed by cell-based 
cytotoxicity assay. This could be done to determine the selectivity of the conjugate, 
between cells, which are highly abundant in certain integrins and cells which are not. 
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7. Experimental section 
 
All chemicals were purchased from Sigma Aldrich (Taufkirchen, Germany), Acros (Geel, 
Belgium), Alfa Aesar (Ward Hill, USA) and VWR (Darmstadt, Germany), Chempur 
(Karlsruhe, Germany), Iris Biotech (Marktredwitz, Germany), Bachem (Bubendorf, 
Switzerland) and were employed without additional purification. Moisture- and air-
sensitive reactions were conducted in flame-dried glassware and under argon atmosphere. 
Dichloromethane and toluene were freshly distilled from CaH2 and Na, respectively. THF 
was kept over KOH before being dried with sodium/benzophenone under reflux and was 
freshly distilled before use. 
 
Analytical RP-HPLC was performed on a Thermo Separation Products system equipped 
with a UV-6000 LP detector, a P-4000 pump, a Hypersil Gold 3 µm (C18; 150∙2.1 mm) 
column. A flow rate of 0.7 ml/min using Eluent A: H2O/CH3CN/TFA (94.9/5.0/0.1) and 
Eluent B: CH3CN/ H2O/TFA (94.9/5.0/0.1) was employed. Gradient Elution: (A, method 1) 
0-0.5 min (100%), 0.5-7.5 min (100% to 0%), 7.5-8.5 min (0%), 8.5-9.5 (0% to 100%), 9.5-10 min 
(100%). Gradient Elution: (A, method 2) 0-3 min (100% to 0%), 3-4 min (0%), 4-5 min (0%-
100%). Gradient Elution: (A, method 3) 0-18 min (100% to 0%), 18-19 (0%), 19-20 min (0%-
100%). 
 
Preparative RP-HPLC was performed on a Hitachi MERCK LaChrom system equipped 
with a UV-Vis L-7420 detector, a L-7150 pump and a Phenomenex Jupiter 10 µm column 
(C18; 300 Å, 250×21.1 mm). A flow rate of 10.0 ml/min using Eluent A: H2O/CH3CN/TFA 
(94.9/5.0/0.1) and Eluent B: CH3CN/H2O/TFA (94.9/5.0/0.1) was employed. Gradient 
Elution: (A, method 2) 0-35 min (100% to 0%), 35-45 min (0%), 45-50 min (0% to 100%). 
 
Optical rotation ([𝛼]𝐷
25, deg∙cm3∙g-1∙dm-1) was measured on a Jasco DIP-360 Digital 
Polarimeter at λ=589 nm. A quartz cell with a path length of 1 dm was used. The average 
value of ten single measurements is given. The sample concentration and solvent are 
mentioned in parentheses. 
 
NMR spectra were recorded at 298 K on a DRX 500 (1H: 500 MHz, 13C: 126 MHz), an Avance 
III 500 (1H: 500 MHz, 13C: 126 MHz) and an Avance 600 spectrometer (1H: 600 MHz, 13C: 
151 MHz) (Bruker Biospin, Rheinstetten, Germany). Chemical shifts are reported relative 
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to residual solvent peaks (DMSO-d6: 1H: 2.50 ppm, 13C: 39.52 ppm), (CDCl3: 1H: 7.26 ppm, 
13C: 77.16 ppm), (CD3OH-d3: 1H: 3.31 ppm, 13C: 49.00 ppm).155 
 
ESI/APCI mass spectra were recorded using an Esquire 3000 ion trap mass spectrometer 
(Bruker Daltonik GmbH, Bremen, Germany) equipped with a standard ESI/APCI source. 
Samples were introduced directly with a syringe pump. Nitrogen served both as the 
nebulizer gas and the dry gas. Nitrogen was generated using a Bruker nitrogen generator 
NGM 11. Helium served as cooling gas for the ion trap and collision gas for MS 
experiments.  
 
High-resolution ESI mass spectra are recorded using an Agilent 6220 time-of-flight mass 
spectrometer (Agilent Technologies, Santa Clara, CA, USA) in extended dynamic range 
mode equipped with a Dual-ESI source, operating with a spray voltage of 2.5 kV. Nitrogen 
served both as the nebulizer gas and the dry gas. Nitrogen was generated by a nitrogen 
generator NGM 11. Samples are introduced with a 1200 HPLC system consisting of an 
autosampler, degasser, binary pump, column oven and diode array detector (Agilent 
Technologies, Santa Clara, CA, USA) using a C18 Hypersil Gold column (length: 50 mm, 
diameter: 2.1 mm, particle size: 1.9 µm) with a short gradient (in 4 min from 0% B to 98% 
B, back to 0% B in 0.2 min, total run time 7.5 min) at a flow rate of 250 µL/min and column 
oven temperature of 40°C. HPLC solvent A consists of 94.9% water, 5.0% acetonitrile and 
0.1% formic acid, solvent B of 5.0% water, 94.9% acetonitrile and 0.1% formic acid. The mass 
axis was externally calibrated with ESI-L Tuning Mix (Agilent Technologies, Santa Clara, 
CA, USA) as calibration standard. The mass spectra are recorded in both profile and 
centroid mode with the Mass Hunter Workstation Acquisition B.04.00 software (Agilent 
Technologies, Santa Clara, CA, USA). Mass Hunter Qualitative Analysis B. 07.00 software 
(Agilent Technologies, Santa Clara, CA, USA) was used for processing and averaging of 
several single spectra. 
 
X-Ray structure analysis of the crystals where obtained by dissolving the respective 
compound in EtOAc, MeOH, or iPrOH (1 mg/mL), followed by slow evaporation of the 
solvent overnight at room temperature. 
A suitable crystal was transferred to an object slide, containing a drop of paraffin-oil and 
taken up by a glas-fiber. The measurements were done using Cu Kα radiation with a 
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Supernova diffractometer at 100.0(1) K. Using Olex2156 the structures were solved and 
refined with the ShelX program package157 with direct methods and least-squares 
minimization. All atoms were refined anisotropically except hydrogen atoms, which were 
placed in calculated positions and reﬁned using a riding model. Absolute configuration of 
all structures could be established by anomalous-dispersion effects in diffraction 
measurements on the crystal. One CH3-group in each molecule of 9d is discorded at two 
positions (ratio 76/24), one of them was restrained to have same C-C distances. Details of 
the X-ray investigation are given section 8. X-ray analysis.  
 
Molecular modelling experiments were performed by Dr. Jerzy Góra and Dr. Joanna 
Krzciuk-Gula (Department of Bioorganic Chemistry, Wroclaw University of Science and 
Technology) as well as Dr. Antoine Marion (Department of Chemistry, Middle East 
Technical Unitersity, Çankaya) and David Schröder (Organic and Bioorganic Chemistry, 
Department of Chemistry, University of Bielefeld) as described by Marion et al.117 
The preparation of the systems and all molecular mechanics (MM) calculations were 
carried out using modules of the Amber16/AmberTools16 suite.158 Peptidotriazolamer 
building blocks and protecting group parameters were adopted from the TZLff force 
field.117 The distance restraints used during molecular dynamics (MD) calculations were 
obtained from the analysis of ROESY spectra measured in DMSO on a Bruker 600 MHz 
spectrometer and calculated based on the Intensity-Ratio Method described by Ämmälahti 
et al.159 All distances were restrained using a half-harmonic potential with a force constant 
of 32.0 kcal∙mol-1∙Å-2 (Amber force constant convention) for the upper boundary of the 
distance, while breaking of the lower limit was permitted. The upper boundary was set as 
+10% of the measured distance. Initially, all restraints derived from the spectra were 
applied. Restraints that broke an arbitrary penalty threshold (value of penalty > 
5.0 kcal∙mol-1) during simulated annealing (SA) were removed from the calculations to 
produce the final set of constraints. This approach allowed to keep a large amount of 
constraints without introducing unnecessary strain on the system that could have been 
caused by assignment of distance restraints based on ROESY peaks with dubious 
volumetric data. The final sets of distance restraints are presented in the Supporting 
Information (Tables SI 2, SI 3).107 The SA protocol consisted of six heat-ing (0 K to 10 K in 
50 ps; 10 K to 100 K in 50 ps; 100 K to 200 K in 100 ps; 200 K to 300 K in 100 ps; 300K to 400 
K in 100 ps; 400 K to 600 K in 100 ps) and six cooling stages (600 K to 400 K in 100 ps; 400 
K to 300 K in 100 ps; 300 K to 200 K in 100 ps; 200 K to 100 K in 75 ps; 100 K to 10K in 20 
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ps; 10 K to 0 K in 5 ps) using a 1 fs time step. The temperature during the simulation was 
controlled by a Langevin thermostat with 2.0 ps-1 collision frequency. The weight of the 
distance restraints was gradually increased over the first 150 ps of the simulations from an 
initial value of 10% to 100%, which persisted for the remainder of the SA run. Structures 
resulting from SA were solvated using tleap in truncated octahedron boxes with a 15 Å 
buffer consisting of DMSO or TIP4PEw water. The minimization of the solvated systems 
was carried out using standard settings of sander. During the first part of the minimization 
the position of the solute except for its hydrogen atoms was restrained by a harmonic 
potential with a force constant of 3.0 kcal∙mol-1∙Å-2. These restraints were released during 
the final stages of minimization. The heat-up of the systems to the target temperature of 
300 K was performed in a stepwise manner. First in the NVT ensemble (from 0 K to 200 K) 
using the Langevin thermostat,160 and in NPT conditions (from 200 K to 300 K) using the 
Berendsen barostat.161 All systems reached the expected density of 0.98 g/cm3 and 
1.10 g/cm3 for TIP4Pew water and DMSO, respectively. All molecular dynamic (MD) 
production runs were carried out for 200 ns with a 2 fs time step in the NPT ensemble with 
periodic boundary conditions and using Amber’s standard pre-sets of the Particle Mesh 
Ewald method. Three types of MD runs were produced for each molecule: unrestrained 
MD in DMSO162 and TIP4PEw163 water and restrained MD in DMSO using the previously 
established NMR-derived sets of distance restraints.  
 
The ThT fluorescence assays were performed by Dr. Julia Kaffy (Fluorinated Molecules 
and Medicinal Chemistry, Department of Chemistry, Université Paris-Sud) as described by 
Kaffy et al.164 Thioflavin T was obtained from Sigma. Aβ42 was purchased from American 
Peptide. The peptide was dissolved in an aqueous 1% ammonia solution to a concentration 
of 1 mM and then, just prior to use, was diluted to 0.2 mM with 10 mM Tris-HCl, 100 mM 
NaCl buffer (pH 7.4). Stock solutions of compounds were dissolved in DMSO with the final 
concentration kept constant at 0.5% (v/v). Thioflavin T fluorescence was measured to 
evaluate the development of Aβ42 fibrils over time using a fluorescence plate reader 
(Fluostar Optima, BMG labtech) with standard 96-well black microtiter plates. Experiments 
were started by adding the peptide (final Aβ42 concentration equal to 10 µM) into a mixture 
containing 40 µM Thioflavin T in 10 mM Tris-HCl, 100 mM NaCl buffer (pH 7.4) with and 
without the tested compounds at different concentrations (100 and 10 µM) at room 
temperature. The ThT fluorescence intensity of each sample (performed in triplicate) was 
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recorded with 440/480 nm excitation/emission filters set for 42 hours performing a double 
orbital shaking of 10 s before the first cycle. 
 
The BODIPY fluorescence assays were performed by Dr. Nicolo Tonali (Fluorinated 
Molecules and Medicinal Chemistry, Department of Chemistry, Université Paris-Sud) as 
described by Tonali et al.165 BODIPY was obtained from the synthesis described in 
literature. Aβ42 was purchased from Bachem. Milli-Q system was used to purify water that 
was used throughout this work. Stock solutions of the BODIPY dye for spectroscopic 
measurements and for time-dependent kinetics were prepared in EtOH (0.0428 mM) and 
subsequently diluted into the PBS buffer (5.3 μM). The peptide was prepared, following the 
procedure B. Stock solutions of compounds were dissolved in DMSO (20 mM) and later 
diluted in PBS buffer to reach three different concentration (400 μM, 40 μM and 4 μM). 
BODIPY fluorescence was measured to evaluate the development of Aβ42 oligomers over 
time using a fluorescence plate reader (Fluostar Optima, BMG labtech) with standard 96-
well black microtiter plates. Experiments were started by adding the peptide (final Aβ42 
concentration equal to 10 µM) into a mixture containing 0.53 µM BODIPY in 20 mM buffer 
(pH 7.4) with and without the tested compounds at different concentrations (100, 10 µM 
and 1 μM) at 25°C. The BODIPY fluorescence intensity of each sample (performed in 
triplicate) was recorded with 518/540 nm excitation/emission filters set for 9 hours 
performing a double orbital shaking of 10 s before the first cycle. The curves are provided 
as the average curves of the triplicate with error bars (+/- standard error) for each 
measured point (every 10 min). The ability of compounds to inhibit Aβ1-42 aggregation 
was assessed considering the time of the half-life of aggregation (t1/2), the intensity of the 
experimental fluorescence plateau (F) and the slope of the linear part of the curve. The t1/2 
extension is defined as the experimental t1/2 in the presence of the tested compound relative 
to the one obtained without the compound and is evaluated as the following percentage: 
t1/2 (Aβ42+compound) – t1/2 (Aβ42) / t1/2 (Aβ42) Χ 100. The F reduction is defined as the 
intensity of experimental fluorescence plateau observed with the tested compound relative 
to the value obtained without the compound and is evaluated as the following percentage: 
(FAβ42+compound – FAβ42) / FAβ42 Χ 100. The slope variation, that is correlated with 
the rate of the oligomerization process, was calculated by fitting the linear part of the curve 
between 0 and 4 hours by RMSD regression. The slope variation is defined as the slope of 
experimental linear curve observed with the tested compound relative to the value 
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obtained without the compound and is evaluated as the following percentage: 
(SlopeAβ42+compound – SlopeAβ42) / SlopeAβ42 Χ 100. 
 
The cell adhesions assay was performed as previously described by Conradi et al.153 by 
Isabell Kemker (Organic and Bioorganic Chemistry, Department of Chemistry, University 
of Bielefeld). Competition assays were performed with WM-115 human epithelial cancer 
cells. Therefore, WM-115 cells were cultivated to a confluence of 70 %, detached with 
Trypsin-EDTA (0.05 %/0.02 % in D-PBS) (PAA, Pasching, Austria), washed with MEM 
medium, resuspended in MEM medium with 1 mg∙mL-1 fluorescein diacetate (Sigma-
Aldrich, St. Louis, USA) to a cell density of 1∙105 cells∙mL-1, and incubated at 37 °C under 
steady shaking for 30 min. Subsequently, cells were washed two times with MEM medium, 
resuspended with MEM medium containing divalent cations Ca2+ and Mg2+ (2 mM) to 
obtain a cell density of 1∙105 cells∙mL-1 and incubated in the dark on ice for 30 min. For the 
cell adhesion assay CagLWT was immobilized on a Nunc MaxisorpTM surface and WM-115 
cells pre-incubated with varying concentrations of vitronectin were dispensed to the 
immobilized CagLWT. Likewise, WM-115 cells were pre-incubated with different CagLWT 
concentrations before adding to immobilized vitronectin (1 mg∙mL-1). The cell suspension 
was added to the peptide solutions to give concentrations ranging from milimolar to 
nanomolar and incubated 30 min at 37 °C. It was then dispensed on the coated microtiter 
plate (5∙104 cells∙well–1) and incubated for 1 h at 37 °C. Unbound cells were aspirated and 
bound cells were washed twice with MEM medium. Fluorescence was measured 
(lex= 485 nm; lem= 514 nm) in an InfiniteTM 200 Microplate Reader (Tecan, Männedorf, 
Switzerland). IC50 values (50 % cell binding inhibition) of the tested peptides were 
evaluated with the GraphPad Prism 4.03 software (GraphPad, San Diego, USA). In cell 
adhesion assays the murine monoclonal antibodies LM609 (EMD Millipore, Billerica, USA) 
against human integrin αvβ3, 3S3 (AbD Serotec, MorphoSys AG, Germany) against β1 
integrin, and P1F6 (EMD Millipore, Billerica, USA) against αvβ5 were used in final 
concentrations of 25 mg∙mL-1. The assay was performed as described above. Instead of 
staining the cells with fluorescein diacetate, they were washed with Puck’s salt solution 
(5.4 mM KCl, 0.4 mM KH2PO4, 5.6 mM D-glucose, 136 mM NaCl, 2 mM MgCl2, 2 mM 
MnCl2), fixed for 30 min at rt using 5 % (w/v) glutaraldehyde, and stained with crystal 
violet 1 % (w/v) in 100 mM MES (pH 6.0) over 60 min at rt. After a second washing step 
with Puck’s salt solution, 100 mM citric acid in ethanol was added and the cells were 
incubated 30 min at rt for visualization. Absorption at 485 nm and emission at 514 nm was 
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measured using the Tecan M200 Microplate Reader and the data was processed with Origin 
(Dose-Response). 
 
ELISA-assay was performed by Isabell Kemker (Organic and Bioorganic Chemistry, 
Department of Chemistry, University of Bielefeld) according to the previously reported 
protocol166 as adapted by Kapp et al.167, using coated extracellular matrix proteins and 
soluble integrins. Cilengitide (cyclo[RGDf(NMe)V]) was used as an internal standard for 
αvβ3 (0.54 nM). Flat-bottom 96-well Immuno Plates (BRAND, Wertheim, Germany) were 
coated overnight at 4 °C with human vitronectin (1.0 mg∙mL-1, 100 mL per well, R&D) in 
carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). Each well was then washed 
with PBS-T-buffer (phosphate-buffered saline/Tween20, 137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, 0.01 % Tween20, pH 7.4; 3 x 200 mL) and blocked for 1 h 
at room temperature with TS-B-buffer (Tris-saline/BSA buffer, 150 mL/well, 20 mM Tris-
HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, pH 7.5, 1 % BSA). In the 
meantime, a dilution series of the compound and internal standard was prepared in an 
extra plate, starting from 2000 mM to 7.1 nM (reference compound 20 mM to 0.43 nM) in 
1:5 dilution steps. After washing the assay plate three times with PBS-T (200 mL), 50 ml of 
the dilution series was transferred to each well from B–G. Well A was filled with 100 ml 
TSB-solution (blank) and well H was filled with 50 ml TS-B-buffer. 50 ml of a solution of 
human αvβ3-integrin (2.0 mg∙ml-1, R&D) in TS-B-buffer was transferred to wells H–B and 
incubated for 1 h at rt. The plate was washed three times with PBS-T buffer, and then the 
primary antibody (2.0 mg∙mL, mouse anti-human CD51/61, BD Biosciences, 100 mL per 
well) was added to the plate. After incubation for 1 h at rt, the plate was washed three 
times with PBS-T. Then, the secondary peroxidase-labeled antibody (1.0 mg∙mL-1, anti-
mouse IgG-POD, Sigma-Aldrich, 100 mL/well) was added to the plate and incubated for 
1 h at rt. After washing the plate three times with PBS-T, the plate was developed by quick 
addition of SeramunBlau (50 mL/well, Seramun Diagnostic GmbH, Heidesee, Germany) 
and incubation until a colour gradient was visible. The reaction was stopped with 3 M 
H2SO4 (50 mL/well), and the absorbance was measured at 450 nm with a plate reader 
(Tecan Reader). The IC50 of each compound was tested in duplicate, and the resulting 
inhibition curves were analyzed using OriginPro 2017G (32-bit) SR1 software. The 
inflection point describes the IC50 value. All determined IC50 were referenced to the activity 
of the internal standard Cilengitide (0.54 nM). 
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7.1. General Procedures 
 
GP1: Condensation of tert-Butanesulfinamide with aliphatic aldehydes. Performed as 
described by the group of Ellman,168 utilizing CuSO4 as Lewis acid or the MgSO4 / PPTS 
pair. We found both procedures to work equally well and used them interchangeable. The 
analytical data was consistent with Wünsch et al.62 
GP2: -Azido Acids. The synthesis of -azido acids was performed based on the 
publication of Pelletier and Wong, without the customized workup for free carboxylic 
acids.64, 65 NaN3 (1.78 g; 27.4 mmol) is dissolved in H2O (4.5 mL) and DCM (7.5 mL), the 
solution is cooled to 0 °C. Tf2O (930 µL; 1.56 g; 5.53 mmol) is added dropwise at RT and 
stirring is continued for 2 h. The DCM phase is removed in a separatory funnel and the 
aqueous phase is extracted with DCM (2x4 mL). The combined organic phases, containing 
the Tf-N3, are pooled and washed with saturated Na2CO3 solution (15 mL). Caution: The 
Tf-N3 is used without further purification or concentration as a solution in DCM. The 
amino acid benzylester salt (2.79 mmol) and K2CO3 (1.55 g; 11.2 mmol; 4.0 eq) are 
suspended in H2O (9 mL) and tBuOH (18 mL). Cu(II)SO4.5H2O (1 mol%; 7 mg; 0.03 µmol) is 
added, followed by dropwise addition of Tf-N3 solution (15 mL). The reaction mixture is 
left to react overnight. Afterwards the tBuOH is removed in vacuum, the aqueous slurry is 
diluted with brine (10 mL) and extracted with DCM (3 × 10 mL), the combined organic 
phases are dried over MgSO4 and concentrated in vacuum. The crude azide is purified by 
column chromatography (PE/EtOAc 10:1). 
GP3: Bus Cleavage and Boc Introduction. The N-sulfinyl propargylamine is dissolved in 
MeOH (0.1 M) and 4M HCl in dioxane (3 eq) is added dropwise. Once TLC indicates 
complete deprotection (15-30 min), the crude HCl salt of the amine is obtained by 
concentrating the solution in vacuum. The residue is dissolved in H2O/THF (1:1) (0.1 M), 
NaHCO3 (4.0 eq) and Boc2O (2.0 eq) are added portion-wise and the reaction mixture is 
stirred overnight. Imidazole (2.0 eq) is added and stirring is continued for 1 h. The reaction 
mixture is diluted with EtOAc and washed with 0.5 M aqueous HCl (3x), brine (1x) and 
dried over MgSO4. If necessary, the Boc protected propargylamine can be purified by flash 
silica chromatography (PE/EtOAc 10:1). 
GP4: RuAAC. The Boc protected propargylamine (1.0 eq) and the azide (1.1 eq) are 
dissolved in dry THF under an argon atmosphere to give a 0.5 M solution. Cp*RuCl(COD) 
(3-5 mol%) is added and the reaction mixture stirred for 1-2 h under microwave irradiation 
(60 °C, 20 W). Once TLC indicates a full conversion of the propargylamine, the solvent is 
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removed under vacuum and the triazole purified by column chromatography (PE/EtOAc 
2:1). 
GP5: Hydrogenolysis of Boc-protected Benzyl esters. The benzyl ester protected triazole 
is dissolved in EtOH (0.05 M), Pd/C (20 wt%) is added and H2 (balloon, 1 atm) is passed 
through the solution for 1-2 h via cannula. Once TLC indicates full conversion of the 
starting material, the solution is filtered through a short plug of silica, which is washed 
several times with EtOH. The filtrate is concentrated under vacuum and lyophilized to 
obtain the free acid, which is used without further purification for the coupling step. 
GP6: Hydrogenolysis of Fmoc-protected Benzyl esters. The cleavage was performed 
according to a publication of Mandal et al.141 The filtrate is concentrated under vacuum 
and lyophilized to obtain the free acid, which is used without further purification for the 
coupling step. 
GP7: Bus Cleavage and Fmoc Introduction. The tert-butyl sulfinamide protected 
propargylamine (1.0 eq) is dissolved in MeOH (0.1 M) and 4 M HCl in dioxane (3.0 eq) is 
added dropwise. After TLC indicates a full conversion of the starting material, usually 
between 15-30 min, the reaction mixture is concentrated under vacuum to obtain the crude 
hydrochloride-salt. THF/H2O 1:1 (0.1 M) is added, followed by Fmoc-OSu (1.2 eq) and 
NaHCO3 (4 eq) and the reaction mixture is left to react overnight. The solvent is evaporated 
under vacuum and the crude dissolved in EtOAc, washed with 5% aqueous KHSO4-solution 
(3x), saturated NaHCO3-solution (3x) and brine (1x), dried over MgSO4 and concentrated 
under vacuum. The Fmoc protected propargylamine is purified by column 
chromatography. 
GP8: Nucleophilic addition of lithium (trimethylsilyl)acetylide. Performed as described by 
Xiao et al.,61 utilizing Ti(OiPr)4 as a lewis acid in THF. The analytical data was found to be 
consistent with Wünsch et al.62 
GP9: Solid phase peptide synthesis. The loading of the 2-chloro trityl resin was performed 
as described by Barlos et al.151 Loading of the rink-amide resin was performed as followed: 
swelling of the resin is performed in DMF (10 mL/g of resin) for 30 min, deprotection of 
the Fmoc group is performed with 20% piperidine in DMF (10 mL/g of resin) for 15 min 
and 30 min, with DMF washing steps in between. The amino acid or triazole (1.0 eq) is 
dissolved in DCM (5 mL/g of resin) and Oxyma or HOAt (1.1 eq) is added, followed by DIC 
(1.1 eq) with a preactivation time of 10 min. During the preactivation time, DMF (5 mL/g 
of resin) is given to the resin, followed by sym-collidine (10 eq). Afterwards, the 
preactivated acid in the DCM solution is given to the resin for a final ratio of DMF/DCM 
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(1:1), followed by stirring overnight.  Remaining amine functions are capped by the 
addition of acetic anhydride (10 eq) and stirring for 30 min. For determination of the 
loading, 1 mg of loaded and dried resin is placed into a 1 cm quartz cuvette with 3 mL of a 
20% piperidine solution in DMF. The absorption is measured at 290 nm which correlates 
with the amount of formed piperidine-dibenzofulven adduct. As a reference, the 20% 
piperidine in DMF solution is used. The loading is determined with Formula 1,169 in which 
“A” is the absorbance at 290 nm and “m” is the amount of weighted resin.  
                                             𝐋𝐨𝐚𝐝𝐢𝐧𝐠 =  𝐀
𝐦∗𝟏,𝟔𝟓
 [𝐦𝐦𝐨𝐥 ∙ 𝐠−𝟏]             (Formula 1) 
Fmoc deprotection: The loaded resin is mixed with a 20% piperidine in DMF solution 
(10 mL/g of resin, containing 0.1 M HOBt) and shaken for 15 and 30 min, with DMF 
washing steps in between. Afterwards the resin is washed (10 mL/g of resin): DMF (5x), 
DCM (3x), MeOH (1x), Et2O (1x). 
Coupling: The amino acid or triazole (1.5 eq) is dissolved in DCM (5 mL/g of resin), Oxyma 
or HOAt (1.65 eq) is added followed by DIC (1.65 eq). The mixture is stirred 10 min for 
preactivation. During the preactivation time, the resin is mixed with DMF (5 mL / g of 
resin). Sym-collidine (10 eq) is added to the resin, followed by the preactivated acid in the 
DCM solution for a final ratio of DMF/DCM (1:1), followed by stirring overnight. 
Afterwards the resin is washed (10 mL/g of resin): DMF (3x), DCM (3x), MeOH, Et2O. If 
desired, the coupling can be verified by Kaiser test.170  
 
 
 
 
 
 
 
 
 
 
 
CCDC 1561604 to CCDC 1561608 contain supplementary crystallographic data for this 
dissertation already published107 that can be obtained free of charge from The Cambridge 
Crystallographic Data Centre at www.ccdc.cam.ac.uk/data_request/cif  
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7.2. Synthesis results 
 
Benzyl (S)-2-Azido-3-methylbutanoate (4a).  
Prepared using general procedure GP2, starting from H-Val-
OBzl.TsOH (1.06 g; 2.79 mmol).  
Yield: 636 mg (2.73 mmol); 98%. Rf (PE/EtOAc 10:1)= 0.55.  
[𝜶]𝑫
𝟐𝟓= -28 (CHCl3, c= 0.2). 1H-NMR (500 MHz, CDCl3): 
δ [ppm]= 7.45-7.34 (m, 5H, Ph-H), 5.25 (d, 2J= 12.2 Hz, 1H, O-CH2), 5.21 (d, 2J= 12.2 Hz, 1H, 
O-CH2), 3.72 (d, 3J= 6.2 Hz, 1H, Hα), 2.24 (m, 1H, Hβ) 1.00 (d, 3J= 7.0 Hz, 3H, Hγ), 0.98 (d, 3J= 
6.8 Hz, 3H, Hγ).  
13C{1H}-NMR (126 MHz, CDCl3): δ [ppm]= 170.02 (C=O), 135.11 (CAr), 128.66 (2C, CHAr, 
meta), 128.59 (CHAr, para), 128.49 (2C, CHAr, ortho), 68.14 (O-CH2-), 67.32 (Cα), 30.99 (Cβ), 19.34 
(Cγ), 17.96 (Cγ). 
 
Benzyl (S)-2-Azidopropanoate (4b).  
Prepared using general procedure GP2, starting from H-Ala-
OBzl.HCl (602 mg; 2.79 mmol).  
Yield: 531 mg (2.59 mmol); 93%. Rf (PE/EtOAc 10:1)= 0.47.  
1H-NMR (300 MHz, CDCl3): δ [ppm]= 7.43-7.35 (m, 5H, Ar-
H), 5.27-5.21 (m, 2H, O-CH2), 4.00 (q, 3J= 7.1 Hz, 1H, Hα), 1.51 (d, 3J= 7.1 Hz, 3H, Hβ). 
 
Benzyl (S)-2-Azido-3-phenylpropanoate (4c).  
Prepared using general procedure GP2, starting from H-Phe-
OBzl.HCl (814 mg; 2.79 mmol).  
Yield: 684 mg (2.43 mmol); 87%. Rf (PE/EtOAc 10:1)= 0.58.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.43-7.19 (m, 10H, Ph-
H), 5.27-5.21 (m, 2H, O-CH2), 4.12 (dd, 3J= 8.5, 5.7 Hz, 1H, Hα), 
3.20 (dd, 2J= 14.0 Hz, 3J= 5.7 Hz, 1H, Hβ), 3.05 (dd, 2J= 14.0 Hz, 3J= 8.5 Hz, 1H, Hβ). 
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Benzyl (S)-2-azido-6-(((benzyloxy)carbonyl)amino)hexanoate (4d)  
Prepared using general procedure GP2, starting from H-
Lys(Cbz)-OBzl.HCl (1.03 g; 2.78 mmol).  
Yield: 954 mg (2.41 mmol); 87%. Rf (PE/EtOAc 2:1)= 0.54.  
MS (ESI): m/z= 419.2 [M+Na]+. 
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.41-7.32 (m, 10H, Ph-
H), 5.26 (d, 2J= 12.2 Hz, 1H, CαCO2CHH), 5.22 (d, 2J= 12.2 Hz, 1H, CαCO2CHH), 5.14-5.10 
(m, 2H, NCO2CH2), 4.78 (dd, 3J= 6.1 Hz, 1H, NH), 3.89 (dd, 3J= 8.3, 5.3 Hz, 1H, Hα), 3.23-3.13 
(m, 2H, Hε), 1.91-1.75 (m, 2H, Hβ), 1.57-1.47 (m, 2H, Hδ), 1.47-1.37 (m, 2H, Hγ). 
13C{1H}-NMR (126 MHz, CDCl3) δ [ppm]= 170.30 (Lys-C), 156.37 (NHCO2), 136.57 (CAr), 
135.04 (CAr), 128.71 (2C; CHAr), 128.66 (2C; CHAr), 128.54 (2C; CHAr), 128.48 (2C; CHAr), 
128.14 (2C; CHAr), 67.50 (CαCO2C), 66.68 (NHCO2C), 61.83 (Cα), 40.70 (Cε), 30.98 (Cβ), 29.43 
(Cδ), 22.86 (Cγ). 
 
(E)-Prop-1-en-1-yl (S)-2-azido-3-methylbutanoate (4e). 
Prepared using general procedure GP2, starting from H-Val-
OAll.TosH (351 mg; 1.07 mmol).  
Yield: 150 mg (0.82 mmol); 77%. Rf (PE/EtOAc 10:1)= 0.59.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 5.87 (dddd, 3J= 17.4, 10.4, 
5.9, 5.9 Hz, 1H, CH2-CH=CH2), 5.31 (dd, 3J= 17.4, 2J= 1.3 Hz, 1H, CH2-CH=CHHE), 5.22 (dd, 
3J = 10.4, 1.3 Hz, 1H, CH2-CH=CHZH), 4.67-4.59 (m, 2H, O-CH2), 3.61 (d, 3J= 6.2 Hz, 1H, 
Hα), 2.15 (m, 1H, Hβ), 0.95 (d, 3J= 6.8 Hz, 3H, Hγ), 0.92 (d, 3J= 6.8 Hz, 3H, Hγ). 
 
(R)-2-Azido-2-cyclohexylacetic acid (4f)  
Synthesized according to the procedure of Lundquist et al.,65 
starting from H-D-chGly-OH (439 mg; 2.79 mmol). 
Yield: 182 mg (0.99 mmol); 36%.  
1H-NMR (500 MHz, CDCl3) δ [ppm]= 3.79 (d, 3J= 6.1 Hz, 1H, 
Hα), 1.94 (m, 1H, Hβ), 1.84-1.69 (m, 5H, CH2), 1.36-1.15 (m, 5H, CH2). 
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(S)-2-Azido-3-(4-(tert-butoxy)phenyl)propanoic acid (4g)  
Synthesized according to the procedure of Lundquist et al.,65 
starting from H-D-Tyr(tBu)-OH (662 mg; 2.79 mmol). 
Yield: 191 mg (0.73 mmol); 26%.  
1H-NMR (500 MHz, CDCl3) δ [ppm]= 7.18 (d, 3J= 7.8 Hz, 2H, 
Hδ), 6.98 (d, 3J= 7.7 Hz, 2H, Hε), 4.15 (dd, 3J= 9.2, 4.9 Hz, 1H, Hα), 
3.22 (dd, 2J= 14.3, 3J= 4.9 Hz, 1H, Hβ), 3.03 (dd, 2J= 14.2, 3J= 8.9 Hz, 1H, Hβ), 1.37 (s, 9H, 
C(CH3)3). 
 
1-Benzyl 4-(tert-butyl) (S)-2-azidosuccinate (4h) 
Fmoc-Asp(tBu)-OBzl (50): Prepared according to Xu et al.171 
starting from Fmoc-Asp(tBu)-OH (1.00 g; 2.43 mmol).  
Yield: 0.863 g (1.72 mmol); 71% (Lit.: 82%).  
Rf (PE/EtOAc 10:1)= 0.16.  
H-Asp(tBu)-OBzl (51): Prepared according to Xu et al.171 
starting from Fmoc-Asp(tBu)-OBzl (0.863 mg; 1.72 mmol). Yield: 313 mg (1.12 mmol); 65% 
(Lit.: 91%). Rf (PE/EtOAc 5:1 including 1% TEA)= 0.39.  
N3-Asp(tBu)-OBzl (4h): Prepared using general procedure GP2, starting from H-
Asp(tBu)-OBzl (313 mg; 1.12 mmol). Yield: 0.17 mg (0.56 mmol); 50%.  
Rf (PE/EtOAc 5:1)= 0.39. MS (ESI): m/z= 328.2 [M+Na]+.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.40-7.31 (m, 5H, Ph-H), 5.26-5.21 (m, 2H, O-CH2), 
4.35 (dd, 3J= 7.6, 5.4 Hz, 1H, Hα), 2.79 (dd, 2J= 16.5, 3J= 5.4 Hz, 1H, Hβ), 2.66 (dd, 2J= 16.5, 
3J= 7.6 Hz, 1H, Hβ), 1.44 (s, 9H, C(CH3)3). 
 
(R)-2-Methylpropane-2-sulfinamide ((R)-5) 
Synthesized according to the literature procedure of the Ellman 
group108 starting from di-tert-Butyldisulfid (30.0 g; 168 mmol). 
Yield: 7.32 g (60.4 mmol); 36% over two steps (Lit.: 75% over two 
steps). [𝜶]𝑫
𝟐𝟓= +2.4 (c= 1, CHCl3). (Lit.: [𝛼]𝐷
23= +4.9 (c = 1, CHCl3). 
Chiral HPLC: ee ≥ 99%, tR= 7.1 min. Rf (PE/EtOAc 4:3)= 0.4.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 1.23 (s, 9H, S-C(CH3)3), 3.69 (s, 2H, -NH2). 
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(S)-2-Methylpropane-2-sulfinamide ((S)-5) 
Synthesized according to the literature procedure of the Ellman 
group108 starting from di-tert-Butyldisulfid (18.9 g; 106 mmol). 
Yield: 3.01 g (24.8 mmol); 23% over two steps (Lit.: 75% over two 
steps). Chiral HPLC: ee ≥ 99%, tR= 9.2 min.  
Rf (PE/EtOAc 4:3)= 0.4.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 1.23 (s, 9H, S-C(CH3)3), 3.66 (s, 2H, -NH2). 
 
(R, E)-N-Ethylidene-2-methylpropane-2-sulfinamide (6a) 
Synthesized according to GP1 starting from (R)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: quant. (Lit.: 81%). The analytical data was found to be 
consistent with the literature.62 
 
(S, E)-N-Ethylidene-2-methylpropane-2-sulfinamide (6b) 
Synthesized according to GP1 starting from (S)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: 967 mg (6.56 mmol); 80% (Lit.: 81%). The analytical data 
was found to be consistent with the literature.62 
 
(R, E)-2-Methyl-N-(2-methylpropylidene)propane-2-sulfinamide (6c) 
Synthesized according to GP1 starting from (R)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: 1.41 g (8.04 mmol); 97% (Lit.: 90%). The analytical data was 
found to be consistent with the literature.62 
 
(S, E)-2-Methyl-N-(2-methylpropylidene)propane-2-sulfinamide (6d) 
Synthesized according to GP1 starting from (S)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: 1.02 g (5.82 mmol); 71% (Lit.: 90%). The analytical data was 
found to be consistent with the literature.62 
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(R, E)-2-Methyl-N-(3-methylbutylidene)propane-2-sulfinamide (6e) 
Synthesized according to GP1 starting from (R)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: 1.23 g (6.50 mmol); 79% (Lit.: 92%). The analytical data was 
found to be consistent with the literature.62 
 
(S, E)-2-Methyl-N-(3-methylbutylidene)propane-2-sulfinamide (6f) 
Synthesized according to GP1 starting from (S)-2-
methylpropane-2-sulfinamide (2.00 g; 16.5 mmol). 
Yield: 2.90 g (15.3 mmol); 93% (Lit.: 92%). The analytical data 
was found to be consistent with the literature.62 
 
(R, E)-N-(Cyclohexylmethylene)-2-methylpropane-2-sulfinamide (6g) 
Synthesized according to GP1 starting from (R)-2-
methylpropane-2-sulfinamide (2.00 g; 16.5 mmol). 
Yield: 3.32 g (15.4 mmol); 93% (Lit.: 96%). The analytical data 
was found to be consistent with the literature.62 
 
(S, E)-N-(Cyclohexylmethylene)-2-methylpropane-2-sulfinamide (6f) 
Synthesized according to GP1 starting from (R)-2-
methylpropane-2-sulfinamide (1.00 g; 8.25 mmol). 
Yield: 824 mg (3.83 mmol); 46% (Lit.: 96%). The analytical data 
was found to be consistent with the literature.62 
 
(R)-N-((R)-But-3-yn-2-yl)-2-methylpropane-2-sulfinamide (7a) 
Synthesized according to GP8 starting (R,E)-N-Ethylidene-2-
methylpropane-2-sulfinamide (1.21 g; 8.25 mmol). 
Yield: 696 mg (4.02 mmol); 49% over two steps (Lit.: 47%).  
The analytical data was found to be consistent with the 
literature.62 
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(S)-N-((S)-But-3-yn-2-yl)-2-methylpropane-2-sulfinamide (7b) 
Synthesized according to GP8 starting (S, E)-N-Ethylidene-2-
methylpropane-2-sulfinamide (967 mg; 6.57 mmol). 
 Yield: 522 mg (3.01 mmol); 46% over two steps (Lit.: 47%).  
The analytical data was found to be consistent with the 
literature.62 
 
(R)-2-Methyl-N-((R)-4-methylpent-1-yn-3-yl)propane-2-sulfinamide (7c) 
Synthesized according to GP8 starting (R,E)-2-Methyl-N-(2-
methylpropylidene)propane-2-sulfinamide (1.18 g; 
6.73 mmol). Yield: 617 mg (3.06 mmol); 45% over two steps 
(Lit.: 61%). The analytical data was found to be consistent with 
the literature.62 
 
(S)-2-Methyl-N-((S)-4-methylpent-1-yn-3-yl)propane-2-sulfinamide (7d) 
Synthesized according to GP8 starting (S,E)-2-Methyl-N-(2-
methylpropylidene)propane-2-sulfinamide (1.02 g; 
5.82 mmol). Yield: 782 mg (3.88 mmol); 67% over two steps 
(Lit.: 61%). The analytical data was found to be consistent with 
the literature.62 
 
(R)-2-Methyl-N-((R)-5-methylhex-1-yn-3-yl)propane-2-sulfinamide (7e) 
Synthesized according to GP8 starting from (R,E)-2-Methyl-N-
(3-methylbutylidene)propane-2-sulfinamide  
Yield: 824 mg (3.83 mmol); 46% over two steps (Lit.: 53%). The 
analytical data was found to be consistent with the literature.62 
 
 
(S)-2-Methyl-N-((S)-5-methylhex-1-yn-3-yl)propane-2-sulfinamide (7f) 
Synthesized according to GP8 starting from (S,E)-2-Methyl-N-
(3-methylbutylidene)propane-2-sulfinamide (1.33 g; 
7.03 mmol). Yield: 793 mg (3.68 mmol); 52% over two steps 
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(Lit.: 53%). The analytical data was found to be consistent with the literature.62 
 
(R)-N-((R)-1-Cyclohexylprop-2-yn-1-yl)-2-methylpropane-2-sulfinamide (7g) 
Synthesized according to GP8 starting from (R,E)-N-
(Cyclohexylmethylene)-2-methylpropane-2-sulfinamide 
(1.71 g; 7.94 mmol). Yield: 1.36 g (5.63 mmol); 71% over two 
steps (Lit.: 65%). The analytical data was found to be consistent 
with the literature.62 
 
(S)-N-((S)-1-Cyclohexylprop-2-yn-1-yl)-2-methylpropane-2-sulfinamide (7h) 
Synthesized according to GP8 starting from (S,E)-N-
(Cyclohexylmethylene)-2-methylpropane-2-sulfinamide 
(1.60 g; 7.43 mmol). Yield: 1.07 g (4.43 mmol); 60% over two 
steps (Lit.: 65%). The analytical data was found to be consistent 
with the literature.62 
 
O-tert-Butyl N-(R)-But-3-yn-2-ylcarbamate (8a). 
Prepared using general procedure GP3, starting from (R)-Bus-D-
Ala≡ (680 mg; 3.92 mmol). Yield: 567 mg (3.35 mmol); 85%. Rf 
(PE/EtOAc 10:1)= 0.32. MS (ESI): m/z= 192.0 [M+Na]+.   
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.30 (d, 3J= 8.3 Hz, 1H, 
NH), 4.27 (dqd, 3J= 8.3, 6.9 Hz, 4J= 2.2 Hz, Hα), 3.10 (d, 4J= 2.2 Hz, 1H, -CCH), 1.39 (s, 9H, -
C(CH3)3), 1.25 (d, 3J= 6.9 Hz, 3H, Hβ). 
 
O-tert-Butyl N-(S)-But-3-yn-2-ylcarbamate (8b).  
Prepared using general procedure GP3, starting from (S)-Bus-
Ala≡ (522 mg; 3.01 mmol). Yield: 313 mg (1.85 mmol); 61%. Rf 
(PE/EtOAc 10:1)= 0.32. 1H-NMR (500 MHz, CDCl3): δ [ppm]= 
4.72 (m, 1H, NH), 4.50 (m, 1H, Hα), 2.27 (d, 4J= 2.3 Hz, 1H, -CCH), 
1.47 (s, 9H, -C(CH3)3), 1.42 (d, 3J= 6.9 Hz, 3H, Hβ). 
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O-tert-Butyl N-(R)-(4-Methylpent-1-yn-3-yl)carbamate (8c).  
Prepared using general procedure GP3, starting from (R)-Bus-
D-Val≡ (610 mg; 3.03 mmol). Yield: 538 mg (2.73 mmol); 90%. Rf 
(PE/EtOAc 10:1)= 0.40. MS (ESI): m/z= 220.1 [M+Na]+.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.28 (d, 3J= 9.0 Hz, 
1H, NH), 4.02 (m, 1H, Hα), 3.13 (d, 4J= 2.3 Hz, 1H, -CCH), 1.75 (m, 1H, Hβ), 1.39 (s, 9H, -
C(CH3)3), 0.93 (d, 3J= 6.7 Hz, 3H, Hγ), 0.88 (d, 3J= 6.6 Hz, 3H, Hγ). 
 
O-tert-Butyl N-(S)-(4-Methylpent-1-yn-3-yl)carbamate (8d).  
Prepared using general procedure GP3, starting from (S)-Bus-
Val≡ (217 mg; 1.08 mmol). Yield: 121 mg (0.61 mmol); 56%. Rf 
(PE/EtOAc 10:1)= 0.40. 1H-NMR (500 MHz, CDCl3): δ [ppm]= 
4.75 (m, 1H, NH), 4.34 (m, 1H, Hα), 2.27 (d, 4J= 2.7 Hz, 1H, -CCH), 
1.92 (m, 1H, Hβ), 1.47 (s, 9H, -C(CH3)3), 1.00 (d, 3J= 6.5 Hz, 6H, Hγ). 
 
O-tert-Butyl N-(R)-(5-Methylhex-1-yn-3-yl)carbamate (8e).  
Prepared using general procedure GP3, starting from (R)-Bus-
D-Leu≡ (415 mg; 1.93 mmol). Yield: 385 mg (1.82 mmol); 94%. 
Rf (PE/EtOAc 10:1)= 0.45. MS (ESI): m/z= 234.1 [M+Na]+.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.26 (d, 3J= 8.8 Hz, 
1H, NH), 4.21 (m, 1H, Hα), 3.11 (d, 4J= 2.3 Hz, 1H, -CCH), 1.67 (m, 1H, Hγ), 1.44 (m, 2H, Hβ), 
1.39 (s, 9H, -C(CH3)3), 0.88-0.86 (m, 6H, Hδ). 
 
O-tert-Butyl N-(S)-(5-Methylhex-1-yn-3-yl)carbamate (8f).  
Prepared using general procedure GP3, starting from (S)-Bus-
Leu≡ (520 mg; 2.41 mmol). Yield: 417 mg (1.97 mmol); 82%. Rf 
(PE/EtOAc 10:1)= 0.45.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 4.56 (m, 1H, NH), 4.37 
(m, 1H, Hα), 2.18 (d, 4J= 2.2 Hz, 1H, -CCH), 1.74 (m, 1H, Hγ), 1.47-1.44 (m, 2H, Hβ), 1.38 (s, 
9H, -C(CH3)3), 0.88 (d, 3J= 6.6 Hz, 3H, Hδ), 0.87 (d, 3J= 6.6 Hz, 3H, Hδ). 
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O-tert-Butyl (S)-(1-cyclohexylprop-2-yn-1-yl)carbamate (8g). 
Prepared using general procedure GP3, starting from (R)-Bus-D-
chGly≡ (892 mg; 3.70 mmol). Yield: 735 mg (3.09 mmol); 84%. Rf 
(PE/EtOAc 10:1)= 0.52. 
1H-NMR (300 MHz, CDCl3): δ [ppm]= 4.74 (d, 3J= 6.6 Hz, 1H, 
NH), 4.32 (m, 1H, Hα), 2.27 (d, 4J= 2.4 Hz, 1H, -CCH), 1.47 (s, 9H, -C(CH3)3), 1.86-1.55 (m, 
5H, CH, CH2), 1.32-1.06 (m, 6H, CH2). 
 
O-tert-Butyl (S)-(1-cyclohexylprop-2-yn-1-yl)carbamate (8h). 
Prepared using general procedure GP3, starting from (S)-Bus-
chGly≡ (209 mg; 0.87 mmol). Yield: 178 mg (0.75 mmol); 86%. Rf 
(PE/EtOAc 10:1)= 0.52.  
1H-NMR (300 MHz, DMSO-d6): δ [ppm]= 7.26 (d, 3J= 9.0 Hz, 1H, 
NH), 3.13 (d, 4J= 2.4 Hz, 1H, CCH), 4.02 (ddd, 3J= 9.0, 8.3, 4J= 2.4 Hz, 1H, Hα), 1.88-1.53 (m, 5H, 
CH, CH2), 1.38 (s, 9H, C(CH3)3), 1.26-0.81 (m, 6H, CH2). 
 
O-tert-Butyl prop-2-yn-1-ylcarbamate (8i). 
 Prop-2-yn-1-amine (1.00 g; 18.15 mmol; 1.0 eq) is dissolved in 
H2O/THF 1:1 (20 mL). After the addition of NaHCO3 (6.1 g; 
72.6 mmol; 4 eq) and Boc2O (8.3 mL; 36 mmol; 2 eq) the reaction 
mixture stirred overnight at rt. Imidazole (3.1 g; 45 mmol; 2.5 eq) is added and the reaction 
mixture stirred for 2 h. The THF is removed under vacuum, the aqueous slurry extracted 
with EtOAC (3x10 mL). The combined organic phases are washed with 5% KHSO4 solution 
(3x10 mL), brine (10 mL) and dried over MgSO4. Evaporation of the solvent gives the 
product in analytically pure form. Yield: 2.17 g (14.0 mmol); 77%. 
H-NMR (500 MHz, CDCl3): δ [ppm] = 4.66 (m, 1H, NH), 3.89-3.78 (m, 2H, Hα), 2.15 (t, 
3J= 2.5 Hz, 1H, CCH), 1.39 (s, 9H, C(CH3)3). 
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(9H-Fluoren-9-yl)methyl (S)-(5-methylhex-1-yn-3-yl)carbamate (8j). 
Prepared according to general procedure GP7, starting from (S)-
Bus-Leu≡ (560 mg; 2.60 mmol).  
Yield: 615 mg (1.84 mmol); 71%. Rf (PE/EtOAc 10:1)= 0.29. 
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.81-7.78 (m, 2H, HAr), 
7.64-7.61 (m, 2H, HAr), 7.45-7.51 (m, 2H, HAr), 7.36-7.32 (m, 2H, HAr), 4.90 (d, 3J= 8.8 Hz, 1H, 
NH), 4.54 (m, 1H, Hα), 4.48-4.43 (m, 2H, CH-CH2-O), 4.25 (dd, 3J= 7.0, 7.0 Hz, 1H, CH-CH2-
O) 2.31 (d, 4J= 2.3 Hz, 1H, CCH), 1.82 (m, 1H, Hγ), 1.62-1.58 (m, 2H, Hβ), 1.01-0.9 (m, 6H, 
Hδ). 
 
(9H-Fluoren-9-yl)methyl prop-2-yn-1-ylcarbamate (8k). 
Propargylamine (0.64 mL; 10 mmol) and DIPEA (1.7 mL; 
10 mmol; 1.0 eq) are dissolved in DCM (30 mL; dry) and cooled 
to 0°C, after the addition of Fmoc-OSu (3.4 g; 10 mmol; 1.0 eq) 
and DMAP (0.12 g; 1.0 mmol; 0.1 eq) the solution is left to stir overnight. The solution is 
diluted with DCM (50 mL) and washed: 5% KHSO4 (2x50 mL), saturated NaHCO3 (2x50 mL) 
and brine (2x50 mL), dried over MgSO4 and concentrated under vacuum. The product is 
purified by column chromatography (PE/EtOAc 5:1). Yield: 2.00 g (7.21 mmol); 72%.  
Rf (PE/EtOAc 5:1)= 0.38. MS (ESI): m/z= 300.1 [M+Na]+. 
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.79-7.76 (m, 2H, HAr), 7.62-7.57 (m, 2H, HAr), 7.43-
7.38 (m, 2H, HAr), 7.34-7.30 (m, 2H, HAr), 4.96 (d, 1H, 3J= 6.9 Hz, NH), 4.43 (d, 3J= 6.9, 
4J= 2.5 Hz, 2H, Hα), 4.23 (dd, 3J= 6.8, 6.6 Hz, CHCH2O), 4.03-3.95 (m, 2H, CHCH2O), 2.26 (t, 
4J= 2.5 Hz, 1H, CCH). 
 
(9H-Fluoren-9-yl)methyl (R)-(1-cyclohexylprop-2-yn-1-yl)carbamate (8l).  
 Prepared using general procedure GP4, starting from (R)-Bus-
D-chGly≡ (700 mg; 2.90 mmol). Yield: 450 mg (1.25 mmol); 43% 
over two steps. Rf (PE/EtOAc 10:1)= 0.20. 
HR-MS (ESI): m/z= 360.1940 [M+H]+ (calc. 360.19581). 
1H-NMR (600 MHz, DMSO-d6) δ [ppm]= 7.90-7.87 (m, 2H, 
CHAr), 7.81 (d, 3J= 8.9 Hz, 1H, NH), 7.74-7.70 (m, 2H, CHAr), 7.44-7.39 (m, 2H, CHAr), 7.35-
7.30 (m, 2H, CHAr), 4.34 (dd, 2J= 10.4, 3J= 7.2 Hz, 1H, CHH-O), 4.28 (dd, 2J= 10.4, 3J= 7.0 Hz, 
1H, CHH-O), 4.21 (dd, 3J= 7.2, 7.0 Hz, CHCH2O), 4.09 (ddd, 3J= 8.9 Hz, 7.1, 4J= 2.4 Hz, Hα), 
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3.20 (d, 4J= 2.4 Hz, 1H, CCH), 1.86 (m, 1H, CH2), 1.75-1.57 (m, 4H, CH2), 1.46 (m, 1H, Hβ), 
1.21-0.92 (m, 5H, CH2).  
13C{1H}-NMR (151 MHz, DMSO) δ [ppm]= 156.13 (CO), 144.33 (CAr), 144.24 (CAr), 141.21 
(CAr), 141.19 (CAr), 128.10 (CHAr), 128.07 (CHAr), 127.49 (2C, CHAr), 125.76 (CHAr), 125.70 
(CHAr), 120.58 (CHAr), 120.55 (CHAr), 83.44 (CCH), 74.49 (CCH), 66.00 (CHCH2O), 48.23 
(Cα), 47.19 (CHCH2O), 42.04 (Cβ), 29.27 (CH2), 29.06 (CH2), 26.29 (CH2), 25.78 (CH2), 25.76 
(CH2). 
 
Boc-Ala[5Tz]Phe-OBzl (9a).  
Prepared according to general procedure GP4, starting from 
8b (100 mg; 0.591 mmol). Yield: 232 mg (0.515 mmol); 87%.  
Rf (PE/EtOAc 2:1)= 0.41. Analytical RP-HPLC: tR= 6.2 min 
(method 1, 220 nm).  
HR-MS (ESI): m/z= 451.2344 [M+H]+ (calc. 451.23398).  
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 7.50 (s, 1H, Tz-H), 7.39 (d, 3J= 8.9 Hz, 1H, NH), 
7.36-6.96 (m, 10H, Ph-H), 5.87 (dd, 3J= 11.3, 4.6 Hz, 1H, Phe-Hα), 5.19 (m, 2H, O-CH2-Ph), 
4.35 (dq, 3J= 8.9, 7.0 Hz, 1H, Ala-Hα), 3.66 (dd, 2J= 13.8, 3J= 4.6 Hz, 1H, Phe-Hβ), 3.43 (dd, 
2J= 13.8, 3J= 11.3 Hz, 1H, Phe-Hβ), 1.29 (s, 9H, C(CH3)3), 0.94 (d, 3J= 7.0 Hz, 3H, Ala-Hβ).   
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 168.18 (Phe-C), 155.25 (tBuO-C), 142.13 (Tz-
C), 136.49 (Phe-CAr), 135.82 (CAr), 130.98 (Tz-CH), 129.41 (2C; CHAr), 128.81 (2C; CHAr), 
128.78 (2C; CHAr), 128.46 (CHAr), 127.90 (2C; CHAr), 127.29 (CHAr), 78.80 (-C(CH3)3), 67.22 
(O-CH2-Ph), 61.32 (Phe-Cα), 39.46 (Ala-Cα), 38.00 (Phe-Cβ), 28.49 (-C(CH3)), 20.27 (Ala-Cβ). 
 
Boc-D-Ala[5Tz]Phe-OBzl (9b).  
Prepared according to general procedure GP4, starting from 
8a (100 mg; 0.59 mmol). Yield: 251 mg (0.56 mmol); 94%.  
Rf (PE/EtOAc 2:1)= 0.42.  
HR-MS (ESI): m/z= 451.23571 [M+H]+ (calc. 451.23398).  
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 7.60 (s, 1H, Tz-H), 
7.39 (d, 3J= 8.5 Hz, 1H, Ala-NH), 7.37-7.31 (m, 3H, Ph-H), 7.24-
7.14 (m, 7H, Ph-H), 5.91 (dd, 3J= 9.2, 6.2 Hz, 1H, Phe-Hα), 5.18 (d, 2J= 12.7 Hz, 1H, O-CH2), 
5.15 (d, 2J= 12.7 Hz, 1H, O-CH2), 4.79 (dq, 3J= 8.5, 6.9 Hz, 1H, Ala-Hα), 3.71 (dd, 2J= 14.4 Hz, 
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3J= 6.2 Hz, 1H, Phe-Hβ), 3.64 (dd, 2J= 14.4 Hz, 3J= 9.3 Hz, 1H, Phe-Hβ), 1.36 (s, 9H, -C(CH3)3) 
1.23 (d, 3J= 6.9 Hz, 3H, Ala-Hβ).  
13C{1H}-NMR (126 MHz; DMSO-d6): δ [ppm]= 168.36 (Phe-C), 155.29 (tBuO-C), 141.71 (Tz-
C), 136.61 (Phe-CAr), 135.69 (CAr), 131.69 (Tz-CH), 129.36 (2C, CHAr), 128.85 (2C, CHAr), 
128.68 (2C, CHAr), 128.63 (1C, CHAr), 128.09 (2C, CHAr), 127.10 (CHAr), 78.92 (-C(CH3)3), 
67.46 (O-CH2), 60.67 (Phe-Cα), 49.07 (Ala-Cα), 36.30 (Phe-Cβ), 28.60 (-C(CH3)3), 20.80 (Ala-
Cβ). 
 
Boc-Val[5Tz]Ala-OBzl (9c).  
Prepared according to general procedure GP4, starting from 
8d (100 mg; 0.507 mmol). Yield: 171 mg (0.425 mmol); 84%. Rf 
(PE/EtOAc 1:1)= 0.50.  
Analytical RP-HPLC: tR= 5.5 min (method 1, 220 nm).  
HR-MS (ESI): m/z= 403.2351 [M+H]+ (calc. 403.23398).  
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 7.63 (s, 1H, Tz-H), 7.41 (d, 3J= 9.1 Hz, 1H, NH), 
7.36–7.25 (m, 5H, PhH), 5.74 (q, 3J= 7.1 Hz, 1H, Ala-Hα), 5.16-5.10 (m, 2H, -O-CH2), 4.53 (dd, 
3J= 9.2 Hz, 1H, Val-Hα), 2.00 (m, 1H, Val-Hβ), 1.76 (d, 3J= 7.1 Hz, 3H, Ala-Hβ), 1.33 (s, 9H, -
C(CH3)3), 0.92 (d, 3J= 6.6 Hz, 3H, Val-Hγ), 0.71 (d, 3J= 6.7 Hz, 3H, Val-Hγ).  
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 169.29 (Ala-C), 155.67 (tBuO-C), 139.60 (Tz-
C), 135.89 (CAr), 132.03 (Tz-CH), 128.81 (2C; CHAr), 128.48 (CHAr), 127.93 (2C; CHAr), 78.61 
(-C(CH3)3), 67.08 (O-CH2-), 55.59 (Ala-Cα), 50.44 (Val-Cα), 32.35 (Val-Cβ), 28.56 (C(CH3)3), 
19.88 (Val-Cγ), 19.27 (Val-Cγ), 18.03 (Ala-Cβ). Crystal structure: CCDC 1561604.  
 
Boc-D-Leu[5Tz]Val-OBzl (9d).  
Prepared according to general procedure GP4, starting from 
8e (50 mg; 0.24 mmol). Yield: 96 mg (0.20 mmol); 88%.  
Rf (PE/EtOAc 2:1)= 0.40.  
HR-MS (ESI): m/z= 445.28273 [M+H]+ (calc. 445.28093). 
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 7.64 (s, 1H, Tz-H), 
7.49 (d, 3J= 9.0 Hz, 1H, Leu-NH), 7.33 (m, 3H, Ph-H), 7.20 (m, 2H, Ph-H), 5.21 (d, 3J= 9.5 Hz, 
1H, Val-Hα), 5.16-5.13 (m, 2H, O-CH2), 4.76 (m, 1H, Leu-Hα), 2.84 (m, 1H, Val-Hβ), 1.74 (ddd, 
2J= 13.2 Hz, 3J= 9.7, 5.1 Hz, 1H, Leu-Hβ), 1.51-1.39 (m, 2H, Leu-Hβ, Leu-Hγ), 1.35 (s, 9H, -
C(CH3)3), 1.05 (d, 3J= 6.7 Hz, 3H, Val-Hγ), 0.80-0.72 (m, 9H, Leu-Hδ, Val-Hγ).  
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13C{1H}-NMR (126 MHz; DMSO-d6): δ [ppm]= 168.04 (Val-C), 155.71 (tBuO-C), 141.58 (Tz-
C), 135.66 (CAr), 131.36 (Tz-CH), 128.88 (2C, CHAr), 128.73 (CHAr), 128.29 (2C, CHAr), 79.06 
(-C(CH3)3), 67.26 (O-CH2), 65.09 (Val-Cα), 42.68 (Leu-Cβ), 41.98 Leu-Cα), 30.00 (Val-Cβ), 
28.58 (-C(CH3)3), 24.72 (Leu-Cγ), 22.86 (Leu-Cδ), 21.75 (Leu-Cδ), 19.64 (Val-Cγ), 18.76 (Val-
Cγ). Crystal structure: CCDC 1561605. 
 
Boc-Leu[5Tz]Val-OBzl (9e).  
Prepared according to general procedure GP4, starting from 
8f (120 mg; 0.568 mmol). Yield: 205 mg (0.461 mmol); 81%.  
Rf (PE/EtOAc 1:1)= 0.71. Analytical RP-HPLC: tR= 6.2 min 
(method 1, 220 nm). [𝜶]𝑫
𝟐𝟏= -72 (CHCl3, c= 0.12).  
HR-MS (ESI): m/z= 445.2818 [M+H]+ (calc. 445.28093).   
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.64 (s, 1H, Tz-H), 7.46 (d, 3J= 8.7 Hz, 1H, NH), 
7.37–7.25 (m, 5H, Ph-H), 5.31 (d, 3J= 8.1 Hz, 1H, Val-Hα), 5.20-5.10 (m, 2H, O-CH2), 4.79 (m, 
1H, Leu-Hα), 2.75 (dqq, 3J= 8.1, 6.8, 6.7 Hz, 1H, Val-Hβ), 1.79 (m, 1H, Leu-Hγ), 1.54-1.46 (m, 
2H, Leu-Hβ), 1.30 (s, 9H, C(CH3)3), 0.96 (d, 3J= 6.7 Hz, 3H, Val-Hγ), 0.87 (d, 3J= 6.2 Hz, 3H, 
Leu-Hδ), 0.84 (d, 3J= 6.0 Hz, 3H, Leu-Hδ), 0.79 (d, 3J= 6.8 Hz, 3H, Val-Hγ).  
13C{1H}-NMR (125 MHz, DMSO-d6): δ [ppm]= 168.09 (Val-C), 155.58 (tBuO-C), 141.01 (Tz-
C), 135.81 (CAr), 131.71 (Tz-CH), 128.85 (2C; CHAr), 128.57 (CHAr), 128.16 (2C; CHAr), 78.75 
(-C(CH3)3), 67.10 (O-CH2-), 65.28 (Val-Cα), 42.69 (Leu-Cβ), 42.56 (Leu-Cα), 31.06 (Val-Cβ), 
28.48 (-C(CH3)3), 24.79 (Leu-Cγ), 23.07 (Leu-Cδ), 21.98 (Leu-Cδ), 19.59 (Val-Cγ), 19.03 (Val-
Cγ). Crystal structure: CCDC 1561606. 
 
Boc-D-Val[5Tz]Ala-OBzl (9f).  
Prepared according to general procedure GP4, starting from 
8c (100 mg; 0.51 mmol). Yield: 180 mg (0.45 mmol); 88%.  
Rf (PE/EtOAc 2:1)= 0.39.  
HR-MS (ESI): m/z= 403.23560 [M+H]+ (calc. 403.23398).  
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 7.65 (s, 1H, Tz-H), 
7.52 (d, 3J= 8.9 Hz, 1H, Val-NH), 7.43-7.28 (m, 5H, Ph-H), 5.82 (q, 3J= 7.0 Hz, 1H, Ala-Hα), 
5.21 (d, 2J= 12.8 Hz, 1H, -O-CH2-), 5.19 (d, 2J= 12.8 Hz, 1H, -O-CH2-), 4.47 (dd, 3J= 8.9, 8.9 Hz, 
1H, Val-Hα), 2.07 (m, 1H, Val-Hβ), 1.81 (d, 3J= 7.0 Hz, 3H, Ala-Hβ), 1.41 (s, 9H, -C(CH3)3), 
0.94 (d, 3J= 6.6 Hz, 3H, Val-Hγ), 0.71 (d, 3J= 6.7 Hz, 3H, Val-Hγ).  
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13C{1H}-NMR (126 MHz; DMSO-d6): δ [ppm]= 169.24 (Ala-C), 155.97 (tBuO-C), 140.36 (Tz-
C), 135.83 (CAr), 131.29 (Tz-CH), 128.81 (2C, CHAr), 128.57 (CHAr), 128.11 (2C, CHAr), 78.87 
(-C(CH3)3), 67.23 (-O-CH2-), 55.45 (Ala-Cα), 50.52 (Val-Cα), 31.75 (Val-Cβ), 28.55 (-C(CH3)3), 
19.95 (Val-Cγ), 19.32 (Val-Cγ), 17.83 (Ala-Cβ). Crystal structure: CCDC 1561607. 
 
Boc-Ala[5Tz]Ala-OBzl (9g).   
Prepared according to general procedure GP4, starting from 
8b (100 mg; 0.591 mmol).  Yield: 170 mg (0.454 mmol); 77%.  
Rf (PE/EtOAc 1:1)= 0.47. MS (ESI): m/z= 397.3 [M+Na]+.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.63 (s, 1H, Tz-H), 
7.42 (d, 3J= 8.8 Hz, 1H, NH), 7.38-7.27 (m, 5H, Ar-H), 5.70 (q, 
3J= 7.1 Hz, 1H, Ala2-Hα), 5.17-5.13 (m, 2H, O-CH2-), 4.93 (dq, 3J= 8.8, 7.2 Hz, 1H, Ala1-Hα), 
1.78 (d, 3J= 7.2 Hz, 3H, Ala2-Hβ), 1.39 (d, 3J= 7.0 Hz, 3H, Ala1-Hβ), 1.33 (s, 9H, C(CH3)3).  
13C{1H}-NMR (126 MHz, DMSO-d6): δ [ppm]= 169.41 (Ala2-C) , 155.23 (tBuO-C), 141.08 
(Tz-C), 135.90 (Ar-C), 131.51 (Tz-CH), 128.86 (2C, CHAr), 128.52 (CHAr), 127.96 (2C, CHAr), 
78.74 (C(CH3)3), 67.11 (O-CH2-), 55.75 (Ala2-Cα), 39.98 (Ala1-Cα), 28.55 (C(CH3)3), 20.92 
(Ala1-Cβ), 18.03 (Ala2-Cβ). 
 
Boc-chGly[5Tz]Phe-OBzl (9h). 
Prepared according to general procedure GP4, starting from 
8h (50 mg; 0.21 mmol). Yield: 98 mg (0.19 mmol); 90%. Rf 
(PE/EtOAc 2:1)= 0.46.  
HR-MS (ESI): m/z= 519.2988 [M+H]+ (519.29658). 
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 7.39 (s, 1H, Tz-H), 
7.26-7.20 (m, 3H, PhH), 7.19 (d, 3J= 9.1 Hz, 1H, chGly1-NH), 7.16-7.13 (m, 2H, Ph-H), 7.08-
7.01 (m, 3H, Ph-H), 6.98-6.94 (m, 2H, Ph-H), 5.69 (dd, 3J= 11.5, 4.3 Hz, 1H, Phe2-Hα), 5.09 (d, 
2J= 12.8 Hz, 1H, -OCHH-), 4.99 (d, 2J= 12.9 Hz, 1H, -OCHH-), 4.04 (dd, 3J= 9.4, 9.1 Hz, 1H, 
chGly1-Hα), 3.55 (dd, 2J= 13.9, 3J= 4.3 Hz, 1H, Phe2-Hβ), 3.43 (dd, 2J= 13.9, 3J= 11.5 Hz, 1H, 
Phe2-Hβ), 1.57-1.34 (m, 4H, CH2), 1.25 (m, 1H, chGly1-Hβ), 1.18 (s, 9H, C(CH3)3), 0.89-0.76 
(m, 3H, CH2), 0.70-0.52 (m, 2H, CH2), 0.01 (m, 1H, CH2). 
13C{1H}-NMR (126 MHz, DMSO-d6) δ [ppm]= 168.24 (Phe2-C), 155.73 (tBuO-C), 140.36 
(Tz-C), 136.55 (Ar-C), 135.81 (Ar-C), 131.54 (Tz-CH), 129.62 (2C; CHAr), 128.83 (2C; CHAr), 
128.75 (CHAr), 128.45 (CHAr), 127.81 (3C; CHAr), 127.18 (CHAr), 78.56 (C(CH3)3), 67.18 (O-
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CH2), 61.36 (Phe2-Cα), 49.03 (chGly1-Cα), 40.54 (chGly1-Cβ), 37.44 (Phe2-Cβ), 29.68 (CH2), 
28.85 (CH2), 28.50 (C(CH3)3), 26.13 (CH2), 25.59 (CH2), 25.56 (CH2). 
 
Boc-D-chGly[5Tz]Phe-OBzl (9i). 
Prepared according to general procedure GP4, starting from 
8g (100 mg; 0.42 mmol). Yield: 189 mg (0.36 mmol); 86%. Rf 
(PE/EtOAc 2:1)= 0.47.  
HR-MS (ESI): m/z= 519.2978 [M+H]+ (calc. 519.29658). 
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 7.53 (s, 1H, Tz-H), 
7.36-7.31 (m, 3H, Ph-H), 7.28 (d, 3J= 9.1 Hz, 1H, NH), 7.25-7.13 
(m, 7H, Ph-H), 5.86 (dd, 3J= 9.3, 6.1 Hz, 1H, Phe-Hα), 5.17 (d, 2J= 12.7 Hz, 1H, O-CHH-), 5.14 
(d, 2J= 12.7 Hz, O-CHH-), 4.39 (d, 3J= 9.4, 9.1 Hz, 1H, chGly-Hα), 3.70 (dd, 2J= 14.1, 3J=6.1 
Hz, 1H, Phe-Hβ), 3.60 (dd, 2J= 14.3, 3J= 9.3 Hz, 1H, Phe-Hβ), 1.80-1.43 (m, 5H, chGly-Hβ, 
CH2), 1.36 (s, 9H, C(CH3)3), 1.10-0.88 (m, 4H, CH2), 0.81 (m, 1H, CH2), 0.5 (m, 1H, CH2).  
13C{1H}-NMR (126 MHz, DMSO-d6): δ [ppm]= 168.40 (Phe-C), 155.79 (tBuO-C), 139.95 (Tz-
C), 136.48 (CAr), 135.58 (CAr), 132.01 (Tz-CH), 129.40 (2C; CHAr), 128.83 (2C; CHAr), 128.68 
(2C; CHAr), 128.30 (2C; CHAr), 127.12 (2C; CHAr), 78.78 (C(CH3)3), 67.50 (O-CH2-), 60.66 
(Phe-Cα), 49.36 (chGly-Cα), 40.85 (chGly-Cβ), 36.76 (Phe-Cβ), 29.94 (CH2), 29.16 (CH2), 28.60 
(C(CH3)3), 26.07 (CH2), 25.60 (CH2), 25.55 (CH2). 
 
Boc-Phe[5Tz]Phe-OBzl (9j).  
Prepared according to general procedure GP4, starting from 
Boc-Phe≡ (34) (200 mg; 0.815 mmol).  
Yield: 318 mg (0.718 mmol); 88%.  Rf (PE/EtOAc 2:1)= 0.28. 
HR-MS (ESI): m/z= 527.2663 [M+H]+ (calc. 527.26528). 
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 7.60 (s, 1H, Tz-H), 
7.38 (d, 3J= 9.2 Hz, 1H, NH), 7.34-6.97 (m, 15H, Ph-H), 5.85 (dd, 3J= 11.1, 4.7 Hz, 1H, Phe2-
Hα), 5.20-5.14 (m, 2H, O-CH2-), 4.48 (ddd, 3J= 11.0, 9.2, 4.5 Hz, 1H, Phe1-Hα),  3.66 (dd, 
2J= 13.8, 3J= 4.7 Hz, 1H, Phe2-Hβ), 3.42 (dd, 2J= 13.8, 3J= 11.1 Hz, 1H, Phe2-Hβ), 2.81 (dd, 2J= 
13.8, 3J= 11.0 Hz, 1H, Phe1-Hβ), 2.29 (dd, 2J= 13.8, 3J= 4.5 Hz, 1H, Phe1- Hβ), 1.17 (s, 9H, -
C(CH3)3).  
13C{1H}-NMR (151 MHz; DMSO-d6): δ [ppm]= 168.14 (Phe2-C), 155.43 (tBuO-C), 141.10 
(Tz-C), 137.67 (CAr), 136.52 (CAr), 135.79 (CAr), 131.43 (Tz-CH), 129.51 (2C, CHAr), 129.43 
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(2C, CHAr), 128.87 (2C, CHAr), 128.81 (2C, CHAr), 128.46 (CHAr), 128.44 (2C, CHAr), 127.86 
(2C, CHAr), 127.37 (CHAr), 126.72 (CHAr), 78.66 (-C(CH3)3), 67.24 (O-CH2), 61.34 (Phe2-Cα), 
45.06 (Phe1-Cα), 39.26 (Phe1-Cβ), 37.93 (Phe2-Cβ), 28.38 (-C(CH3)3). 
 
Fmoc-Leu[5Tz]Val-OBzl (9k). 
Prepared according to general procedure GP4, starting from 
Fmoc-Leu≡ (413 mg; 1.24 mmol).  
Yield: 621 mg (1.10 mmol); 89%. Rf (PE/EtOAc 3:1)= 0.27.  
MS (ESI): m/z= 589.3 [M+Na]+. [𝜶]𝑫
𝟐𝟓= -70 (CHCl3, c= 1).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 7.90-7.83 (m, 3H, 
HAr, NH), 7.64-7.61 (m, 2H, HAr), 7.42-7.38 (m, 2H, HAr), 7.31-7.27 (m, 2H, HAr), 7.27-7.16 
(m, 5H, Ph-H), 7.69 (s, 1H, Tz-H), 5.22 (d, 3J= 8.4 Hz, 1H, Val2-Hα), 5.08 (d, 2J= 12.6 Hz, 1H, 
O-CHH-), 4.98 (d, 2J= 12.6 Hz, 1H, O-CHH-), 4.84 (m, 1H, Leu1-Hα), 4.37 (dd, 2J= 10.4, 3J= 
6.7 Hz, 1H, CH-CHH-O), 4.14 (dd, 3J= 7.0, 6.7 Hz, 1H), 4.08 (dd, 2J= 10.4, 3J= 7.0 Hz, 1H, 
CH-CHH-O), 2.74 (m, 1H, Val2-Hβ), 1.82 (m, 1H, Leu1-Hβ), 1.55-1.44 (m, 2H, Leu1-Hβ, Leu1-
Hγ), 0.96 (d, 3J= 6.7 Hz, 3H, Val2-Hγ), 0.87 (d, 3J = 6.1 Hz, 3H, Leu1-Hδ), 0.85 (d, 3J = 5.9 Hz, 
3H, Leu1-Hδ), 0.76 (d, J = 6.7 Hz, 3H, Val2-Hγ). 
13C{1H}-NMR (151 MHz, DMSO-d6) δ [ppm]= 168.10 (Val-C), 156.12 (OCON), 144.18 (CAr), 
144.10 (CAr), 141.21 (CAr), 141.20 (CAr), 140.63 (Tz-C), 135.72 (CAr), 131.84 (Tz-CH), 128.76 
(2C; CHAr), 128.51 (CHAr), 128.10 (2C; CHAr), 128.07 (CHAr), 127.45 (2C; CHAr), 127.43 
(CHAr), 125.65 (CHAr), 125.49 (CHAr), 120.57 (CHAr), 120.54 (CHAr), 67.06 (CH2-Ph), 65.99 
(C-CH2-O), 65.48 (Val2-Cα), 47.07 (CH-CH2O), 43.10 (Leu1-Cα), 42.71 (Leu-Cβ), 31.00 (Val2-
Cβ), 24.71 (Leu-Cγ), 23.14 (Leu-Cδ), 21.95 (Leu-Cδ), 19.56 (Val-Cγ), 19.14 (Val-Cγ). 
 
Fmoc-Phe[5Tz]Phe-OBzl (9l). 
Prepared according to general procedure GP4, starting from 
Fmoc-Phe≡ (300 mg; 0.816 mmol). Yield: 482 mg 
(0.743 mmol); 91%. [𝜶]𝑫
𝟐𝟓= -95 (CHCl3, c= 1). 
Rf (PE/EtOAc 1:1)= 0.54.  
HR-MS (ESI): m/z= 671.2629 [M+Na]+ (calc. 671.26288).  
1H-NMR (600 MHz; CDCl3): δ [ppm]= 7.77-7.75 (m, 2H, HAr), 7.46 (s, 1H, Tz-H), 7.43-7.34 
(m, 4H, HAr), 7.30-7.17 (m, 11H, HAr), 7.14-7.10 (m, 2H, HAr), 7.05-7.01 (m, 2H, HAr), 6.92-
6.88 (m, 2H, HAr), 5.54 (dd, 3J= 11.2, 4.5 Hz, 1H, Phe2-Hα), 5.11 (d, 2J= 12.4 Hz, 1H, O-CHH-
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Ph), 5.05 (d, 2J= 12.4 Hz, 1H, O-CHH-Ph), 4.84 (d, 3J= 9.4 Hz, 1H, NH), 4.62 (ddd, 3J= 9.4, 
9.4, 5.5 Hz, 1H, Phe1-Hα), 4.30 (m, 1H, CH-CHHO), 4.03-3.97 (m, 2H, CH-CH2O, CH-
CHHO),  3.76-3.60 (m, 2H, Phe2-Hβ), 2.81 (dd, 2J= 14.3, 3J= 9.4 Hz, 1H, Phe1-Hβ), 2.73 (dd, 
2J= 14.3, 3J= 5.5 Hz, 1H, Phe1-Hβ).  
13C{1H}-NMR (151 MHz, CDCl3) δ [ppm]= 167.55 (Phe2-C), 155.53 (OCON), 143.60 (CAr), 
143.47 (CAr), 141.23 (2C; CAr), 138.97 (Tz-C), 136.00 (CAr), 135.55 (CAr), 134.83 (CAr), 131.13 
(Tz-CH), 129.08 (2C; CHAr), 128.93 (2C; CHAr), 128.79 (2C; CHAr), 128.59 (2C; CHAr), 128.48 
(2C; CHAr), 128.32 (CHAr), 127.84 (CHAr), 127.78 (2C; CHAr), 127.75 (CHAr), 127.25 (2C; 
CHAr), 127.07 (2C; CHAr), 125.05 (CHAr), 124.92 (CHAr), 119.99 (CHAr), 119.98 (CHAr), 67.70 
(O-CH2-Ph), 67.05 (CH-CH2O), 62.15 (Phe2-Cα), 46.96 (CH-CH2O), 45.24 (Phe1-Cα), 39.79 
(Phe1-Cβ), 37.93 (Phe2-Cβ). 
 
Fmoc-Gly[5Tz]Asp(tBu)-OBzl (9m). 
Prepared according to general procedure GP4, starting from 
Fmoc-Gly≡ (0.15 g; 0.54 mmol).  
Yield: 0.23 g (0.40 mmol); 74%. Rf (PE/EtOAc 2:1)= 0.20.  
MS (ESI): m/z= 605.3 [M+Na]+. 
1H-NMR (500 MHz, DMSO-d6) δ [ppm]= 7.94 (dd, 3J= 6.1, 6.0 Hz, 1H, NH), 7.91-7.88 (m, 
2H, HAr), 7.68-7.64 (m, 2H, HAr), 7.56 (s, 1H, Tz-H), 7.44-7.40 (m, 2H, HAr), 7.34-7.23 (m, 7H, 
HAr, Ph-H), 5.85 (dd, 3J= 8.2, 6.1 Hz, 1H, Asp-Hα), 5.15-5.09 (m, 2H, CH2Ph), 4.39-4.36 (m, 
2H, Gly-Hα), 4.33 (dd, 2J= 10.5, 3J= 6.9 Hz, CHCHHO), 4.30 (dd, 2J= 10.5, 3J= 6.7 Hz, 1H, 
CHCHHO), 4.21 (dd, 3J= 6.9, 6.7 Hz, 1H, CH-CH2O), 3.36-3.26 (m, 2H, Asp-Hβ), 1.28 (s, 9H).  
13C{1H}-NMR (151 MHz, CDCl3) δ [ppm]= 168.59 (CO2tBu), 167.81 (Asp-C), 156.68 
(OCON), 144.21 (2C; CAr), 141.21 (2C; CAr), 137.07 (Tz-C), 135.62 (CAr), 132.96 (Tz-CH), 
128.83 (2C; CHAr), 128.58 (CHAr), 128.10 (2C; CHAr), 128.01 (2C; CHAr), 127.50 (2C; CHAr), 
125.55 (2C; CHAr), 120.59 (2C; CHAr), 81.43 (C(CH3)3), 67.54 (CO2CH2Ph), 66.15 (CHCH2O), 
56.62 (Asp-Cα), 47.10 (CHCH2O), 36.99 (Asp-Cβ), 33.52 (Gly-Cα), 27.93 (C(CH3)3). 
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Fmoc-D-Phe[5Tz]Val-OBzl (9n). 
Prepared according to general procedure GP4, starting from 
Fmoc-D-Phe≡ (100 mg; 0.28 mmol).  
Yield: 142 mg (0.24 mmol); 86%. Rf (PE/EtOAc 2:1)= 0.22.  
MS (ESI): m/z= 623.3 [M+Na]+. 
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.06 (d, 3J= 8.8 Hz, 
1H, NH), 7.88-7.84 (m, 2H, HAr), 7.79 (s, 1H, Tz-H), 7.57-7.52 (m, 2H, HAr), 7.41-7.38 (m, 2H, 
HAr), 7.33-7.18 (12H, HAr, Ph-H), 5.21 (d, 3J= 9.0 Hz, 1H, Val-Hα), 5.13 (d, 2J= 12.6 Hz, 1H, 
CO2CHHPh), 5.10 (d, 2J= 12.6 Hz, 1H, CO2CHHPh), 4.97 (ddd, 3J= 10.0, 8.8, 5.2 Hz, 1H, Phe-
Hα), 3.08 (dd, 2J= 13.8, 3J= 10.0 Hz, 1H, Phe-Hβ), 2.97 (dd, 2J= 13.8, 5.2 Hz, 1H, Phe-Hβ), 4.23 
(dd, 2J= 10.6, 3J= 7.0 Hz, 1H, CH-CHHO), 4.18 (dd, 2J= 10.5, 3J= 6.9 Hz, 1H, CH-CHHO), 
4.10 (dd, 3J= 7.0, 6.9 Hz, 1H, CH-CH2O), 2.76 (m, 1H, Val-Hβ), 0.97 (d, 3J= 6.7 Hz, 3H, Val-
Hγ), 0.67 (d, 3J= 6.7 Hz, 3H, Val-Hγ). 
13C{1H}-NMR (151 MHz, DMSO) δ [ppm]= 167.93 (Val2-C), 156.00 (OCON), 144.08 (CAr), 
143.98 (CAr), 141.14 (CAr), 141.10 (CAr), 140.78 (Tz-C), 137.68 (CAr), 135.75 (CAr), 131.77 (Tz-
CH), 129.60 (2C; CHAr), 128.86 (2C; CHAr), 128.67 (CHAr), 128.57 (2C; CHAr), 128.28 (2C; 
CHAr), 128.07 (2C; CHAr), 127.48 (CHAr), 127.45 (CHAr), 126.93 (CHAr), 125.55 (CHAr), 125.43 
(CHAr), 120.55 (2C; CHAr), 67.24 (CO2CH2Ph), 66.09 (CHCH2O), 65.13 (Val-Cα), 46.97 
(CHCH2O), 46.39 (Phe-Cα), 39.63 (Phe-Cβ), 30.24 (Val-Cβ), 19.55 (Val-Cγ), 18.86 (Val-Cγ). 
 
Fmoc-D-Phe[5Tz]Lys(Cbz)-OBzl (9o). 
Prepared according to general procedure GP4, starting from 
Fmoc-D-Phe≡ (250 mg; 0.68 mmol).  
Yield: 411 mg (0.54 mmol); 79%. Rf (PE/EtOAc 2:1)= 0.15.  
HR-MS (ESI): m/z= 764.3409 [M+H]+ (calc. 764.34426). 
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.03 (d, 3J= 8.8 Hz, 
1H, FmocNH), 7.89-7.83 (m, 2H, HAr), 7.79 (s, 1H, Tz-H), 7.56-
7.51 (m, 2H, HAr), 7.40.7.37 (m, 2H, HAr), 7.33-7.15 (m, 17H, HAr, Ph-H), 7.11 (t, 3J= 5.6 Hz, 
1H, NHZ), 5.51 (dd, 3J= 9.0, 5.9 Hz, 1H, Lys-Hα), 5.13 (d, 2J= 12.6 Hz, 1H, CHHPh), 5.09 (d, 
2J= 12.7 Hz, 1H, CHHPh) 4.96 (ddd, 3J= 10.0 8.8, 5.2 Hz, 1H, Phe-Hα), 4.94-4.89 (m, 2H, 
NCO2CH2), 4.22 (dd, 2J= 10.6, 3J= 7.1 Hz, 1H, CHCHHO), 4.16 (dd, 2J= 10.7, 3J= 7.0 Hz, 1H, 
CHCHHO), 4.07 (dd, 3J= 7.1, 7.0 Hz, 1H, CHCH2O), 3.07 (dd, 2J= 13.8, 3J= 10.0 Hz, 1H, Phe-
Hβ), 2.97 (dd, 2J= 13.8, 3J= 5.2 Hz, 1H, Phe-Hβ), 2.88-2.81 (m, 2H, Lys-Hε), 2.32-2.23 (m, 2H, 
Lys-Hβ), 1.40-1.23 (m, 2H, Lys-Hδ), 1.19 (m, 1H, Lys-Hγ), 0.98 (m, 1H, Lys-Hγ). 
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13C{1H}-NMR (151 MHz, DMSO-d6) δ [ppm]= 168.61 (Lys-C), 156.45 (NCO2Bzl), 156.05 
(CHCH2OC), 144.06 (CAr), 143.99 (CAr), 141.13 (CAr), 141.10 (CAr), 140.64 (Tz-C), 137.65 (2C; 
CAr), 135.78 (CAr), 132.06 (Tz-CH), 129.64 (2C; CHAr), 129.39 (CHAr), 128.86 (2C; CHAr), 
128.75 (2C; CHAr), 128.62 (CHAr), 128.57 (2C; CHAr), 128.15 (2C; CHAr), 128.09 (CHAr), 
128.07 (CHAr), 127.75 (CHAr), 127.45 (CHAr), 126.93 (CHAr), 125.53 (CHAr), 125.45 (CHAr), 
121.84 (CHAr), 120.54 (CHAr), 120.48 (CHAr), 110.22 (CHAr), 67.32 (OCH2Ph), 66.06 
(CHCH2O), 65.52 (NCO2CH2Ph), 59.97 (Lys-Cα), 47.01 (CHCH2O), 46.49 (Phe-Cα), 40.22 
(Lys-Cε), 30.44 (Lys-Cβ), 29.21 (Lys-Cδ), 22.88 (Lys-Cγ). 
 
Boc-Val[5Tz]Ala-Leu[5Tz]Val-OBzl (10).  
Boc-Leu[5Tz]Val-OBzl (9e) (58 mg; 0.13 mmol; 1.2 eq) 
is dissolved in DCM/(4 M HCl in dioxane) 1:1 (1 mL) 
and stirred overnight at rt. After evaporation of the 
solvent, the ammonium salt is used without further 
purification. Boc-Val[5Tz]Ala-OH (35 mg; 0.11 mmol; 
synthesized from 9c according to GP5) and Oxyma (17 mg; 0.12 mmol; 1.1 eq) are dissolved 
in DCM (dry; 1 mL) under an argon atmosphere. After addition of DIC (18 µL; 15 mg; 
0.12 mmol; 1.1 eq) the solution is stirred 5 min at rt for preactivation. After preactivation 
of the carboxylic acid, the ammonium salt is dissolved in DCM (dry; 1 mL) and added 
dropwise to the reaction mixture, followed by sym-colldine (22 µL; 17 mg; 0.13 mmol; 
1.2 eq). After 5 min, another amount of sym-collidine (22 µL) is added and the reaction 
mixture left to stir overnight. After evaporation of the solvent, the product is purified by 
preparative HPLC.  
Yield: 57 mg (89 µmol); 81%. Analytical RP-HPLC: tR= 6.0 min (method 1, 220 nm).  
[𝜶]𝑫
𝟐𝟏= -55 (CHCl3, c= 0.1). HR-MS (ESI): m/z= 639.3996 [M+H]+ (calc. 639.39769).  
1H-NMR (600 MHz; MeOH-d3): δ [ppm]= 7.91 (d, 3J= 9.3 Hz, 1H, Leu-NH), 7.69 (s, 1H, Tz2-
H), 7.64 (d, 3J= 6.1 Hz, 1H, Val1-NH), 7.58 (s, 1H, Tz1-H), 7.39-7.23 (m, 5H, Ph-H), 5.32 (dt, 
3J= 9.3, 4.7 Hz, 1H, Leu-Hα), 5.26 (d, 2J= 12.6 Hz, 1H, O-CH2-), 5.17 (d, 2J= 12.6 Hz, 1H, O-
CH2-), 5.13 (d, 3J= 9.3 Hz, 1H, Val4-Hα), 5.10 (q, 3J= 6.9 Hz, 1H, Ala-Hα), 4.14 (dd, 3J= 8.7, 
6.1 Hz, 1H, Val1-Hα), 2.91 (m, 1H, Val4-Hβ), 1.98 (m, 1H, Val1-Hβ), 1.72 (ddd, 2J= 13.9 Hz, 
3J= 10.7, 4.7 Hz, 1H, Leu-Hβ), 1.63 (d, 3J= 6.9 Hz, 3H, Ala-Hβ), 1.56 (ddd, 2J= 13.9, 3J= 9.4, 4.7 
Hz, 1H, Leu-Hβ), 1.35 (s, 9H, -C(CH3)3), 1.25 (m, 1H, Leu-Hγ), 1.11 (d, 3J= 6.7 Hz, 3H, Val4-
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Hγ), 1.04 (d, 3J= 6.6 Hz, 3H, Val1-Hγ), 0.88 (d, 3J= 6.5 Hz, 3H, Leu-Hδ), 0.85 (d, 3J= 6.7 Hz, 
3H, Val4-Hγ), 0.78 (d, 3J= 6.6 Hz, 3H, Leu-Hδ), 0.77 (d, 3J= 7.4 Hz, 3H, Val1-Hγ).  
13C{1H}-NMR (151 MHz, MeOH-d3): δ [ppm]= 167.86 (Val4-C), 167.63 (Ala-C), 156.97 
(tBuO-C), 140.62 (Tz1-C), 140.54 (Tz2-C), 135.33 (CAr), 131.10 (Tz2-CH), 130.15 (Tz1-CH), 
128.28 (2C, CHAr), 128.05 (CHAr), 127.49 (2C, CHAr), 79.66 (-C(CH3)3), 67.03 (O-CH2-), 66.45 
(Val-Cα), 55.46 (Ala-Cα), 42.22 (Leu-Cβ), 40.84 (Leu-Cα), 32.50 (Val1-Cβ), 30.78 (Val4-Cβ), 
27.41 (3C, -C(CH3)3), 23.78 (Leu-Cγ), 21.99 (Leu-Cδ), 20.35 (Leu-Cδ), 18.66 (Val1-Cγ), 18.40 
(Val4-Cγ), 18.05 (Val1-Cγ), 17.89 (Val4-Cγ), 16.20 (Ala-Cβ).  
Crystal structure: CCDC 1561608. 
 
Boc-Ala[5Tz]Phe-Val[5Tz]Ala-Leu[5Tz]Val-OBzl (11).  
10 (40 mg; 63 µmol) is dissolved in 
DCM/(4 M HCl in dioxane) 1:1 (2 mL) and 
stirred for 3 h at rt. After evaporation of the 
solvent, the ammonium salt is used without 
further purification. Boc-Ala[5Tz]Phe-OH 
(25 mg; 69 µmol; 1.1 eq; synthesized from 9a according to GP5), Oxyma (11 mg; 76 µmol; 
1.2 eq) are dissolved in DCM (dry; 0.7 mL), after the addition of DIC (12 µL; 76 µmol; 1.2 eq) 
the mixture is stirred 5 min for preactivation. The ammonium salt is dissolved in DCM 
(dry; 0.7 mL) together with sym-collidine (84 µL; 0.63 mmol; 10 eq) and stirred at rt. The 
activated acid is added dropwise to the amine solution, after this the combined mixture is 
stirred overnight. After evaporation of the solvent, the product is purified by preparative 
RP-HPLC. Yield: 47 mg (53 µmol); 84%. Analytical RP-HPLC: tR= 6.4 min (method 1, 220 
nm). HR-MS (ESI): m/z= 881.5162 [M+H]+ (calc. 881.51445).  
1H-NMR (600 MHz; MeOH-d3): δ [ppm]= 8.28 (d, 3J= 6.6 Hz, 1H, Val3-NH), 8.17 (d, 
3J= 8.7 Hz, 1H, Leu-NH), 7.80 (s, 1H, Tz3-H), 7.61 (s, 1H, Tz2-H), 7.54 (s, 1H, Tz1-H), 7.47 
(d, 3J= 5.2 Hz, 1H, Boc-NH), 7.37-7.27 (m, 5H, Ph-H), 7.19-7.16 (m, 3H, Ph-H), 6.91-6.89 (m, 
2H, Ph-H), 5.54 (dd, 3J= 7.8, 7.8 Hz, 1H, Phe-Hα), 5.32 (m, 1H, Leu-Hα), 5.27 (d, 2J= 12.5 Hz, 
1H, O-CH2-), 5.25-5.22 (m, 2H, Ala4-Hα, Val6-Hα), 5.20 (d, 2J= 12.5 Hz, 1H, O-CH2-), 4.48 
(dd, 3J= 10.0, 6.6 Hz, 1H, Val3-Hα), 4.37 (qd, 3J= 6.9, 5.2 Hz, 1H, Ala1-Hα), 3.42-3.41 (m, 2H, 
Phe2-Hβ), 2.93 (m, 1H, Val6-Hβ), 2.04 (m, 1H, Val3-Hβ), 1.91 (ddd, 2J= 14.5 Hz, 3J= 9.9, 5.4 Hz, 
1H, Leu-Hβ), 1.64 (m, 1H, Leu-Hβ), 1.63 (d, 3J= 7.0 Hz, 3H, Ala4-Hβ), 1.39 (s, 9H, -C(CH3)3), 
1.31 (m, 1H, Leu-Hγ), 1.13 (d, 3J= 6.7 Hz, 3H, Val6-Hγ), 0.91 (d, 3J= 6.5 Hz, 3H, Val6-Hγ), 0.88 
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(d, 3J= 6.7 Hz, 6H, Leu-Hδ), 0.78 (d, 3J= 6.5 Hz, 3H, Val3-Hγ), 0.72 (d, 3J= 6.7 Hz, 3H, Val3-
Hγ), 0.60 (d, 3J= 6.9 Hz, 3H, Ala1-Hβ).  
13C-NMR (151 Mhz; MeOH-d3): δ [ppm]= 168.59 (Phe-C), 167.65 (Ala4-C), 167.56 (Val6-C), 
156.67 (tBuO-C), 143.89 (Tz1-C), 140.45 (Tz3-C), 139.76 (Tz2-C), 136.29 (Phe-CAr), 135.41 
(CAr), 131.28 (Tz3-CH), 130.30 (Tz2-CH), 129.46 (Tz1-CH), 128.90 (2C, CHAr), 128.40 (2C, 
CHAr), 128.32 (2C, CHAr), 128.09 (2C, CHAr), 127.71 (CHAr), 126.78 (CHAr), 79.48 (-C(CH3)3), 
67.16 (O-CH2-Ph), 66.47 (Val6-Cα), 61.79 (Phe-Cα), 55.84 (Ala4-Cα), 50.87 (Val3-Cα), 42.29 
(Leu-Cβ), 41.41 (Leu-Cα), 40.67 (Ala1-Cα), 37.31 (Phe-Cβ), 32.64 (Val3-Cβ), 30.83 (Val6-Cβ), 
27.30 (3C, -C(CH3)3), 24,16 (Leu-Cγ), 20.64 (Val6-Cγ), 18.88 (Ala1-Cβ), 18.49 (Val3-Cγ), 18.46 
(Val6-Cγ), 18.27 (Val3-Cγ), 17.94 (2C, Leu-Cδ), 16.43 (Ala4-Cβ). 
 
Boc-D-Ala[5Tz]Phe-D-Val[5Tz]Ala-OBzl (12).  
Boc-D-Val[5Tz]Ala-OBzl (9f) (41 mg; 0.10 mmol; 
1.0 eq) is dissolved in 1 mL DCM/(4 M HCl in dioxane) 
1:1 and stirred for 2 h at RT. The solvent is removed 
under vacuum to obtain the crude ammonium salt. 
Boc-D-Ala[5Tz]Phe-OH (37 mg; 0.10 mmol; 1.0 eq; 
synthesized from 9b according to GP5), HOAt (15 mg; 
0.11 mmol; 1.1 eq) and DCC (23 mg; 0.11 mg; 1.1 eq) are dissolved in DCM (1.5 mL; dry) 
and stirred for 10 min at RT. The ammonium salt is dissolved in DCM (1 mL; dry) and 
added dropwise to the activated acid, followed by sym-collidine (66 µL; 61 mg; 0.50 mmol; 
5.0 eq), the reaction mixture is stirred overnight. The reaction mixture is diluted with DCM 
(10 mL) and filtered to remove dicyclohexylurea. The filtrate is concentrated in vacuum, 
the crude products purified by preparative HPLC. Yield: 33 mg (0.051 mmol); 51%.  
MS (ESI): m/z= 667.4 [M+Na]+. Analytical RP-HPLC: tR= 5.9 (method 1, 220 nm).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.89 (d, 3J= 8.5 Hz, 1H, Val3-NH), 7.66 (s, 1H, 
Tz2-H), 7.55 (s, 1H, Tz1-H), 7.47 (d, 3J= 8.2 Hz, 1H, Ala1-NH), 7.35-7.15 (m, 10H, Ph-H), 5.62 
(q, 3J= 7.0 Hz, 1H, Ala4-Hα), 5.56 (dd, 3J= 8.0, 7.4 Hz, 1H, Phe2-Hα), 5.12 (d, 2J= 12.7 Hz, 1H, 
-O-CH2-), 5.10 (d, 2J= 12.7 Hz, 1H, -O-CH2-), 4.73 (dq, 3J= 8.2, 7.0 Hz, 1H, Ala1-Hα), 4.61 (dd, 
3J= 8.5, 8.5 Hz, 1H, Val3-Hα), 3.66 (dd, 2J= 13.9 Hz, 3J= 8.0 Hz, 1H, Phe2-Hβ), 3.49 (dd, 2J= 
13.9 Hz, 3J= 7.4 Hz, 1H, Phe2-Hβ), 2.03 (m, 1H, Val3-Hβ), 1.57 (d, 3J= 7.0 Hz, 3H, Ala4-Hβ), 
1.36 (s, 9H, -C(CH3)3), 1.04 (d, 3J= 7.0 Hz, 3H, Ala1-Hβ), 0.64 (d, 3J= 6.6 Hz, 3H, Val3-Hγ), 
0.58 (d, 3J= 6.6 Hz, 3H, Val3-Hγ).  
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13C{1H}-NMR (151 MHz; DMSO-d6): δ [ppm]= 169.19 (Ala4-C), 167.34 (Phe2-C), 155.50 
(tBuO-C), 141.44 (Tz1-C), 139.35 (Tz2-C), 136.84 (Phe2-CAr), 135.78 (CAr), 131.42 (Tz1-CH), 
131.24 (Tz2-CH), 129.45 (2C, CHAr), 128.79 (2C, CHAr), 128.58 (CHAr), 128.56 (2C, CHAr), 
128.10 (2C, CHAr), 127.04 (CHAr), 78.96 (-C(CH3)3), 67.25 (-O-CH2-), 61.92 (Phe2-Cα), 55.42 
(Ala4-Cα), 49.00 (Val3-Cα), 39.88 (Ala1-Cα), 37.01 (Phe2-Cβ), 31.36 (Val3-Cβ), 28.59 (-
C(CH3)3), 20.64 (Ala1-Cβ), 19.82 (Val3-Cγ), 18.90 (Val3-Cγ), 17.34 (Ala4-Cβ). 
 
Boc-D-Ala[5Tz]Phe-D-Val[5Tz]Ala-D-Leu[5Tz]Val-OBzl (13).  
Boc-D-Leu[5Tz]Val-OBzl (9d) (18 mg; 
0.040 mmol; 1.0 eq) is dissolved in 2 mL 
DCM/(4 M HCl in dioxane) 1:1 and stirred 
for 2 h at RT. The solvent is removed under 
vacuum to obtain the crude ammonium 
salt. Boc-D-Ala[5Tz]Phe-D-Val[5Tz]Ala-OH (22 mg; 0.040 mmol; 1.0 eq; synthesized from 
12 according to GP5), HOAt (6 mg; 0.04 mmol; 1.0 eq) and DCC (9 mg; 0.04 mg; 1.0 eq) are 
dissolved in DCM (1 mL; dry) and stirred for 10 min at RT. The ammonium salt is dissolved 
in DCM (1 mL; dry) and added dropwise to the activated acid, followed by sym-collidine 
(29 µL; 27 mg; 0.22 mmol; 5.5 eq), the reaction mixture is stirred overnight. The solvent is 
removed under vacuum, the residue dissolved in EtOAc (10 mL) and filtered to remove 
insoluble dicyclohexylurea. After washing with 5% KHSO4 solution (3x5 mL), 5% NaHCO3 
solution (3x5 mL), brine (1x5 mL), and drying over MgSO4 the triazole is purified by flash 
chromatography. Yield: 25 mg (0.028 mmol); 70%. Rf (PE/EtOAc 1:3)= 0.50.  
HR-MS (ESI): m/z= 881.51325 [M+H]+ (calc. 881.51445).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.91 (d, 3J= 8.1 Hz, 1H, Leu5-NH), 8.87 (d, 
3J= 8.5 Hz, 1H, Val3-NH), 7.72 (s, 1H, Tz3-H), 7.61 (s, 1H, Tz2-H), 7.54 (s, 1H, Tz1-H), 7.48 
(d, 3J= 8.1 Hz, 1H, BocNH), 7.35-7.16 (m, 10H, Ph-H), 5.55 (dd, 3J= 7.9, 7.5 Hz, 1H, Phe2-Hα), 
5.25 (q, 3J= 7.1 Hz, 1H, Ala4-Hα), 5.17 (d, 2J= 12.4 Hz, 1H, O-CH2-), 5.11 (d, 2J= 12.4 Hz, 1H, 
O-CH2-), 5.05 (d, 3J= 8.7 Hz, 1H, Val6-Hα), 4.91 (ddd, 3J= 10.4, 8.1, 4.8 Hz, 1H, Leu5-Hα), 4.69 
(dq, 3J= 8.1, 6.9 Hz, 1H, Ala1-Hα), 4.39 (dd, 3J= 8.9, 8.5 Hz, Val3-Hα), 3.65 (dd, 2J= 14.0 Hz, 
3J= 7.9 Hz, 1H, Phe2-Hβ), 3.52 (dd, 2J= 13.9, 3J= 7.5 Hz, 1H, Phe2-Hβ), 2.76 (dqq, 3J= 8.7, 6.7, 
6.7 Hz, 1H, Val6-Hβ), 1.86 (m, 1H, Val3-Hβ), 1.72 (ddd, 2J= 13.6, 3J= 10.4, 5.0 Hz, 1H, Leu5-
Hβ), 1.62 (d, 3J= 7.1 Hz, 3H, Ala4-Hβ), 1.51 (m, 1H, Leu5-Hγ), 1.36 (s, 9H, C(CH3)3), 1.32 (ddd, 
2J= 13.6 Hz, 3J= 8.9, 4.8 Hz, 1H, Leu5-Hβ), 0.99 (d, 3J= 6.9 Hz, 3H, Ala1-Hβ) 0.96 (d, 3J= 6.7 
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Hz, 3H, Val6-Hγ), 0.75 (d, 3J= 6.6 Hz, 3H, Leu5-Hδ), 0.72 (d, 3J= 6.6 Hz, 3H, Leu5-Hδ), 0.67 
(d, 3J= 6.7 Hz, 3H, Val6-Hγ), 0.54 (d, 3J= 6.6 Hz, 3H, Val3-Hγ), 0.34 (d, 3J= 6.6 Hz, 3H, Val3-
Hγ).  
13C-NMR (151 MHz; DMSO-d6): δ [ppm]= 168.92 (Ala4-C), 168.08 (Val6-C), 167.45 (Phe2-
C), 155.49 (tBuO-C), 141.54 (Tz1-C), 141.21 (Tz3-C), 139.01 (Tz2-C), 136.79 (Phe2-Cγ), 135.61 
(CAr), 131.41 (2C, Tz2-CH, Tz3-CH), 131.14 (Tz1-CH), 129.42 (2C, CHAr), 128.86 (2C, CHAr), 
128.75 (CHAr), 128.59 (2C, CHAr), 128.50 (2C, CHAr), 127.06 (CHAr), 78.98 (-C(CH3)3), 67.34 
(O-CH2-), 65.37 (Val6-Cα), 61.89 (Phe2-Cα), 56.64 (Ala4-Cα), 48.86 (Val3-Cα), 42.96 (Leu5-
Cβ), 41.66 (Leu5-Cα), 40.07 (Ala1-Cα), 36.97 (Phe2-Cβ), 31.25 (Val3-Cβ), 30.20 (Val6-Cβ), 28.60 
(-C(CH3)3), 24.75 (Leu5-Cγ), 23.05 (Leu5-Cδ), 21.39 (Leu5-Cδ), 20.60 (Ala1-Cβ), 19.70 (Val3-
Cγ), 19.54 (Val6-Cγ), 18.95 (Val6-Cγ), 18.75 (Val3-Cγ), 17.82 (Ala4-Cβ). 
 
Boc-Val[5Tz]Ala-Leu[5Tz]Val-Ala-OBzl (14). 
Boc-Val[5Tz]Ala-Leu[5Tz]Val-OH (32 mg; 
58 µmol; synthesized from 10 according to GP5), 
COMU (50 mg; 0.12 mmol; 2.0 eq) and Oxyma 
(16 mg; 0.12 mmol; 2.0 eq) are dissolved in DCM 
(2 mL; dry), after addition of sym-collidine 
(15 µL; 0.12 mmol; 2.0 eq), the mixture is stirred 
for 10 min at RT for preactivation. H-Ala-OBzl.Tos (41 mg; 0.12 mmol; 2.0 eq) is added, 
followed by sym-collidine (15 µL; 0.12 mmol; 2.0 eq) and the reaction mixture is left to stir 
overnight. Afterwards the solvent is removed under vacuum and the peptidotriazolamer 
purified by preparative HPLC. Yield: 37 mg (52 µmol); 90%. Analytical RP-HPLC: tR= 3.4 
min (method 2, 254 nm). HR-MS (ESI): m/z= 710.4340 (calc. 710.43481).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.66 (d, 3J= 6.5 Hz, 1H, Ala5-NH), 7.92 (d, 3J= 8.6 
Hz, 1H, Leu3-NH), 7.76 (d, 3J= 7.2 Hz, 1H, Boc-NH), 7.70 (s, 1H, Tz2-H), 7.57 (s, 1H, Tz1-H), 
7.39-7.30 (m, 5H, Ph-H), 5.43 (q, 3J= 6.7 Hz, 1H, Ala2-Hα), 5.13 (s, 2H, O-CH2-), 5.34 (m, 1H, 
Leu3-Hα) 4.91 (d, 3J= 10.4 Hz, 1H, Val4-Hα), 4.52 (dd, 3J= 7.8, 7.2 Hz, 1H, Val1Hα), 4.28 (qd, 
3J= 7.3 Hz, 6.5 Hz, Ala5-Hα), 2.82 (dqq, 3J= 10.4, 6.6, 6.5 Hz, 1H, Val4-Hβ), 1.91 (dqq, 3J= 7.8, 
6.8, 6.5 Hz, 1H, Val1-Hβ), 1.62 (m, 1H, Leu3-Hβ), 1.58 (d, 3J= 6.8 Hz, 3H, Ala2-Hβ), 1.43 (m, 
1H, Leu3-Hβ), 1.37 (s, 9H, C(CH3)3), 1.33 (d, 3J= 7.3 Hz, 3H, Ala5-Hβ), 1.24 (m, 1H, Leu3-Hγ), 
0.98 (d, 3J= 6.6 Hz, 3H, Val4-Hβ), 0.93 (d, 3J= 6.5 Hz, 3H, Val1-Hγ), 0.79 (d, 3J= 6.5 Hz, 3H, 
Leu3-Hδ), 0.71 (d, 3J= 6.7 Hz, 3H, Leu3-Hδ), 0.69 (d, 3J= 6.8 Hz, 3H, Val1-Hγ), 0.63 (d, 3J= 
6.5 Hz, 3H, Val4-Hβ).  
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13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 172.40 (Phe6-C), 167.75 (Ala2-C), 167.13 
(Val4-C), 156.53 (tBuO-C), 140.75 (Tz2-C), 140.30 (Tz1-C), 136.28 (CAr), 132.33 (Tz2-CH), 
131.17 (Tz1-CH), 128.86 (2C, CHAr), 128.49 (CHAr), 128.26 (2C, CHAr), 79.26 (C(CH3)3), 68.21 
(Val4-Cα), 66.49 (O-CH2-), 55.67 (Ala3-Cα), 51.10 (Val1-Cα), 48.62 (Ala5-Cα), 44.05 (Leu3-
Cβ), 41.91 (Leu3-Cα), 32.93 (Val1-Cβ), 30.18 (Val4-Cβ), 28.59 (C(CH3)3), 24.61 (Leu3-Hγ), 
23.17 (CH3), 22.07 (CH3), 19.45 (2C, CH3), 19.40 (CH3), 19.15 (CH3), 17.72 (Ala3-Cβ), 17.04 
(Ala5-Cβ). 
 
Boc-Ala[5Tz]Ala-Ala[5Tz]Ala-OBzl (15). 
Boc-Ala[5Tz]Ala-OBzl (9g) (52 mg; 0.14 mmol; 1.1 eq) 
is dissolved in DCM/(4 M HCl in dioxane) 1:1 (1.5 mL) 
and stirred overnight at rt. After evaporation of the 
solvent, the ammonium salt is used without further 
purification. Boc-Ala[5Tz]Ala-OH (36 mg; 0.13 mmol; 
synthesized from 9g according to GP5), Oxyma (20 mg; 0.14 mmol; 1.1 eq) and COMU 
(60 mg; 0.14 mmol; 1.1 eq) are dissolved in DCM (dry; 1 mL) under an argon atmosphere, 
after the addition of sym-collidine (34 µL;0.26 mmol; 2.0 eq) the mixture is preactivated for 
5 min at RT. After preactivation of the carboxylic acid, the ammonium salt is dissolved in 
DCM (dry; 1 mL) and added dropwise to the reaction mixture, followed by sym-collidine 
(34 µL; 0.26 mmol; 2.0 eq). The reaction mixture left to stir overnight. After evaporation of 
the solvent, the product is purified by preparative HPLC.  
Yield: 52 mg (0.10 mmol); 77%. Analytical RP-HPLC: tR= 2.9 min (method 2, 220 nm).  
HR-MS (ESI): m/z= 541.2897 [M+H]+ (calc. 541.28814).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.45 (d, 3J= 8.4 Hz, 1H, Ala3-NH), 7.73 (s, 1H, 
Tz2-H), 7.61 (s, 1H, Tz1-H), 7.46 (d, 3J= 7.5 Hz, 1H, Boc-NH), 7.39-7.30 (m, 5H, Ph-H), 5.64 
(q, 3J= 7.2 Hz, 1H, Ala4-Hα), 5.23 (dq, 3J= 8.4, 6.9 Hz, Ala3-Hα), 5.18 (q, 3J= 7.1 Hz, Ala2-Hα), 
5.19-5.16 (m, 2H, O-CH2-), 4.81 (dq, 3J= 7.5, 7,0 Hz, 1H, Ala1-Hα), 1.78 (d, 3J= 7.2 Hz, 3H, 
Ala4-Hβ), 1.61 (d, 3J= 7.1 Hz, 3H, Ala2-Hβ), 1.40 (d, 3J= 6.9 Hz, 3H, Ala3-Hβ) 1.35 (s, 9H, 
C(CH3)3), 1.34 (d, 3J= 7.0 Hz, 3H, , Ala1-Hβ).  
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 168.91 (Ala4-C), 167.41 (Ala2-C), 154.95 
(tBuO-C), 140.80 (Tz1-C), 139.80 (Tz2-C), 135.43 (CAr), 131.33 (Tz2-CH), 131.04 (Tz1-CH), 
128.42 (2C, CHAr), 128.12 (CHAr), 127.74 (2C, CHAr), 78.46 (C(CH3)3), 66.85 (O-CH2-), 56.26 
(Ala2-Cα), 55.41 (Ala4-Cα), 40.33 (Ala1-Cα), 38.24 (Ala3-Cα), 28.13 (C(CH3)3), 21.18 (Ala1-
Cβ), 19.90 (Ala3-Cβ), 17.49 (2C, Ala2-Cβ, Ala4-Cβ). 
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Boc-D-Val[5Tz]Ala-D-Leu[5Tz]Val-OBzl (16). 
Boc-D-Leu[5Tz]Val-OBzl (9d) (71 mg; 0.16 mmol; 
1.1 eq) is dissolved in DCM/(4 M HCl in dioxane) 1:2 
(1.5 mL) and stirred overnight at rt. After evaporation 
of the solvent, the ammonium salt is used without 
further purification. Boc-D-Val[5Tz]Ala-OH (45 mg; 
0.14 mmol; synthesized from 9f according to GP5) and Oxyma (23 mg; 0.16 mmol; 1.1 eq) 
are dissolved in DCM (dry; 1 mL) under an argon atmosphere. After addition of DIC (25 µL; 
0.16 mmol; 1.1 eq) the solution is stirred 5 min at rt for preactivation. After preactivation 
of the carboxylic acid, the ammonium salt is dissolved in DCM (dry; 1 mL) and added 
dropwise to the reaction mixture, followed by DIPEA (56 µL; 0.32 mmol; 2.2 eq). After 
evaporation of the solvent, the product is purified by preparative HPLC. Yield: 66 mg 
(0.10 mmol); 71%. Rf (ethylacetate)= 0.60. MS (ESI): m/z= 661.4 [M+Na]+. 
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.86 (d, 3J= 8.2 Hz, 1H, Leu3-NH), 7.73 (s, 1H, 
Tz2-H), 7.52 (s, 1H, Tz1-H), 7.39 (d, 3J= 9.0 Hz, 1H, Boc-NH), 7.35-7.31 (m, 3H, Ph-H), 7.25-
7.21 (m, 2H, Ph-H), 5.37 (q, 3J= 7.0 Hz, 1H, Ala2-Hα), 5.17 (d, 2J= 12.2 Hz, 1H, O-CHH), 5.11 
(d, 2J = 12.2 Hz, 1H, O-CHH), 5.10 (d, 3J= 9.0 Hz, 1H, Val4-Hα), 4.94 (m, 1H, Leu3-Hα), 4.25 
(dd, 3J= 9.0, 8.9 Hz, 1H, Val1-Hα), 2.76 (m, 1H, Val4-Hβ), 1.85-1.74 (m, 2H, Val1-Hβ, Leu3-
Hβ), 1.76 (d, 3J= 7.0 Hz, 3H, Ala2-Hβ), 1.51 (m, 1H, Leu3-Hγ), 1.32 (m, 1H, m, 1H, Leu3-Hβ), 
0.97 (d, 3J= 6.7 Hz, 3H, Val4-Hγ), 0.73 (d, 3J= 6.6 Hz, 3H, Leu3-Hδ), 0.77 (d, 3J= 6.6 Hz, 6H, 
Leu3-Hδ, Val1-Hγ), 0.66 (d, 3J= 6.7 Hz, 3H, Val4-Hγ), 0.43 (d, 3J= 6.7 Hz, 3H, Val1-Hγ). 
13C{1H}-NMR (126 MHz; DMSO-d6): δ [ppm]= 168.81 (Ala2-C), 168.14 (Val4-C), 156.01 
(tBuO-C), 140.98 (Tz2-C), 140.09 (Tz1-C), 135.62 (CAr), 131.57 (Tz2-CH), 131.19 (Tz1-CH), 
128.87 (CHAr; 2C), 128.75 (CHAr), 128.51 (CHAr; 2C), 78.81 (C(CH3)3), 67.34 (OCH2), 65.35 
(Val4-Cα), 56.50 (Ala2-Cα), 50.30 (Val1-Cα), 42.93 (Leu3-Cβ), 41.45 (Leu3-Cα), 31.68 (Val1-
Cβ), 30.11 (Val4-Cβ), 28.56 (C(CH3)3), 24.75 (Leu3-Cγ), 23.03 (Val1-Cγ), 21.45 (Leu3-Cδ), 19.83 
(Val1-Cγ), 19.53 (Val4-Cγ), 18.98 (Leu3-Cδ), 18.93 (Val4-Cγ), 18.38 (Ala2-Cβ). 
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Boc-D-Val[5Tz]Ala-D-Leu[5Tz]Val-D-chGly[5Tz]Phe-OBzl (17). 
 Boc-D-chGly[5Tz]Phe-OBzl (9i) (32 mg; 
 61 µmol; 1.1 eq) is dissolved in DCM/(4 M 
HCl in dioxane) 1:1 (2 mL) and stirred 
overnight at rt. After evaporation of the 
solvent, the ammonium salt is used 
without further purification. Boc-D-
Val[5Tz]Ala-D-Leu[5Tz]Val-OH (30 mg; 55 µmol; synthesized from 16 according to GP5), 
COMU (24 mg; 55 µmol; 1.0 eq) and Oxyma (8 mg; 0.06 mmol; 1.0 eq) are dissolved in DCM 
(1 mL; dry), after addition of sym-collidine (7.3 µL; 55 µmol; 1.0 eq), the mixture is stirred 
for 5 min at RT for preactivation. After preactivation of the carboxylic acid, the ammonium 
salt is dissolved in DCM (dry; 0.5 mL) and added dropwise to the reaction mixture, followed 
by sym-colldine (7.3 µL; 55 µmol; 1.0 eq). The reaction mixture left to stir overnight. After 
evaporation of the solvent, the product is purified by preparative HPLC.  
Yield: 40 mg (42 µmol); 76%. Analytical RP-HPLC: tR= 3.6 min (method 2, 254 nm).   
HR-MS (ESI): m/z= 475.2933 [M+2H]2+ (calc. 475.29216).  
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 8.84 (d, 3J= 8.0 Hz, 1H, Leu3-NH), 8.69 (d, 
3J= 8.5 Hz, 1H, chGly5-NH), 7.66 (s, 1H, Tz2-H), 7.63 (s, 1H, Tz3-H), 7.51 (s, 1H, Tz1-H), 
7.37 (d, 3J= 8.9 Hz, 1H, Boc-NH), 5.97 (dd, 3J= 7.9, 7.3 Hz, 1H, Phe6-Hα), 5.35 (q, 3J= 7.0 Hz, 
1H, Ala2-Hα), 5.09 (d, 2J= 12.5 Hz, 1H, -O-CHH-), 5.05 (d, 2J= 12.5 Hz, 1H, -O-CHH-), 4.88 
(ddd, 3J= 10.7, 8.0, 4.9 Hz, 1H, Leu3-Hα), 4.77 (d, 3J= 9.9 Hz, 1H, Val4-Hα), 4.68 (dd, 3J= 8.8, 
8.5 Hz, 1H, chGly5-Hα), 4.22 (dd, 3J= 8.9, 8.8 Hz, 1H, Val1-Hα), 3.64 (dd, 2J= 14.0, 3J= 7.9 Hz, 
1H, Phe6-Hβ), 3.28 (dd, 2J= 14.0, 3J= 7.3 Hz, 1H, Phe6-Hβ), 2.83 (dqq, 3J= 9.9, 6.8 6.5 Hz, 1H, 
Val4-Hβ), 1.77 (d, 3J= 7.0 Hz, 3H, Ala2-Hβ), 1.77-1.71 (m, 2H, Val1-Hβ, chGly5-Hβ), 1.66-1.59 
(m, 2H, Leu3-Hβ, CH2), 1.58-1.44 (m, 3H, CH2), 1.36 (m, 1H, Leu3-Hγ), 1.35 (s, 9H, C(CH3)3), 
1.12 (m, 1H, CH2), 1.04-0.87 (m, 4H, Leu3-Hβ, CH2), 0.80 (d, 3J= 6.8 Hz, 3H, Val4-Hγ), 0.72 
(d, 3J= 6.7 Hz, 3H, Val1-Hγ), 0.69 (d, 3J= 6.6 Hz, 6H, Leu3-Hδ), 0.67 (m, 1H, CH2), 0.56 (d, 3J= 
6.5 Hz, 3H, Val4-Hγ), 0.50 (m, 1H, CH2), 0.39 (d, 3J= 6.7 Hz, 3H, Val1-Hγ). 
13C{1H}-NMR (126 MHz, DMSO-d6): δ [ppm]= 168.78 (Ala2-C), 168.37 (Phe6-C), 167.48 
(Val4-C), 156.02 (tBuO-C), 141.01 (Tz2-C), 140.07 (Tz1-C), 139.37 (Tz3-C), 136.12 (CAr), 
135.54 (CAr), 131.78 (Tz3-CH), 131.38 (Tz2-CH), 131.16 (Tz1-CH), 129.56 (2C; CHAr), 
128.76(2C; CHAr), 128.63(CHAr), 128.51(2C; CHAr), 128.31(2C; CHAr), 127.02(CHAr), 78.81 
(C(CH3)3), 67.60 (Val4-Cα), 67.39 (-OCH2-), 60.45 (Phe6-Cα), 56.43 (Ala2-Cα), 50.37 (Val1-
Cα), 47.97 (chGly5-Cα), 43.33 (Leu3-Cβ), 41.57 (Leu3-Cα), 40.71 (chGly5-Cβ), 37.27 (Phe6-
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Cβ), 31.70 (Val1-Cβ), 30.08 (Val4-Cβ), 29.74 (CH2), 28.92(CH2), 28.57 (C(CH3)3), 25.97 (CH2), 
25.57 (CH2), 25.54 (CH2), 24.85 (Leu3-Cγ), 23.07 (Leu3-Cδ), 21.41 (Leu3-Cδ), 19.80 (Val1-Cγ), 
19.36 (Val4-Cγ), 18.90 (Val4-Cγ), 18.81 (Val1-Cγ), 18.42 (Ala2-Cβ). 
 
Boc-D-Val[4Tz]Phe-OBzl (18a). 
Boc-D-Val≡ (8c) (85 mg; 0.43 mmol) and N3-Phe-OBzl (4c) 
(133 mg; 0.47 mmol; 1.1 eq) are dissolved in DMF/H2O 2:1 
(1.5 mL), CuSO4.5H2O (54 mg; 0.22 mmol; 0.5 eq) and sodium 
ascorbate (85 mg; 0.43 mmol; 1.0 eq) are added and the 
reaction mixture left to stir overnight. The solvent is 
removed by rotary evaporator and the triazole purified by flash chromatography 
(PE/EtOAc 3:1). Yield: 138 mg (0.29 mmol); 67%. Rf (PE/EtOAc 3:1)= 0.40.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.92 (s, 1H, Tz-H), 7.38-7.31 (m, 3H, BocNH, Ph-
H), 7.28-7.24 (m, 2H, Ph-H), 7.20-7.15 (m, 3H, Ph-H), 7.13-7.08 (m, 3H, Ph-H), 5.91 (dd, 3J= 
10.7, 5.3 Hz, 1H, Phe-Hα), 5.21-5.18 (m, 2H, OCH2), 4.43 (dd, J = 9.3, 7.3 Hz, 1H, Val-Hα), 
3.58 (dd, 2J= 14.2, 3J= 5.3 Hz, 1H, Phe-Hβ), 3.48 (dd, 2J= 14.2, 3J= 10.7 Hz, 1H, Phe-Hβ), 1.89 
(m, 1H, Val-Hβ), 1.37 (s, 9H, C(CH3)3), 0.77 (d, 3J= 6.7 Hz, 3H, Val-Hγ), 0.62 (d, 3J= 6.8 Hz, 
3H, Val-Hγ). 
 
Boc-D-Leu[4Tz]Phe-OBzl (18b). 
Boc-D-Leu≡ (8e) (90 mg; 0.43 mmol) and N3-Phe-OBzl (4c) 
(133 mg; 0.47 mmol; 1.1 eq) are dissolved in DMF/H2O 2:1 
(1.5 mL), CuSO4.5H2O (54 mg; 0.22 mmol; 0.5 eq) and sodium 
ascorbate (85 mg; 0.43 mmol; 1.0 eq) are added and the 
reaction mixture left to stir overnight. The solvent is removed 
by rotary evaporator and the triazole purified by flash chromatography (PE/EtOAc 3:1). 
Yield: 130 mg (0.26 mmol); 60%. Rf (PE/EtOAc 3:1)= 0.42. MS (ESI): m/z= 515.3 [M+Na]+.   
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.94 (s, 1H, Tz-H), 7.39-7.30 (m, 3H, Boc-NH, Ph-
H), 7.28-7.23 (m, 2H, Ph-H), 7.21-7.15 (m, 4H, Ph-H), 7.12-7.09 (m, 2H, Ph-H), 5.89 (dd, 3J= 
10.4, 5.6 Hz, 1H, Phe-Hα), 5.20-5.18 (m, 2H, OCH2), 4.67 (m, 1H, Leu-Hα), 3.57 (dd, 2J= 14.2, 
3J= 5.6 Hz, 1H, Phe-Hβ), 3.50 (dd, 2J= 14.2, 3J= 10.4 Hz, 1H, Phe-Hβ), 1.56-1.47 (m, 2H, Leu-
Hβ), 1.37 (s, 9H, C(CH3)3), 1.30 (m, 1H, Leu-Hγ), 0.86 (d, 3J= 6.6 Hz, 3H, Leu-Hδ), 0.83 (d, 3J= 
6.6 Hz, 3H, Leu-Hδ). 
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Boc-Gly[4Tz]Phe-OBzl (18d). 
Boc-Gly≡ (200 mg; 1.27 mmol) and N3-Phe-OBzl (4c) (394 mg; 
1.40 mmol; 1.1 eq) are dissolved in DMF/H2O 2:1 (4.5 mL), 
CuSO4.5H2O (160 mg; 0.64 mmol; 0.5 eq) and sodium ascorbate 
(252 mg; 1.27 mmol; 1.0 eq) are added and the reaction mixture 
left to stir overnight. The solvent is removed by rotary 
evaporator and the triazole purified by flash chromatography (PE/EtOAc 2:1). Yield: 
490 mg (1.12 mmol); 88%. Rf (PE/EtOAc 3:1)= 0.36.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 8.04 (s, 1H, Tz-H), 7.45-7.29 (m, 6H, Boc-NH, 
Phe-H), 7.28-7.17 (m, 5H, Phe-H), 5.97 (dd, 3J= 10.1, 5.8 Hz, 1H, Phe-Hα), 5.25-5.23 (m, 2H, 
OCH2), 4.18 (m, 2H, Gly-Hα), 3.63 (dd, 2J= 14.5, 3J= 5.8 Hz, 2H, Phe-Hβ), 3.58 (dd, 2J= 14.5, 
3J= 10.1 Hz, 1H, Phe-Hβ), 1.44 (s, 9H, C(CH3)3). 
 
Boc-D-Leu[4Tz]Val-OAll (18c). 
Boc-D-Leu≡ (8e) (88 mg; 0.42 mmol) and N3-Val-OAll (4d) 
(86 mg; 0.47 mmol; 1.1 eq) are dissolved in DMF/H2O 2:1 
(1.5 mL), CuSO4.5H2O (54 mg; 0.22 mmol; 0.5 eq) and sodium 
ascorbate (85 mg; 0.43 mmol; 1.0 eq) are added and the reaction 
mixture left to stir overnight. The solvent is removed by rotary 
evaporator and the triazole purified by flash chromatography (PE/EtOAc 3:1).  
Yield: 136 mg (0.34 mmol); 81%. Rf (PE/EtOAc 3:1)= 0.50. MS (ESI): m/z= 417.3 [M+Na]+, 
811.4 [2M+Na]+.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 7.96 (s, 1H, Tz-H), 7.22 (d, 3J= 8.8 Hz, 1H, 
BocNH), 5.90 (dddd, 3J= 17.2, 10.7, 5.4,5.4 Hz, 1H, CH2-CH=CH2), 5.31 (d, 3J= 8.4 Hz, 1H, 
Val-Hα), 5.27 (dd, 3J= 17.2, 2J= 1.6 Hz, 1H, CH2-CH=CHHE), 5.23 (dd, 3J = 10.7, 1.6 Hz, 1H, 
CH2-CH=CHZH), 4.74 (m, 1H, Leu-Hα), 4.71-4.63 (m, 2H, CH2-CH=CH2), 2.54 (m, Val-Hβ), 
1.68-1.48 (m, 3H, Leu-Hβ, Leu-Hγ), 1.38 (s, 9H, C(CH3)3), 0.95 (d, 3J= 6.7 Hz, 3H, Val-Hγ), 
0.89 (d, 3J= 6.5 Hz, 3H, Leu-Hδ), 0.89 (d, 3J= 6.3 Hz, 3H, Leu-Hδ), 0.78 (d, 3J= 6.7 Hz, 3H, Val-
Hγ). 
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Boc-GLY[4Tz]Val-OAll (18e). 
Boc-Gly≡ (100 mg; 0.64 mmol) and N3-Val-OAll (4d) (129 mg; 
0.70 mmol; 1.1 eq) are dissolved in DMF/H2O 2:1 (2.25 mL), 
CuSO4.5H2O (80 mg; 0.32 mmol; 0.5 eq) and sodium ascorbate 
(126 mg; 0.64 mmol; 1.0 eq) are added and the reaction mixture 
left to stir overnight. The solvent is removed by rotary evaporator and the triazole purified 
by flash chromatography (PE/EtOAc 2:1).  
Yield: 176 mg (0.34 mmol); 81%. Rf (PE/EtOAc 2:1)= 0.35.  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 8.03 (s, 1H, Tz-H), 7.39 (dd, 3J= 5.9,5.9 Hz, 1H, 
Boc-NH), 5.96 (dddd, 3J= 17.3, 10.7, 5.5, 5.5 Hz, 1H, CH2-CH=CH2), 5.37 (d, 3J= 8.7 Hz, 1H, 
Val-Hα), 5.34 (dd, 3J= 17.3, 2J= 1.5 Hz, 1H, CH2-CH=CHHE) 5.29 (dd, 3J= 10.5, 2J= 1.5 Hz, 
1H, CH2-CH=CHZH), 4.76-4.68 (m, 2H, CH2-CH=CH2), 4.27-4.23 (m, 2H, Gly-Hα), 2.61 (m, 
1H, Val-Hβ), 1.44 (s, 9H, C(CH3)3), 1.00 (d, J = 6.7 Hz, 3H, Val-Hγ), 0.84 (d, J = 6.7 Hz, 3H, 
Val-Hγ). 
 
Fmoc-Leu[4Tz]Val-OBzl (18f). 
Fmoc-Leu≡ (142 mg; 426 µmol) and N3-Val-OBzl (109 mg; 
469 µmol; 1.1 eq) are suspended in DMF/H2O (2:1) (4.3 mL). 
CuSO4.5H2O (54 mg; 0.22 mmol; 0.5 eq) and sodium ascorbate 
(85 mg; 0.43 mmol; 1.0 eq) are added and the reaction stirred at 
rt overnight. The solvent is co-evaporated with toluene and the 
crude triazole purified by column chromatography (PE/EtOAc 2:1). Yield: 222 mg 
(392 µmol); 92%. Rf (PE/EtOAc 2:1)= 0.21.  HR-MS (ESI): m/z= 567.2987 (calc. 567.29658). 
1H-NMR (600 MHz; DMSO-d6): δ [ppm]= 7.99 (s, 1H, Tz-H), 7.90-7.86 (m, 2H, HAr), 7.75 (d, 
3J= 9.0 Hz, 1H, NH), 7.72-7.67 (m, 2H, HAr), 7.43-7.38 (m, 2H, HAr), 7.37-7.28 (m, 7H, HAr), 
5.32 (d, 3J= 8.3 Hz, 1H, Val2-Hα), 5.22 (d, 2J= 12.4 Hz, 1H, O-CHH-Ph), 5.17 (d, 2J= 12.4 Hz, 
1H, O-CHH-Ph), 4.80 (ddd, 3J= 9.0, 5.9, 5.9 Hz, 1H, Leu1-Hβ), 4.35 (dd, 2J= 10.5, 3J= 7.2 Hz, 
1H, CH-CHHO), 4.28 (dd, 2J= 10.5, 3J= 6.9 Hz, 1H, CH-CHHO), 4.21 (dd, 3J= 7.2, 6.9 Hz, 1H, 
CH-CH2O), 2.54 (m, 1H, Val2-Hβ), 1.68 (m, 1H, Leu1-Hβ), 1.62 (m, 1H, Leu1-Hβ), 1.54 (m, 
1H, Leu1-Hγ), 0.93-0.85 (m, 9H, Val2-Hγ, Leu1-Hδ), 0.75 (d, 3J= 6.7 Hz, 3H, Val2-Hγ). 
13C{1H}-NMR (151 MHz, DMSO) δ [ppm]= 168.58 (Val2-C), 156.12 (OCON), 149.96 (Tz-C), 
144.39 (CAr), 144.21 (CAr), 141.20 (CAr), 141.18 (CAr), 135.70 (CAr), 128.90 (2C; CHAr), 128.73 
(CHAr), 128.50 (2C; CHAr), 128.06 (CHAr), 128.04 (CHAr), 127.47 (CHAr), 127.46 (CHAr), 125.66 
(CHAr), 125.63 (CHAr), 122.28 (Tz-CH), 120.57 (CHAr), 120.54 (CHAr), 67.92 (Val2-Cα), 67.33 
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(O-CH2-Ph), 65.74 (CH-CH2-O), 47.25 (CH-CH2-O), 46.09 (Leu1-Cα), 44.42 (Leu1-Cβ), 31.18 
(Val2-Cβ), 24.74 (Leu1-Cγ), 23.23 (Leu1-Cδ), 22.25 (Leu1-Cδ), 19.24 (Val2-Cγ), 18.69 (Val2-
Cγ). 
 
Fmoc-Phe[4Tz]Phe-OBzl (18g). 
Fmoc-Phe≡ (156 mg; 425 µmol) and N3-Phe-OBzl (132 mg; 
468 µmol; 1.1 eq) are suspended in H2O/tBuOH (1:1) (4 mL). 
CuSO4.5H2O (21 mg; 84 µmol; 0.2 eq) and sodium ascorbate 
(34 mg; 0.17 µmol; 0.4 eq) are added and the reaction stirred at 
60°C for 1 h under microwave condition (20W). The solvent is 
co-evaporated with toluene and the crude triazole purified by column chromatography 
(PE/EtOAc 2:1). Yield: 205 mg (316 µmol); 74%. Rf (PE/EtOAc 2:1)= 0.35. HR-MS (ESI): 
m/z= 649.2803 [M+H]+ (calc. 649.28093). 
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 8.02 (s, 1H, Tz-H), 7.91-7.83 (3H, NH, HAr), 7.66-
7.60 (2H, HAr), 7.44-7.39 (m, 2H, HAr), 7.37-7.07 (m, 17H, HAr, Ph-H), 5.90 (dd, 3J= 10.2, 5.6 
Hz, 1H, Phe2-Hα), 5.18 (s, 2H, O-CH2-Ph), 4.88 (ddd, J= 9.4, 9.0, 5.8 Hz, 1H, Phe1-Hα), 4.23 
(m, 1H, CH-CHH-O), 4.17-4.10 (m, 2H, CH-CHH-O, CH-CHH-O), 3.58 (dd, 2J= 14.2, 3J= 5.6 
Hz, 1H, Phe2-Hβ), 3.51 (dd, 2J= 14.3, 3J= 10.2 Hz, 1H, Phe2-Hβ), 3.13 (dd, 2J= 13.6, 3J= 5.8 
Hz, 1H, Phe1-Hβ), 3.01 (dd, 2J= 13.6, 3J= 9.4 Hz, 1H, Phe1-Hβ). 
13C{1H}-NMR (126 MHz, DMSO) δ [ppm]= 168.61 (Phe2-C), 155.92 (OCON), 148.90 (CAr), 
144.27 (CAr), 144.24 (CAr), 141.15 (CAr), 138.71 (Tz-C), 136.20 (CAr), 135.73 (2C; CAr), 129.70 
(2C; CHAr), 129.39 (2C; CHAr), 128.89 (3C; CHAr), 128.76 (2C; CHAr), 128.62 (CHAr), 128.52 
(2C; CHAr), 128.16 (3C; CHAr), 128.07 (CHAr), 127.51 (CHAr), 127.30 (CHAr), 126.62 (CHAr), 
125.75 (CHAr), 125.67 (CHAr), 122.93 (Tz-CH), 120.56 (2C; CHAr), 67.37 (O-CH2-Ph), 65.93 
(CH-CH2-O), 63.39 (Phe2-Cα), 49.59 (CH-CH2-O), 47.10 (Phe1-Cα), 39.50 (Phe1-Cβ), 37.11 
(Phe2-Cβ). 
 
Fmoc-D-chGly[4Tz]-D-Tyr(tBu)-OH (18h). 
Fmoc-D-chGly≡ (100 mg; 0.28 mmol; 1.0 eq) and N3-
Tyr(tBu)-OH (81 mg; 0.31 mmol; 1.1 eq) are suspended in 
2.8 mL DMF/H2O 2:1, after the addition of sodium 
ascorbate (55 mg; 0.28 mmol; 1.0 eq) and CuSO4.5H2O 
(35 mg; 0.14 mmol; 0.5 eq) the reaction mixture is left to 
stir overnight. EtOAc (50 mL) and 5% KHSO4-solution (50 mL) are added and the phases 
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separated. The aqueous layer is extracted with EtOAc (50 mL x 1), the combined organic 
layers dried over MgSO4 and concentrated under vacuum. The crude triazole is purified by 
column chromatography (gradient: PE/EtOAc 2:1 to 1:1, containing 1% AcOH).  
Yield: 142 mg (0.23 mmol); 82%. Rf (PE/EtOAc 1:1, 1% AcOH)= 0.14.  
HR-MS (ESI): m/z= 623.3212 [M+H]+ (calc. 623.32280). 
1H-NMR (600 MHz, DMSO) δ [ppm]= 7.90 (s, 1H, Tz-H), 7.90-7.88 (m, 2H, HAr), 7.74-7.67 
(m, 3H, NH, HAr), 7.42-7.39 (m, 2H, HAr), 7.33-7.29 (m, 2H, HAr), 6.96 (d, 3J= 8.4 Hz, 2H, 
Tyr2-Hδ), 6.72 (d, 3J= 8.4 Hz, 2H, Tyr2-Hε), 5.62 (dd, 3J= 11.0, 4.8 Hz, 1H, Tyr2-Hα), 4.48 (m, 
1H, chGly1-Hα), 4.34 (dd, 2J= 10.1, 3J= 6.9 Hz, 1H, CHH-O), 4.26-4.18 (m, 2H, CH-CH2O, 
CHH-O), 3.46 (dd, 2J= 14.3, 3J= 4.8 Hz, 1H, Tyr2-Hβ), 3.34 (dd, 2J= 14.3, 3J= 11.0 Hz, 1H), 
1.71-1.52 (m, 5H, chGly1-Hβ, CH2), 2.30 (m, 1H, CH2), 1.18 (s, 9H, C(CH3)3), 1.15-1.02 (m, 
3H, CH2), 0.87 (m, 1H, CH2), 0.74 (m, 1H, CH2). 
13C{1H}-NMR (151 MHz, DMSO-d6) δ [ppm]= 170.26 (Tyr2-C), 156.22 (O-CO), 154.22 
(Tyr2-Cζ), 147.85 (Tz-C), 144.44 (CAr), 144.18 (CAr), 141.20 (CAr), 141.17 (CAr), 131.05 (Tyr2-
Cγ), 129.90 (2C, Tyr2-Cδ), 128.06 (CHAr), 128.04 (CHAr), 127.48 (2C, CHAr), 125.71 (2C, 
CHAr), 123.72 (2C, Tyr2-Cε), 122.74 (Tz-CH), 120.56 (CHAr), 120.52 (CHAr), 78.11 (C(CH3)3), 
65.77 (CH-CH2-O), 63.80 (Tyr2-Cα), 52.87 (chGly1-Cα), 47.25 (CH-CH2-O), 42.37 (chGly1-
Cβ), 36.86 (Tyr2-Cβ), 29.65 (CH2), 28.99 (CH2), 28.92 (3C, C(CH3)3), 26.37 (CH2), 25.96 (CH2), 
25.92 (CH2). 
 
Fmoc-D-chGly[4Tz]-D-chGly-OH (18i). 
Fmoc-D-chGly≡ (50 mg; 0.14 mmol; 1.0 eq) and N3-chGly-OH 
(28 mg; 0.15 mmol; 1.1 eq) are suspended in 1.4 mL DMF/H2O 
2:1, after the addition of sodium ascorbate (28 mg; 0.14 mmol; 
1.0 eq) and CuSO4.5H2O (17 mg; 0.07 mmol; 0.5 eq) the 
reaction mixture is left to stir for two days. EtOAc (25 mL) and 
5% KHSO4-solution (25 mL) are added and the phases 
separated. The aqueous layer is extracted with EtOAc (1x25 mL), the combined organic 
layers are washed with brine (25 mL), dried over MgSO4 and concentrated under vacuum. 
The crude triazole is purified by column chromatography (gradient: PE/EtOAc 2:1 to 1:1, 
both containing 1% AcOH). Yield: 55 mg (0.10 mmol); 72%. Rf (PE/EtOAc 1:1, 1% AcOH)= 
0.20. HR-MS (ESI): m/z= 543.2966 [M+H]+ (calc. 543.29658). 
1H-NMR (600 MHz, DMSO-d6) δ [ppm]= 7.99 (s, 1H, Tz-H), 7.74 (d, 3J= 9.5 Hz, 1H, NH), 
5.14 (d, 3J= 8.3 Hz, 1H, chGly2-Hα), 4.59 (dd, 3J= 9.5, 7.4 Hz, 1H, chGly1-Hα), 4.35 (dd, 2J= 
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10.5, 3J= 7.2 Hz, 1H, CH-CHH-O), 4.27 (dd, 2J= 10.5, 3J= 6.9 Hz, 1H, CH-CHH-O), 4.21 (dd, 
3J= 7.2, 6.9 Hz, 1H, CH-CH2-O), 2.15 (m, 1H, chGly2-Hβ), 1.79-1.46 (m, 8H, chGly1-Hβ, CH2), 
1.43 (m, 1H, CH2), 1.29-0.61 (m, 12H, CH2). 
13C{1H}-NMR (151 MHz, DMSO) δ [ppm]= 170.06 (chGly2-C), 156.31 (O-CO), 148.13 (Tz-
C), 144.41 (CAr), 144.18 (CAr), 141.20 (CAr), 141.17 (CAr), 128.06 (CHAr), 128.03 (CHAr), 127.46 
(2C, CHAr), 125.69 (2C, CHAr), 122.57 (Tz-CH), 120.57 (CHAr), 120.53 (CHAr), 67.61 (chGly2-
Cα), 65.78 (CH2-O), 52.88 (chGly1-Cα), 47.25 (CH-CH2-O), 42.45 (chGly1-Cβ), 40.09 (chGly2-
Cβ), 29.80 (CH2), 29.61 (CH2), 28.87 (CH2), 28.53 (CH2), 26.41 (CH2), 25.96 (CH2), 25.92 (CH2), 
25.91 (CH2), 25.59 (CH2), 25.53 (CH2). 
 
Boc-D-Leu[4Tz]Phe-D-Leu[4Tz]Val-OAll (19). 
Boc-D-Leu[4Tz]Val-OAll (18c) (87 mg; 
0.22 mmol; 1.0 eq) is dissolved in 3 mL of a 1:1 
mixture of DCM and HCl (4 M in dioxane) and 
stirred for 2 h at rt. After complete cleavage of 
the Boc-group, the free amine is evaporated to 
dryness. In a second flask, Boc-D-Leu[4Tz]Phe-
OH (93 mg; 0.23 mmol; 1.0 eq; synthesized from 18b according to GP5) and HOAt (34 mg; 
0.25 mmol; 1.1 eq) are dissolved in DCM (4 mL, dry). After addition of DIC (39 µL; 
0.25 mmol; 1.1 eq), the mixture is stirred 5 min at RT for preactivation and is then added 
to the free amine, followed by TMP (155 µL; 1.17 mmol; 5.0 eq). This solution is left stirring 
over night at rt. After evaporation of the solvent, the crude product is dissolved in EtOAC 
(50 mL) and washed: 5% KHSO4 (3x25 mL), saturated NaHCO3 (3x25 mL), brine (1x25 mL) 
and dried over MgSO4. The organic phase is concentrated under vacuum and the crude 
product purified by column chromatography (PE/EtOAc 1:3). Yield: 127 mg (187 µmol); 
81%. Rf (PE/EtOAc 1:3)= 0.81. MS (ESI): m/z= 701.4 [M+Na]+. 
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 8.98 (d, 3J= 8.6 Hz, 1H, Leu3-NH), 8.10 (s, 1H, 
Tz1-H), 8.05 (s, 1H, Tz2-H), 7.32-7.24 (m, 5H, Ph-H), 7.19 (d, 3J= 9.0 Hz, 1H, Boc-NH), 5.94 
(dddd, 3J= 17.3, 10.8, 5.5, 5.5 Hz, 1H, CH2-CH=CH2 ), 5.66 (dd, 3J= 8.0, 7.4 Hz, 1H, Phe2-Hα), 
5.33 (d, 3J= 8.5 Hz, 1H, Val4-Hα), 5.30 (dd, 3J= 17.3, 2J= 1.4 Hz, 1H, CH2-CH=CHEH), 5.25 
(dd, 3J= 10.4, 2J= 1.4 Hz, 1H, CH2-CH=CHHZ), 5.06 (m, 1H, Leu3-Hα), 4.75 (m, 1H, Leu1-
Hα), 4.74-4.66 (m, 2H, CH2-CH=), 3.44 (dd, 2J= 13.7, 3J= 7.4 Hz, 1H, Phe2-Hβ), 3.40 (dd, 2J= 
13.7, 3J= 8.0 Hz, 1H, Phe2-Hβ), 2.50 (m, 1H, Val4-Hβ), 1.64-1.57 (m, 4H, Leu1-Hβ, Leu3-Hβ), 
1.50 (m, 1H, Leu1-Hγ), 1.44 (s, 9H, C(CH3)3), 1.30 (m, 1H, Leu3-Hγ), 0.98 (d, 3J= 6.7 Hz, 3H, 
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Val4-Hγ), 0.93 (d, 3J= 6.5 Hz, 3H, Leu1-Hδ), 0.91 (d, 3J= 6.5 Hz, 3H, Leu1-Hδ), 0.87 (d, 3J= 6.8 
Hz, 3H, Leu3-Hδ), 0.86 (d, 3J= 6.9 Hz, 3H, Leu3-Hδ) 0.78 (d, 3J= 6.7 Hz, 3H, Val4-Hγ). 
 
Boc-D-Val[4Tz]Phe-D-Leu[4Tz]Phe-D-Leu[4Tz]Val-OAll (20). 
Boc-D-Leu[4Tz]Phe-D-
Leu[4Tz]Val-OAll (19) (110 mg; 
162 µmol; 1.0 eq) is dissolved in 
2 mL of a 1:1 mixture of DCM and 
HCl (4 M in dioxane) and stirred for 
2 h at rt. After complete cleavage of 
the Boc-group, the free amine is evaporated to dryness. In a second flask, Boc-D-
Val[4Tz]Phe-OH (68 mg; 0.18 mmol; 1.1 eq; synthesized from 18a according to GP5) and 
HOAt (26 mg; 0.19 mmol; 1.2 eq) are dissolved in DCM (4 mL, dry). After addition of DIC 
(30 µL; 0.19 mmol; 1.2 eq), the mixture is stirred 5 min at RT for preactivation and is then 
added to the free amine, followed by TMP (106 µL; 0.800 mmol; 5.0 eq). This solution is left 
stirring over night at rt. After evaporation of the solvent, the crude product is purified by 
preparative HPLC.  
Yield: 29 mg (31 µmol); 19%. Analytic RP-HPLC: tR= 6.96 min (method 1, 220 nm). 
The product was characterized after the last step, the coupling of Boc-Ala-OH to the N-
terminus. 
 
Boc-Ala-D-Val[4Tz]Phe-D-Leu[4Tz]Phe-D-Leu[4Tz]Val-OAll (21). 
Boc-D-Val[4Tz]Phe-D-
Leu[4Tz]Phe-D-Leu[4Tz]Val-
OAll (20) (23.3 mg; 25.0 µmol; 
1.0 eq) is dissolved in 1 mL of 
a 1:1 mixture of DCM and HCl 
(4 M in dioxane) and stirred 
for 2 h at rt. After complete cleavage of the Boc-group, the free amine is evaporated to 
dryness. In a second flask, Boc-Ala-OH (9.5 mg; 50 µmol; 2.0 eq) and HOAt (7.5 mg; 
55 µmol; 2.2 eq) are dissolved in DCM (2 mL, dry). After addition of DIC (8.5 µL; 55 µmol; 
2.2 eq), the mixture is stirred 5 min at RT for preactivation and is then added to the free 
amine, followed by TMP (16.5 µL; 125 µmol; 5.0 eq). This solution is left stirring over night 
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at rt. After evaporation of the solvent, the crude product is purified by preparative HPLC. 
Yield: 15.4 mg (15.1 µmol); 60%. Analytic RP-HPLC: tR= 6.6 min (method 1, 220 nm).  
HR-MS (ESI): mz-1= 1020.6126 [M+H]+ (calc. 1020.6142).  
1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 8.92 (d, 3J= 8.6 Hz, 1H, NH), 8.89 (d, 3J= 8.7 Hz, 
1H, NH) 8.19 (s, 1H, Tz2-H), 8.14 (s, 1H, Tz1-H), 8.00 (s, 1H, Tz3-H), 7.88 (d, 3J= 9.2 Hz, 1H, 
Val2-NH), 7.23–7.14 (m, 10H, Ph-H) 6.89 (d, 3J= 7.6 Hz, 1H, Boc-NH), 5.86 (ddt, 3J= 17.2, 
10.6, 5.5 Hz, 1H, -CH=C), 5.63-5.58 (m, 2H, Phe3+Phe5-Hα), 5.26 (d, 3J= 8.4 Hz, 1H, Val7-
Hα), 5.23 (dd, 3J= 17.2, 2J= 1.7 Hz, 1H, =CHE), 5.18 (dd, 3J= 10.6, 2J= 1.5 Hz, 1H, =CHZ), 5.01-
4.96 (m, 2H, Leu4+Leu6-Hα), 4.81 (dd, 3J= 9.2, 6.4 Hz, 1H, Val2-Hα), 4.68-4.61 (m, 2H, O-
CH2-), 4.03 (dq, 1H, 3J= 7.6, 7.2 Hz, Ala1-Hα), 3.40-3.26 (m, 4H, Bzl-H), 2.50 (m, 1H, Val7-
CH(Me)2), 2.01 (m, 1H, Val2-CH(Me)2), 1.58-1.50 (m, 4H, Leu4+Leu6-CH2), 1.36 (s, 9H, tBu-
H), 1.28-1.14 (m, 2H, Leu4+Leu6-CH(Me)2, 1.18 (d, 3J= 7.2 Hz, 1H, Ala1-Hβ), 0.91 (d, 3J= 6.7 
Hz, 3H, Val7-CH3), 0.82-0.78 (m, 12H, Leu4+Leu6-CH3), 0.75 (d, 3J= 6.7 Hz, 3H, Val2-CH3), 
0.72 (d, 3J= 6.8 Hz, 3H, Val7-CH3), 0.70 (d, 3J= 6.8 Hz, 3H, Val2-CH3).  
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm] = 172.77 (Ala1-C), 168.32 (Val7-C), 166.96 
(Phe-C), 166.94 (Phe-C), 155.42 (tBuOC), 148.53 (Tz3-Cquart), 148.04 (Tz1-Cquart), 147.33 
(Tz2-Cquart), 136.27 (Phe-Cγ), 136.22 (Phe-Cγ), 132.16 (CH2-C=), 129.50 (Phe-CAr), 129.48 
(Phe-CAr), 128.62 (Phe-CAr), 127.20 (Phe-CAr), 122.46 (Tz3-CH), 122.28 (Tz2-CH), 121.82 
(Tz1-CH), 118.91 (=CH2), 78.49 (-C(Me)3), 67.96 (Val7-Cα), 66.14 (O-CH2-), 64.17 
(Phe3+Phe5-Cα), 50.82 (Val2-Cα), 50.38 (Ala1-Cα), 44.21 (Leu-Cβ), 44.05 (Leu-Cβ), 43.90 
(Leu4+Leu6-Cα), 38.81 (Bzl-C), 38.41 (Bzl-C), 32.80 (Val2-CH(Me)2), 31.08 (Val7-CH(Me)2), 
28.63 (-C(CH3)3), 24.56 (Leu4-CH(CH3)2), 24.46 (Leu6-CH(CH3)2), 23.09 (Leu4-CH3), 22.97 
(Leu4-CH3), 22.37 (Leu6-CH3), 22.26 (Leu6-CH3), 19.34 (Val2-CH3),19.24 (Val7-CH3), 18.84 
(Ala1-Cβ), 18.68 (Val7-CH3), 18.41 (Val2-CH3). 
 
Boc-Gly[4Tz]Phe-Gly[4Tz]Val-OAll (22). 
Boc-Gly[4Tz]Val-OAll (18e) (170 mg; 0.502 
mmol; 1.0 eq) is dissolved in 4 mL of a 1:1 mixture 
of DCM and HCl (4 M in dioxane) and stirred for 
2 h at rt. After complete cleavage of the Boc-
group, the free amine is evaporated to dryness. In 
a second flask, Boc-Gly[4Tz]Phe-OH (0.19 g; 0.55 mmol; 1.1 eq; synthesized from 18d 
according to GP5) and HOAt (82 mg; 0.60 mmol; 1.2 eq) are dissolved in DCM (5 mL, dry). 
After addition of EDCxHCl (115 mg; 0.600 mmol; 1.2 eq), the mixture is stirred 5 min at RT 
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for preactivation and is then added to the free amine, followed by TMP (0.33 mL; 2.5 mmol; 
5.0 eq). This solution is left stirring over night at rt. After evaporation of the solvent, the 
crude product is dissolved in EtOAC (100 mL) and washed: 5% KHSO4 (3x50 mL), saturated 
NaHCO3 (3x50 mL), brine (1x50 mL) and dried over MgSO4. The organic phase is 
concentrated under vacuum, the crude product obtained as a colourless solid.  
Yield: 269 mg (187 µmol); 94% crude. Rf (PE/EtOAc 1:3)= 0.16.  
MS (ESI): m/z= 589.3 [M+Na]+.   
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 9.02 (dd, 3J = 5.5, 5.5 Hz, 1H, Gly3-NH), 8.04 (s, 
1H, Tz1-H), 7.91 (s, 1H, Tz2-H), 7.26 (dd, 3J= 6.0, 6.0 Hz, 1H, Boc-NH), 7.23-7.11 (m, 5H, Ph-
H), 5.89 (dddd, 3J= 17.2, 10.7, 5.5, 5.5 Hz, 1H, CH2-CH=), 5.58 (dd, 3J= 9.4, 6.2 Hz, 1H, Phe2-
Hα), 5.29 (d, 3J= 8.4 Hz, 2H, Val4-Hα), 5.28 (dd, 3J= 17.2, 2J= 1.4 Hz, CH=CHEH), 5.22 (dd, 3J= 
10.5, 2J=1.4 Hz, 1H, CH=CHHZ), 4.69-4.61 (m, 2H, O-CH2), 4.40-4.30 (m, 2H, Gly3-Hα), 4.16-
4.10 (m, 2H, Gly1-Hα), 3.40 (dd, 2J= 14.1, 3J= 6.2 Hz, Phe2-Hβ), 3.32 (dd, 2J= 14.1, 3J= 9.4 Hz, 
1H, Phe2-Hβ), 2.53 (m, 1H, Val4-Hα), 1.39 (s, 9H, C(CH3)3), 0.94 (d, 3J= 6.7 Hz, 3H, Val4-Hγ), 
0.76 (d, 3J= 6.7 Hz, 3H, Val4-Hγ). 
 
Boc-Gly[4Tz]Phe-Gly[4Tz]Phe-Gly[4Tz]Val-OAll (23). 
Boc-Gly[4Tz]Phe-Gly[4Tz]Val-
OAll (22) (130 mg; 0.229 mmol; 
1.0 eq) is dissolved in 2 mL of a 1:1 
mixture of DCM and HCl (4 M in 
dioxane) and stirred for 2 h at rt. 
After complete cleavage of the Boc-
group, the free amine is evaporated to dryness. In a second flask, Boc-Gly[4Tz]Phe-OH 
(88 mg; 0.25 mmol; 1.1 eq; synthesized from 18d according to GP5) and HOAt (38 mg; 
0.28 mmol; 1.2 eq) are dissolved in DCM (5 mL, dry). After addition of EDCxHCl (54 mg; 
0.28 mmol; 1.2 eq), the mixture is stirred 5 min at RT for preactivation and is then added 
to the free amine, followed by TMP (152 µL; 1.15 mmol; 5.0 eq). This solution is left stirring 
over night at rt. After evaporation of the solvent, the crude product is dissolved in EtOAC 
(100 mL) and washed: 5% KHSO4 (3x50 mL), saturated NaHCO3 (3x50 mL), brine (1x50 mL) 
and dried over MgSO4. The organic phase is concentrated under vacuum, the crude product 
is purified by preparative HPLC. Yield: 120 mg (0.151 mmol); 66%.  
Analytic RP-HPLC: tR= 5.52 min (method 1, 220 nm). MS (ESI): m/z= 817.3 [M+Na]+. 
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The product was characterized after the last step, the coupling of Boc-Ala-OH to the N-
terminus. 
 
Boc-Ala-Gly[4Tz]-Phe-Gly[4Tz]-Phe-Gly[4Tz]-Val-OAll (24). 
Boc-Gly[4Tz]-Phe-Gly[4Tz]-
Phe-Gly[4Tz]-Val-OAll (23) 
(50 mg; 63 µmol; 1.0 eq) is 
dissolved in 2 mL of a 1:1 
mixture of DCM and HCl (4 M 
in dioxane) and stirred for 2 h 
at rt. After complete cleavage of the Boc-group, the free amine is evaporated to dryness. In 
a second flask, Boc-Ala-OH (24 mg; 126 µmol; 2.0 eq) and HOAt (19 mg; 140 µmol; 2.2 eq) 
are dissolved in DCM (5 mL, dry). After addition of DIC (22 µL; 140 µmol; 2.2 eq), the 
mixture is stirred 5 min at RT for preactivation and is then added to the free amine, 
followed by TMP (42 µL; 0.32 µmol; 5.0 eq). This solution is left stirring over night at rt. 
After evaporation of the solvent, the crude product is purified by preparative HPLC.  
Yield: 41 mg (47 µmol); 75%.  Analytic RP-HPLC: tR= 5.3 min (method 1, 220 nm).  
HR-MS (ESI): m/z1= 866.4413 [M+H]+ (calc. 866.44202).  
1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 9.04 (dd, 1H, 3J= 5.6, 5.6 Hz, Gly6-NH), 9.00 (dd, 
1H, 3J= 5.6, 5.4 Hz, Gly4-NH), 8.26 (dd, 1H, 3J= 6.0, 5.9 Hz, Gly2-NH), 8.08 (s, 1H, Tz1-H), 
8.04 (s, 1H, Tz2-H), 7.94 (s, 1H, Tz3-H), 7.25-7.08 (m, 10H, PhH), 6.91 (d, 3J= 7.4 Hz, 1H, Boc-
NH), 5.90 (m, 1H, -CH=CH2), 5.62-5.57 (m, 2H, Phe3+Phe5-Hα), 5.30 (d, 3J= 8.4 Hz, 1H, Val-
Hα), 4.70-4.62 (m, 2H, CH2-CH=), 4.41-4.24 (m, 6H, Gly-Hα), 3.97 (dq, 1H, 3J= 7.4, 7.2 Hz, 
Ala1-Hα), 3.42-3.27 (m, 4H, Phe-Hβ) 2.54 (dqq, 3J= 8.4, 6.7, 6.5 Hz, 1H, Val-Hβ), 1.38 (s, 9H, 
C(CH3)3), 1.17 (d, 3J= 7.2 Hz, 3H, Ala1-Hβ), 0.94 (d, 3J= 6.5 Hz, 3H, Val-Hγ), 0.77 (d, 3J= 6.7 
Hz, 3H, Val-Hγ).  
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 173.15 (Ala1-C), 168.33 (Val7-C), 167.73 (2C, 
Phe3+Phe5-C), 155.51 (tBuO-C), 145.26 (Tz1-C), 144.25 (Tz3-C), 144.03 (Tz2-C), 136.52 
(Phe-Cγ), 136.49 (Phe-Cγ), 132.21 (CH2-CH=), 129.25 (Phe-C), 128.24 (Phe-C), 127.24 (Phe-
C), 123.49 (Tz3-CH), 122.66 (Tz2-CH), 122.40 (Tz1-CH), 119.06 (=CH2), 78.44 (-C(Me)3), 
67.98 (Val7-Cα), 66.23 (O-CH2-), 64.16 (2C, Phe3+Phe5-Cα), 50.13 (Ala1-Cα), 38.29 (Phe-Cβ), 
38.08 (Phe-Cβ), 34.84 (Gly-Cα), 34.83 (Gly-Cα), 34.80 (Gly-Cα), 31.12 (Val7-Cβ), 28.68 
(C(CH3)3), 19.26 (Val7-Cγ), 18.71 (Ala1-Cβ). 
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Dimethyl (1-diazo-2-oxopropyl)phosphonate (25). 
p-ABSA (35) (10.5 g; 43.7 mmol; 1.2 eq) is suspended in ACN 
(360 mL). After addition of DOP (5.03 mL; 36.4 mmol; 1.0 eq) and 
K2CO3 (10.1 g; 72.8 mmol; 2.0 eq) the reaction mixture is left to 
stir overnight. After filtration, the filtrate is concentrated and 
the product purified by flash chromatography (gradient: PE/EtOAc 2:1 to 1:2 to 0:1). Yield: 
5.71 g (29.7 mmol); 82%. Rf (EtOAc)= 0.43.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 3.88 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 2.29 (s, 3H, 
CH3).  
 
(S)-1-Phenyl-N-tritylbut-3-yn-2-amine ((S)-31). 
L-Phenylalaninol (28): H-L-Phe-OH (5.00 g; 30.3 mmol) is 
suspended in THF (60 mL; dry) and cooled to 0°C. LiAlH4 (2.1 eq; 
64.0 mmol; 2.43 g) is added portion-wise. After stirring the 
reaction mixture for 2 h at 0°C, it is stirred at reflux overnight. 
Afterwards the suspension is diluted with Et2O (50 mL) and 
cooled to 0°C. Water (50 mL) is added dropwise to quench remaining LiAlH4. The salts are 
removed by filtration and the filtrate concentrated under vacuum. The basic aqueous slurry 
is extracted with EtOAc (3x50 mL). The combined organic phases are dried over MgSO4 
and concentrated to obtain (S)-Phenylalaninol as a yellow solid. Yield: 4.02 g (26.6 mmol); 
88%. 
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.28-7.09 (m, 5H, Ph-H), 3.57 (dd, 2J=10.6, 3J= 3.9 Hz, 
1H, CHH-OH), 3.31 (dd, 2J= 10.6, 3J= 7.2 Hz, 1H, CHH-OH), 3.05 (dddd, 3J= 8.6, 7.2, 5.2, 3.9 
Hz, 1H, Hα), 2.73 (dd, 2J= 13.5, 3J= 5.3 Hz, 1H, Hβ), 2.46 (dd, 2J= 13.5, 3J= 8.6 Hz, 1H, Hβ). 
Trt-L-Phenylalaninol ((S)-29): L-Phenylalaninol ((S)-28) (1.00 g; 6.61 mmol) is dissolved 
in DCM (13 mL) and cooled to 0°C. After the addition of DIPEA (1.2 mL; 6.6 mmol; 1.0 eq) 
and Trt-Cl (1.84 g; 6.61 mmol; 1.0 eq; dissolved in 7 mL DCM) the solution is left to stir 
overnight at rt. The reaction mixture is diluted with DCM (100 mL) and washed with H2O 
(3x50 mL), brine (1x50 mL), dried over MgSO4 and concentrated under vacuum. Yield: 
2.23 g (5.67 mmol); 86%. Rf (PE/EtOAc 10:1)= 0.13. 
1H-NMR (300 MHz; CDCl3): δ [ppm]= 7.63-7.54 (m, 5H, Ph-H), 7.37-7.14 (m, 13H, Ph-H), 
6.99-6.91 (m, 2H, Ph-H), 3.15 (dd, 2J= 10.9, 3J= 2.8 Hz, 1H, CHHOH) 2.96 (dd, 2J= 10.9, 3J= 4.1 
Hz, 1H, CHHOH), 2.84 (dddd, 3J= 9.5, 4.7, 4.1, 2.8 Hz, 1H, Hα), 2.54 (dd, 2J= 13.1, 3J= 9.5 Hz, 
1H, Hβ), 2.31 (dd, 2J= 13.0, 3J= 4.7 Hz, 1H, Hβ). 
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Trt-L-Phe≡ ((S)-31): The aldehyde ((S)-30) was synthesized utilizing Swern’s procedure,53 
starting from Trt-Phenylalaninol ((S)-29) (2.23 g; 5.67 mmol). Rf (PE/EtOAc 10:1)= 0.43.  
The crude aldehyde was immediately used for the following Bestmann-Ohira reaction:  
DOP (940 µL; 1.13 g; 6.80 mmol; 1.2 eq), K2CO3 (17 mmol; 2.4 g; 3 eq) and p-ABSA (1.63 g; 
6.80 mmol; 1.2 eq) are dissolved in acetonitrile (85 mL; dry) and stirred at rt overnight. The 
aldehyde (30) obtained above is dissolved in DCM (3 mL; dry) and added to the suspension, 
followed by MeOH (17 mL; dry), the reaction mixture is once more stirred overnight. The 
solvent is removed by rotary evaporator, the crude product dissolved in EtOAc (100 mL) 
and washed with H2O (3x50 mL), brine (1x50 mL), dried over MgSO4 and concentrated 
under vacuum. The crude propargylamine is purified by silica chromatography (PE/EtOAc 
20:1, containing 1% TEA).  
Yield: 1.81 g (4.67 mmol); 82% over two steps. Rf (PE/EtOAc 10:1)= 0.63. 
1H-NMR (300 MHz; CDCl3): δ [ppm]= 7.62-7.53 (m, 8H, Ph-H), 7.37-7.17 (m, 12H, Ph-H), 
3.55 (ddd, 3J= 7.7, 5.8, 4J= 2.2 Hz, 1H, Hα), 2.76-2.72 (m, 2H, Hβ), 1.87 (d, 4J= 2.1 Hz, 1H, 
CCH). 
 
(9H-Fluoren-9-yl)methyl (S)-(1-phenylbut-3-yn-2-yl)carbamate ((S)-33) 
Trt-Phe≡ ((S)-31) (370 mg; 0.955 mmol) is dissolved in 
DCM/TFA/MeOH (92.5/2.5/5) (10 mL) and stirred for 1.5 h at rt. 
After full conversion of the starting material, the solvent is 
removed under vacuum, by co-evaporation with toluene. The 
residual free amine is Fmoc protected using GP7, starting the 
procedure by dissolving the residual material in THF/H2O (1:1) (10 mL).   
Yield: 232 mg (0.631 mmol); 66% over two steps. Rf (PE/EtOAc 10:1)= 0.26.  
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.79-7.75 (m, 2H, HAr), 7.59-7.54 (m, 2H, HAr), 7.43-
7.38 (m, 2H, HAr), 7.34-7.23 (m, 7H, HAr, Ph-H), 4.92 (d, 3J= 7.5 Hz, 1H, NH), 4.76 (m, 1H, 
Hα), 4.46 (dd, 2J= 10.6, 3J= 7.1 Hz, 1H, CH-CHH), 4.37 (dd, 2J= 10.6, 3J= 6.9 Hz, 1H, CH-
CHH), 4.21 (dd, 3J= 7.1, 6.9 Hz, 1H, CHCH2), 3.06-2.92 (m, 2H, Hβ), 2.31 (d, 4J= 2.4 Hz, 1H, 
CCH). 
 
 
 
 
 
7. Experimental section 
 
 
- 137 - 
 
(9H-Fluoren-9-yl)methyl (R)-(1-phenylbut-3-yn-2-yl)carbamate ((R)-33). 
D-Phenylalaninol ((R)-28): H-D-Phe-OH (5.00 g; 30.3 mmol) 
is suspended in THF (60 mL; dry) and cooled to 0°C. LiAlH4 
(2.1 eq; 64.0 mmol; 2.43 g) is added portion-wise. After stirring 
the reaction mixture for 2 h at 0°C, it is stirred at reflux 
overnight. Afterwards the suspension is diluted with Et2O 
(50 mL) and cooled to 0°C. Water (50 mL) is added dropwise to quench remaining LiAlH4. 
The salts are removed by filtration and the filtrate concentrated under vacuum. The basic 
aqueous slurry is extracted with EtOAc (3x50 mL). The combined organic phases are dried 
over MgSO4 and concentrated to obtain (R)-Phenylalaninol as a yellow solid.  
Yield: 3.09 g (20.4 mmol); 67%. 
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.35-7.31 (m, 2H, Ph-H), 7.27-7.20 (m, 3H, Ph-H), 
3.68 (dd, 2J= 10.7, 3J= 3.8 Hz, 1H, CHH-OH), 3.43 (dd, 2J= 10.7, 3J= 7.2 Hz, 1H, CHH-OH), 
3.18 (dddd, 3J= 8.5, 7.2, 5.5, 3.8 Hz, 1H, Hα), 2.83 (dd, 2J= 13.5, 3J= 5.5 Hz, 1H, Hβ), 2.60 (dd, 
2J= 13.5, 3J= 8.5 Hz, 1H, Hβ). 
Trt-D-Phenylalaninol ((R)-29): D-Phenylalaninol (1.50 g; 9.92 mmol) is dissolved in 
DCM (15 mL) and cooled to 0°C. After the addition of TEA (2.75 mL; 19.8 mmol; 2.0 eq) and 
Trt-Cl (2.77 g; 9.92 mmol; 1.0 eq) the solution is left to stir overnight at rt. The reaction 
mixture is diluted with DCM (15 mL) and washed with H2O (2x20 mL), brine (1x20 mL), 
dried over MgSO4 and concentrated under vacuum.  
Yield: 3.67 g (9.33 mmol); 94%. Rf (PE/EtOAc 10:1)= 0.13. 
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.58-7.55 (m, 5H, Ph-H), 7.31-7.25 (m, 6H, Ph-H), 
7.22-7.12 (m, 7H, Ph-H), 6.95-6.92 (m, 2H, Ph-H), 3.12 (dd, 2J= 10.9, 3J= 2.7 Hz, 1H, CHH-
OH), 2.93 (dd, 2J= 10.9, 3J= 4.1 Hz, 1H, CHH-OH), 2.82 (dddd, 3J= 9.6, 4.7, 4.1, 2.7 Hz, 1H, 
Hα), 2.52 (dd, 2J= 13.1, 3J= 9.6 Hz, 1H, Hβ), 2.29 (dd, 2J= 13.1, 3J= 4.7 Hz, 1H, Hβ). 
Trt-D-Phe≡ ((R)-31): The aldehyde ((R)-30) was synthesized utilizing Swern’s 
procedure,53 starting from Trt-Phenylalaninol (3.66 g; 9.30 mmol). 
Rf (PE/EtOAc 10:1)= 0.44. The crude aldehyde (3.37 g; 8.61 mmol; 93%) was immediately 
used for the following Bestmann-Ohira reaction:  DOP (1.4 mL; 10 mmol; 1.2 eq), K2CO3 
(3.6 g; 26 mmol; 3 eq) and p-ABSA (2.48 g; 10.3 mmol; 1.2 eq) are dissolved in acetonitrile 
(103 mL; dry) and stirred at rt overnight. The aldehyde obtained above is dissolved in DCM 
(10 mL; dry) and added to the suspension, followed by MeOH (20 mL; dry), the reaction 
mixture is once more stirred overnight. The solvent is removed by rotary evaporator, the 
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crude product dissolved in EtOAc (100 mL) and washed with H2O (3x50 mL), brine 
(1x50 mL), dried over MgSO4 and concentrated under vacuum. Rf (PE/EtOAc 10:1)= 0.64. 
Fmoc-D-Phe≡ ((R)-33): The crude propargylamine is dissolved in DCM/TFA/TES 
95:2.5:2.5 (100 mL) and stirred 30 min at rt. Saturated NaHCO3 solution (50 mL) is added 
and the organic phase dried over MgSO4 and concentrated under vacuum. The crude amine 
is dissolved in ACN/H2O 1:1 (60 mL), Fmoc-OSu (3.4 g; 10 mmol; 1.2 eq) and NaHCO3 
(2.89 g; 34.4 mmol; 4 eq) are added and the reaction mixture left to stir overnight at rt. The 
acetonitrile is removed by rotary evaporator and the aqueous slurry extracted with Et2O 
(1x50 mL), the organic phase is dried over MgSO4 and concenctrated in vacuum, the cruce 
propargylamine is purified by column chromatography (PE/EtOAc 10:1).  
Yield: 32% over four steps. Rf (PE/EtOAc 10:1)= 0.13. 
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.82-7.78 (m, 2H, HAr), 7.62-7.57 (m, 2H, HAr), 7.45-
7.41 (m, 2H, HAr), 7.36-7.24 (m, 7H, HAr, Ph-H), 4.94 (d, 3J= 6.8 Hz, 1H, NH), 4.79 (m, 1H, 
Hα), 4.50 (m, 1H, CHHO), 4.40 (m, 1H, CHHO), 4.23 (dd, 3J= 6.9, 6.9 Hz, 1H, CH-CH2O), 
3.11-2.94 (m, 2H, Hβ), 2.34 (d, 4J= 2.3 Hz, 1H, CCH). 
 
O-tert-Butyl (S)-(1-phenylbut-3-yn-2-yl)carbamate (34). 
Trt-Phe≡ ((S)-31) (1.15 g; 2.97 mmol) is dissolved in 
DCM/TFA/MeOH (2/1/1) (16 mL) and stirred for 30 min at rt. 
After full conversion of the starting material, the solvent is 
removed under vacuum, by co-evaporation with toluene. The 
residual free amine is Boc protected using GP3, starting the 
procedure by dissolving the residual material in THF/ H2O (1:1) (30 mL).  
Yield: 415 mg (1.69 mmol); 57% over two steps. Rf (PE/EtOAc 10:1)= 0.31.  
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.33-7.25 (m, 5H, Ph-H), 4.74-4.61 (m, 2H, Hα, NH), 
3.04-2.91 (m, 2H, Hβ), 2.28 (m, 1H, CCH), 1.43 (s, 9H, C(CH3)3). 
 
4-Acetamidobenzenesulfonyl azide (35). 
 4-Acetamidobenzenesulfonyl chloride (11.7 g; 50.0 mmol) is 
dissolved in DCM (90 mL; dry) and cooled to 0°C. 
Tetrabutylammoniumchloride (28 mg; 0.1 mmol; 0.2 mol%) is 
added followed by a solution of sodium azide (4.9 g; 75 mmol; 
1.5 eq) in H2O (20 mL), the reaction mixture is left to stir overnight. After separation of the 
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phases, the organic phase is washed: H2O (3x90 mL), brine (1x90 mL), dried over Na2SO4 
and concentrated in vacuum. Yield: 10.8 g (44.9 mmol); 90%.  
1H-NMR (500 MHz; CDCl3): δ [ppm]= 7.91 (d, 3J= 8.9 Hz, 2H, HAr), 7.80 (d, 3J= 8.9 Hz, 2H, 
HAr), 7.77 (s, 1H, NH), 2.27 (s, 3H, CH3). 
 
(9H-Fluoren-9-yl)methyl tert-butyl hept-6-yne-1,5-diyl(S)-dicarbamate (39). 
Fmoc-Lys(Boc)-ol (36): Prepared according to Hwang et al.133 
starting from Fmoc-Lys(Boc)-OH (1.4 g; 3.0 mmol). Yield: 1.2 g 
(2.6 mmol); 87% (Lit.: 88%). 
Trt-Lys(Boc)-ol (37): The Fmoc deprotection was realised 
according to Sheppeck II et al.134 with octanethiol, starting from 
Fmoc-Lys(Boc)-ol (1.07 g; 2.35 mmol), the product was isolated by trituration as described 
in the literature and used without purification for the next step. Trityl protection: The 
residual oil is dissolved in DCM (20 mL; dry), TEA (0.98 mL; 7.1 mmol; 3.0 eq) is added 
followed by Tritylchloride (655 mg; 2.35 mmol; 1.0 eq) and the reaction mixture stirred for 
2 h at rt. Afterwards it is concentrated under vaccum and the product purified by column 
chromatography (PE/EtOAc 5:1, containing 1% TEA).  
Yield: 461 mg (0.97 mmol); 41% over two steps. Rf (PE/EtOAc 5:1)= 0.17 
Trt-Lys(Boc)-al: The aldehyde was synthesized utilizing Swern’s procedure,53 starting 
from Trt-Lys(Boc)-ol (37) (455 mg; 0.96 mmol) and used without further purification for 
the next step.  
Trt-Lys(Boc)≡ (38): DOP (159 µL; 1.15 mmol; 1.2 eq), K2CO3 (398 mg; 2.88 mmol; 3 eq) and 
p-ABSA (277 mg; 1.15 mmol; 1.2 eq) are dissolved in acetonitrile (15 mL; dry) and stirred 
at rt overnight. The aldehyde obtained above is dissolved in DCM (3 mL; dry) and added 
to the suspension, followed by MeOH (3 mL; dry), the reaction mixture is once more stirred 
overnight. The solvent is removed by rotary evaporator, the crude product dissolved in 
EtOAc (50 mL) and washed with H2O (3x25 mL), brine (1x25 mL), dried over MgSO4, 
concentrated under vacuum and purified by column chromatography (PE/EtOAc 20:1, 
containing 1% TEA). Yield: 239 mg (0.51 mmol), 53% over two steps.  
Rf (PE/EtOAc 10:1 containing 1% TEA)= 0.25.  
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.50-7.45 (m, 5H, Ph-H), 7.23-7.17 (m, 7H, Ph-H), 
7.14-7.09 (m, 3H), 4.37 (m, 1H, Boc-NH), 3.17 (m, 1H, Hα), 3.00-2.93 (m, 2H, Hε), 1.76 (d, 4J= 
2.1 Hz, 1H, CCH), 1.37 (s, 9H, C(CH3)3), 1.33-1.15 (m, 6H, CH2). 
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Fmoc-Lys(Boc)≡ (39): The trityl protected propargylamine (239 mg; 0.51 mmol) is 
dissolved in DCM/TFA/MeOH 92.5:2.5:5 (100 mL) and stirred 1.5 h at rt. After full 
conversion, the reaction mixture is concentrated under vacuum by co-evaporation with 
toluene. The crude amine is dissolved in THF/H2O 1:1 (5.5 mL), Fmoc-OSu (258 mg; 
0.77 mmol; 1.5 eq) and NaHCO3 (171 mg; 2.04 mmol; 4 eq) are added and the reaction 
mixture left to stir overnight at rt. The reaction mixture is diluted with EtOAC (50 mL) and 
washed: 5% KHSO4 (3x25 mL); NaHCO3 (3x25 mL) and brine (1x25 mL). The organic phase 
is dried over MgSO4 and concenctrated under vacuum, the crude propargylamine is 
purified by column chromatography (PE/EtOAc 3:1).  
Yield: 164 mg (0.37 mmol), 73% over two steps. Rf (PE/EtOAc 3:1)= 0.36.  
MS (ESI): m/z= 471.2 [M+Na]+. 
1H-NMR (500 MHz, CDCl3): δ [ppm]= 7.80-7.77 (m, 2H, HAr), 7.63-7.60 (m, 2H, HAr), 7.44-
7.40 (m, 2H, HAr), 7.36-7.31 (m, 2H, HAr), 5.09 (d, 3J= 8.6 Hz, 1H, Fmoc-NH), 4.60 (m, 1H, 
Boc-NH), 4.48 (m, 1H, Hα), 4.46-4.42 (m, 2H, CHCH2O), 4.24 (dd, 3J= 6.9, 6.9 Hz, 1H, 
CHCH2O), 3.18-3.07 (m, 2H, Hε), 2.32 (d, 4J= 2.3 Hz, 1H, CCH), 1.76-1.69 (m, 2H, Hβ), 1.57-
1.41 (m, 13H, C(CH3)3), Hγ, Hδ). 
13C{1H}-NMR (151 MHz, CDCl3) δ [ppm]= 156.01 (NCO2tBu), 155.44 (NCO2CH2), 143.85 
(CAr), 143.78 (CAr), 141.32 (2C; CAr), 127.71 (2C; CHAr), 127.06 (2C; CHAr), 125.04 (CHAr), 
125.01 (CHAr), 119.98 (2C; CHAr), 82.93 (CCH), 79.16 (C(CH3)3), 71.56 (CCH), 66.91 
(CHCH2O), 47.20 (CHCH2O), 43.19 (Cα), 40.22 (Cε), 35.46 (Cβ), 29.57 (Cδ), 28.43 (C(CH3)3), 
22.66 (Cγ). 
 
Boc-Leu[5Tz]Val-chGly[5Tz]Phe-OBzl (40). 
Boc-chGly[5Tz]Phe-OBzl (66 mg; 0.13 mmol) is 
dissolved in DCM/(4 M HCl in dioxane) 1:1 (1 mL) and 
stirred overnight at rt. After evaporation of the 
solvent, the crude ammonium salt is used without 
further purification. Boc-Leu[5Tz]Val-OH (51 mg; 
0.14 mmol; 1.1 eq), Oxyma (20 mg; 0.14 mmol; 1.1 eq) 
and COMU (60 mg; 0.14 mmol; 1.1 eq) are dissolved in DCM (1 mL; dry) under an argon 
atmosphere, after addition of sym-collidine (19 µL; 0.14 mmol; 1.1 eq), the reaction mixture 
is stirred 10 min for preactivation at rt. The crude ammonium salt is dissolved in DCM 
(1 mL; dry) and added dropwise to the activated acid mixture, followed by sym-collidine 
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(52 µL; 0.39 mmol; 3.0 eq). The reaction mixture is left to stir overnight. The solvent is 
removed under vacuum, the crude peptidotriazolamer purified by preparative HPLC.  
Yield: 46 mg (61 µmol); 47%. Analytical RP-HPLC: tR= 2.85 min (method 2, 254 nm).  
HR-MS (ESI): m/z= 755.4582 [M+H]+ (calc. 755.46029). 
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 8.36 (m, 1H, chGly3-NH), 7.62 (s, 1H, Tz1-H), 
7.55 (s, 1H, Tz2-H), 7.44 (d, 3J= 8.3 Hz, 1H, Leu1-NH), 7.37-7.25 (m, 5H, Ph-H), 7.19-7.13 (m, 
3H, Ph-H), 7.09-06 (m, 2H, Ph-H), 5.86 (dd, 3J= 11.5, 4.2 Hz, 1H, Phe4-Hα), 5.28 (d, 
2J= 12.9 Hz, 1H, O-CHH), 5.10 (d, 2J= 12.9 Hz, 1H, O-CHH), 5.07 (m, 1H, Leu1-Hα), 4.81 (d, 
3J= 10.6 Hz, 1H, Val2-Hα), 4.46 (dd, 3J= 9.0, 9.0 Hz, 1H, chGly-Hα), 3.69 (dd, 2J= 13.9, 
3J= 4.1 Hz, 1H, Phe4-Hβ), 3.54 (dd, 2J= 13.9, 3J= 11.5 Hz, 1H, Phe4-Hβ), 2.75 (m, 1H, Val2-
Hβ), 1.73 (ddd, 2J= 14.0, 3J= 10.6, 4.5 Hz, 1H, Leu1-Hβ), 1.63 (m, 1H, Leu1-Hγ), 1.44-1.37 (m, 
1H, CH2), 1.35 (s, 9H, C(CH3)3), 1.32-1.21 (m, 3H, chGly3-Hβ, Leu1-Hβ, CH2), 1.15-1.09 (m, 
1H, CH2), 0.97-0.76 (m, 4H, CH2), 0.91 (d, 3J= 6.6 Hz, 3H, Leu1-Hδ), 0.89 (d, 3J= 6.6 Hz, 3H, 
Leu1-Hδ), 0.71-0.63 (m, 1H, CH2), 0.67 (d, 3J= 6.4 Hz, 3H, Val2-Hγ), 0.52-0.39 (m, 1H, CH2), 
0.46 (d, 3J= 6.6 Hz, 3H, Val2-Hγ), 0.00 (m, 1H, CH2). 
13C NMR (151 MHz, DMSO-d6) δ [ppm]= 168.11 (Phe4-C), 166.96 (Val2-C), 155.63 (tBuO-
C), 141.47 (Tz1-C), 139.60 (Tz2-C), 136.52 (CAr), 135.89 (CAr), 132.36 (Tz1-CH), 131.44 (Tz2-
CH), 129.71 (2C, CHAr), 128.80 (2C, CHAr), 128.37 (2C, CHAr), 127.77 (2C, CHAr), 127.27 (2C, 
CHAr), 78.85 (C(CH3)3), 68.09 (Val2-Cα), 67.22 (O-CH2), 61.51 (Phe4-Cα), 47.37 (chGly3-Cα), 
44.71 (Leu1-Cβ), 43.19 (Leu1-Cα), 37.61 (Phe4-Cβ), 29.65 (Val2-Cβ), 29.41 (CH2), 28.56 
(C(CH3)3), 28.18 (CH2), 25.93 (CH2), 25.49 (CH2), 25.43 (CH2), 25.05 (Leu1-Cγ), 23.61 
(chGly3-Cβ), 21.90 (2C, Leu-Cδ), 19.58 (Val2-Cγ), 19.08 (Val2-Cγ). 
 
Cbz-Lys(Boc)-Leu[5Tz]Val-chGly[5Tz]Phe-OBzl (41). 
Boc-Leu[5Tz]Val-chGly[5Tz]Phe-OBzl (42 mg; 
56 µmol) is dissolved in DCM/(4 M HCl in 
dioxane) 1:1 (1 mL) and stirred for 2 h at rt. After 
evaporation of the solvent, the crude ammonium 
salt is used without further purification. Cbz-
Lys(Boc)-OH (42 mg; 0.11 mmol; 2.0 eq), Oxyma 
(16 mg; 0.11 mmol; 2.0 eq) and COMU (47 mg; 
0.11 mmol; 2.0 eq) are dissolved in DCM (1 mL; dry) under an argon atmosphere, after 
addition of sym-collidine (15 µL; 0.11 mmol; 2.0 eq), the reaction mixture is stirred 10 min 
for preactivation at rt. The crude ammonium salt is dissolved in DCM (2 mL; dry) and 
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added dropwise to the activated acid mixture, followed by sym-collidine (15 µL; 0.11 mmol; 
2.0 eq). The reaction mixture is left to stir overnight. The solvent is removed under vacuum, 
the crude peptidotriazolamer purified by preparative HPLC.  
Yield: 34 mg (33 µmol); 59%. Analytical RP-HPLC: tR= 3.9 min (method 2, 254 nm). 
MS (ESI): m/z= 1039.7 [M+Na]+. 
The Peptidotriazolamer was fully characterized after cleavage of the protecting groups. 
 
H-Lys-Leu[5Tz]Val-chGly[5Tz]Phe-OH (42a). 
25 mg (25 µmol) Cbz-Lys(Boc)-Leu[5Tz]Val-
chGly[5Tz]Phe-OBzl are dissolved in 4M 
HCl/DCM (1:1) (1 mL) and stirred 3 h at rt. The 
solvent is evaporated under vacuum and the 
residual slurry dissolved in EtOH (2 mL). After 
addition of Pd/C (2.5 mg; 10 wt%), H2 (1 atm) is 
passed through the solution via cannula. The Pd/C 
is filtered off over a short plug of silica, which is thoroughly washed with EtOH. The 
combined filtrate is concentrated under vacuum to obtain the peptidotriazolamer in 
analytically pure form. Yield: 15 mg (22 µmol); 88%. Analytical RP-HPLC: tR= 2.6 min 
(method 2, 254 nm). HR-MS (ESI): 715.43808 [M+Na]+ (calc. 715.4384). 
1H-NMR (600 MHz, MeOH-d3): δ [ppm]= 9.05 (d, 3J= 7.7 Hz, 1H, Leu2-NH), 8.38 (d, 
3J= 9.2 Hz, 1H, chGly4-NH), 7.77 (s, 1H, Tz1-H), 7.54 (s, 1H, Tz2-H), 7.21-7.14 (m, 3H, PhH), 
7.09-7.04 (m, 2H, PhH), 5.66 (dd, 3J= 12.1, 3.6 Hz, 1H, Phe5-Hα), 5.46 (m, 1H, Leu2-Hα), 4.84 
(d, 3J= 11.1 Hz, 1H, Val3-Hα), 4.44 (dd, 3J= 9.2, 9.2 Hz, 1H, chGly4-Hα), 3.88 (dd, 3J= 6.6, 
6.6 Hz, 1H, Lys1-Hα), 3.76 (dd, 2J= 14.0, 3J= 3.5 Hz, 1H, Phe5-Hβ), 3.63 (dd, 2J= 14.0, 3J= 12.0 
Hz, 1H, Phe5-Hβ), 2.89 (dqq, 3J= 11.1, 6.7, 6.6 Hz, 1H, Val3-Hβ), 2.86-2.81 (m, 2H, Lys1-Hε), 
1.90 (m, 1H, Leu2-Hβ), 1.80 (m, 1H, Leu2-Hγ), 1.74-1.69 (m, 2H, Lys1-Hβ), 1.61-1.55 (m, 2H, 
Lys1-Hδ), 1.52-1.46 (m, 2H, Leu2-Hβ, CH2), 1.44 (m, 1H, chGly4-Hβ), 1.35 (m, 1H, CH2), 1.32-
1.25 (m, 2H, Lys1-Hγ), 1.19 (m, 1H, CH2), 1.06 (d, 3J= 6.5 Hz, 3H, Leu2-Hδ), 1.01 (d, 3J= 6.7 
Hz, 3H, Leu2-Hδ), 0.98 (d, 3J= 6.6 Hz, 3H, Val3-Hγ), 0.97-0.87 (m, 4H, CH2), 0.81 (m, 1H, 
CH2), 0.64 (d, 3J= 6.7 Hz, 3H, Val3-Hγ), 0.51 (m, 1H, CH2), 0.00 (m, 1H, CH2). 
13C NMR (151 MHz, MeOH-d3) δ [ppm]= 169.66 (Phe5-C), 168.57 (Lys1-C), 166.84 (Val3-
C), 141.17 (Tz1-C), 139.44 (Tz2-C), 136.63 (CAr), 131.76 (Tz1-CH), 130.70 (Tz2-CH), 128.93 
(2C, CHAr), 128.38 (2C, CHAr), 126.77 (CHAr), 69.18 (Val3-Cα), 62.38 (Phe5-C), 52.67 (Lys1-
Cα), 47.43 (chGly4-Cα), 43.93 (Leu2-Cβ), 42.22 (Leu2-Cα), 40.06 (chGly4-Cβ), 39.09 (Lys1-Cε), 
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37.52 (Phe5-Cβ), 30.83 (Lys1-Cβ), 29.55 (Val3-Cβ), 28.30 (CH2), 26.71 (Lys1-Cδ), 25.55 (CH2), 
25.10 (CH2), 24.97 (2C; CH2), 24.71 (Leu2-Cγ), 22.31 (Leu2-Cδ), 21.59 (Lys1-Cγ), 20.38 (Leu2-
Cδ), 18.71 (Val3-Cγ), 18.16 (Val3-Cγ). 
 
Boc-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl (43). 
Boc-Phe[5Tz]Phe-OBzl (220 mg; 0.42 mmol) is 
dissolved in DCM/(4 M HCl in dioxane) 1:1 (5 mL) 
and stirred for 2 h at rt. After evaporation of the 
solvent, the crude ammonium salt is used without 
further purification. Boc-Leu-[5Tz]-Val-OH (164 mg; 
0.46 mmol; 1.1 eq; synthesized according to GP3), 
Oxyma (1.21 eq; 0.51 mmol; 72 mg) and DIC (1.21 eq; 0.51 mmol; 79 µL) are dissolved in 
DCM (3 mL; dry) under an argon atmosphere and stirred 10 min for preactivation. The 
crude ammonium salt is dissolved in DCM (3 mL; dry) and the activated acid mixture is 
added dropwise, followed by TMP (10 eq; 4.2 mmol; 555 µL). The reaction mixture is left to 
stir overnight. The solvent is removed under vacuum, the residue dissolved in EtOAc and 
washed with 10% citric acid (2x), water (2x), satured NaHCO3 (2x), brine and dried over 
MgSO4. The filtrate is concentrated and the crude peptidotriazolamer purified by column 
chromatography PE/EtOAc 1:1. Yield: 190 mg (0.249 mmol); 59%. Rf (PE/EtOAc 1:1)= 0.57.  
HR-MS (ESI): m/z= 382.2184 [M+2H]2+ (calc. 382.21813). 
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 8.87  (m, 1H, Phe3-NH), 7.70 (s, 1H, Tz2-H), 7.57 
(s, 1H, Tz1-H), 7.37-7.19 (m, 9H, Ph-H, Boc-NH), 7.01-6.91 (m, 5H, Ph-H), 6.70-6.66 (m, 2H, 
Ph-H), 5.86 (dd, 3J=11.0, 4.5 Hz, 1H, Phe4-Hα), 5.28 (d, 2J=12.8 Hz, 1H, O-CHH-), 5.11 (d, 
2J=12.8 Hz, 1H, O-CHH), 5.09 (m, 1H, Leu1-Hα) 4.73 (d, 3J=11.2 Hz, 1H, Val2-Hα), 4.60 (m, 
1H, Phe3-Hα), 3.66 (dd, 2J=13.8, 3J=4.5 Hz, 1H, Phe4-Hβ), 3.36 (dd, 2J=13.8, 3J=11.1 Hz, 1H, 
Phe4-Hβ), 2.77 (dd, 2J=13.7, 3J=10.7 Hz, 1H, Phe3-Hβ), 2.76 (m, 1H, Val2-Hβ), 2.22 (dd, 
2J=13.7, 3J=4.1 Hz, 1H, Phe3-Hβ), 1.47 (m, 1H, Leu1-Hγ), 1.39 (m, 1H, Leu1-Hβ), 1.32 (s, 9H, 
-C(CH3)3), 0.85 (d, 3J=6.6 Hz, 3H, Leu1-Hδ), 0.82 (d, 3J=6.7 Hz, 3H, Leu1-Hδ), 0.71 (m, 1H, 
Leu1-Hβ), 0.61 (d, 3J=6.5 Hz, 3H, Val2-Hγ), 0.37 (d, 3J=6.5 Hz, 3H, Val2-Hγ). 
13C NMR (151 MHz, DMSO-d6): δ [ppm]= 167.93 (Phe4-C), 166.84 (Val2-C), 155.37 (tBuO-
C), 141.37 (Tz1-C), 140.27 (Tz2-C), 136.72 (CAr), 136.43 (CAr), 135.79 (CAr), 133.05 (Tz1-CH), 
131.76 (Tz2-CH), 129.51 (2C, CHAr), 129.16 (2C, CHAr), 128.93 (2C, CHAr), 128.83 (3C, CHAr), 
128.43 (CHAr), 128.36 (CHAr), 127.86 (2C, CHAr), 127.53 (CHAr), 126.62 (CHAr), 78.51 (-
C(CH3)3), 69.52 (Val2-Cα), 67.29 (O-CH2-), 61.57 (Phe4-Cα), 44.56 (Leu1-Cβ), 43.75 (Phe3-
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Cα), 42.89 (Leu1-Cα), 39.13 (Phe3-Cβ), 38.21 (Phe4-Cβ), 29.08 (Val2-Cβ), 28.55 (C(CH3)3), 
24.94 (Leu1-Cγ), 23.65 (Leu1-Cδ), 21.73 (Leu1-Cδ), 19.50 (Val2-Cγ), 18.79 (Val2-Cγ). 
 
Z-Lys(Z)-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl (44).  
Boc-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl 
(107 mg; 0.140 mmol) is dissolved in DCM/(4 M 
HCl in dioxane) 1:1 (2 mL) and stirred overnight 
at rt. After evaporation of the solvent, the crude 
ammonium salt is used without further 
purification. Z-Lys(Z)-OH (64 mg; 0.15 mmol; 
1.1 eq), Oxyma (1.21 eq; 0.17 mmol; 24 mg) and 
DIC (1.21 eq; 0.17 mmol; 26 µL) are dissolved in DCM (1 mL; dry) under an argon 
atmosphere and stirred 10 min for preactivation. The crude ammonium salt is dissolved in 
DCM (1 mL; dry) and the activated acid mixture is added dropwise, followed by TMP 
(10 eq; 1.4 mmol; 185 µL). The reaction mixture is left to stir overnight. The solvent is 
removed under vacuum, the residue dissolved in EtOAc and washed with 10% citric acid 
(2x), water (2x), satured NaHCO3 (2x), brine and dried over MgSO4. The filtrate is 
concentrated and the crude peptidotriazolamer purified by column chromatography 
PE/EtOAc 1:1. Yield: 108 mg (0.102 mmol); 73%. Rf (PE/EtOAc 1:1)= 0.21.  
HR-MS (ESI): m/z= 530.2748 [M+2H]2+ (calc. 530.27618).  
1H-NMR (500 MHz, DMSO-d6): δ [ppm]= 8.90 (m, 1H, Phe4-NH), 8.39 (Leu2-NH), 7.76 (s, 
1H, Tz2-H), 7.62 (s, 1H, Tz1-H), 7.40 (d, 3J=7.9 Hz, 1H, Lys1-NH), 7.37-7.14 (m, 18H, Ph-H), 
7.18 (Lys1(Z-NH)), 6.99-6.88 (m, 5H, Ph-H), 6.57-6.54 (m, 2H, Ph-H), 5.89 (dd, 3J=11.1, 4.4 
Hz, 1H, Phe5-Hα), 5.27 (m, 1H, Leu2-Hα), 5.27 (d, 2J=12.8 Hz, 1H, Phe5-O-CHH), 5.13 (d, 
2J=12.8 Hz, 1H, Phe5-O-CHH), 5.00 (d, 2J=13.5 Hz, 4H, Z-CH2), 4.77 (d, 3J=11.0 Hz, 1H, Val3-
Hα), 4.60 (m, 1H, Phe4-Hα), 3.92 (m, 1H, Lys1-Hα), 3.68 (dd, 2J=13.8, 3J=4.4 Hz, 1H, Phe5-
Hβ), 3.38 (dd, 2J=13.8, 3J=11.2 Hz, 1H, Phe5-Hβ), 2.92-2.84 (m, 2H, Lys1-Hε), 2.76 (dd, 2J=13.7, 
3J=10.7 Hz, 1H, Phe4-Hβ), 2.67 (m, 1H, Val3-Hβ), 2.20 (dd, 2J=13.8, 3J=4.0 Hz, 1H, Phe4-Hβ), 
1.60-1.48 (m, 2H, Leu2-Hβ, Leu2-Hγ), 1.44-1.37 (m, 2H, Lys1-Hβ), 1.31-1.18 (m, 4H, Lys1-Hγ, 
Lys1-Hδ), 0.84 (d, 3J=6.5 Hz, 6H, Leu2-Hδ), 0.75 (m, 1H, Leu2-Hβ), 0.67 (d, 3J=6.5 Hz, 3H, 
Val3-Hγ), 0.34 (d, 3J=6.6 Hz, 3H, Val3-Hγ). 
13C-NMR (600 MHz, DMSO-d6): δ [ppm]= 172.33 (Lys1-C), 167.95 (Phe5-C), 166.43 (Val-
C), 156.47 (BzlO-C), 156.36 (BzlO-C), 141.20 (Tz1-C), 140.37 (Tz2-C), 137.70 (CAr), 137.48 
(CAr), 136.75 (Phe4-CAr), 136.47 (Phe5-CAr), 135.79 (CAr), 132.37 (Tz1-CH), 131.85 (Tz2-CH), 
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129.49 (CHAr), 129.10 (CHAr), 128.93 (CHAr), 128.84 (2C, CHAr), 128.78 (3C, CHAr), 128.44 
(CHAr), 128.23 (CHAr), 128.17 (CHAr), 128.13 (CHAr), 127.86 (CHAr), 127.52 (CHAr), 126.55 
(CHAr),  68.70 (Val3-Cα), 67.30 (Phe5-O-CH2), 61.59 (Phe5-Cα), 54.86 (Lys1-Cα), 44.45 (Leu2-
Cβ), 43.61 (Phe4-Cα), 41.56 (Leu2-Cα), 40.49 (Lys1-Cε), 39.12 (Phe4-Cβ), 38.19 (Phe5-Cβ), 
31.71 (Lys1-Cβ), 29.47 (2C, Lys1-Cδ, Val3-Cβ), 24.78 (Leu2-Cγ), 23.76 (Leu2-Cγ), 23.18 (Lys1-
Cγ), Leu2-Cδ), 21.68 (Leu2-Cδ), 19.54 (Val3-Cγ), 18.90 (Val3-Cγ). 
 
H-Lys-Leu[5Tz]Val-Phe[5Tz]Phe-OH (42b).  
Prepared according to GP6, starting with Z-
Lys(Z)-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl (44) (103 
mg; 97.2 µmol) for 6 h. The product was purified 
by preparative HPLC.  
Yield: 51 mg (0.55 mmol); 57%, TFA-salt.  
Analytical RP-HPLC: tR= 3.06 min (method 1, 
254 nm).  
HR-MS (ESI): m/z= 701.4276 [M+H]+ (calc. 701.42457). 
1H-NMR (600 MHz, DMSO-d6): δ [ppm]= 9.12 (m, 1H, Phe4-NH), 8.83 (d, 3J=8.2 Hz, 1H, 
Leu2-NH), 8.22-8.13 (m, 3H, Lys1-CαNH3), 7.80-7.73 (m, 3H, CεNH3), 7.71 (s, 1H, Tz2-H), 
7.62 (s, 1H, Tz1-H), 7.29-7.18 (m, 3H, Ph-H), 6.99-6.85 (m, 5H, Ph-H), 6.64-6.61 (m, 2H, Ph-
H), 5.65 (dd, 3J=11.8, 4.0 Hz, 1H, Phe5-Hα), 5.43 (m, 1H, Leu-Hα), 4.79 (d, 3J=11.6 Hz, 1H, 
Val3-Hα), 4.45 (m, 1H, Phe4-Hα), 3.71 (m, 1H, Lys1-Hα), 3.61 (dd, 2J=13.8, 3J=4.0 Hz, 1H, 
Phe5-Hβ), 3.35 (dd, 1H, 2J=13.8, 3J=11.8 Hz Phe5-Hβ), 2.79-2.72 (m, 2H, Val-Hβ, Phe4-Hβ), 
2.62-2.55 (m, 2H, Lys1-Hε), 2.22 (dd, 2J=13.7, 3J=3.4 Hz, 1H, Phe4-Hβ), 1.59-1.47 (m, 3H, Leu-
Hγ, Lys1-Hβ), 1.43-1.36 (m, 2H, Lys1-Hδ), 1.33-1.15 (m, 2H, Leu2-Hβ), 1.13-1.06 (m, 2H, Lys1-
Hγ),  0.87 (d, 3J= 6.5 Hz, 3H, Leu-Hδ), 1.19 (m, 1H, Leu2-Hβ), 0.81 (d, 3J=6.7 Hz, 3H, Leu-Hδ), 
0.78 (d, 3J=6.5 Hz, 3H, Val-Hγ), 0.36 (d, 3J= 6.5 Hz, 3H, Val-Hγ).  
13C-NMR (151 MHz, DMSO-d6): δ [ppm]= 169.59 (Phe5-C), 168.27 (Lys1-C), 166.38 (Val3-
C), 140.69 (Tz1-C), 140.10 (Tz2-C), 137.03 (CAr), 136.86 (CAr), 133.43 (Tz1-CH), 131.68 (Tz2-
CH), 129.38 (2C, CHAr), 129.12 (2C, CHAr), 128.85 (2C, CHAr), 128.37 (2C, CHAr), 127.39 
(CHAr), 126.48 (CHAr), 70.43 (Val3-Cα), 61.93 (Phe5-Cα), 52.16 (Lys1-Cα), 44.15 (Leu2-Cβ), 
43.77 (Phe4-Cα), 41.78 (Leu2-Cα), 39.11 (Phe4-Cβ), 38.84 (Lys1-Cε), 38.41 (Phe5-Cβ), 30.86 
(Lys1-Cβ), 28.61 (Val3-Cβ), 26.76 (Lys1-Cδ), 24.61 (Leu-Cγ), 23.83 (Leu2-Cδ), 21.49 (Lys1-Cγ), 
21.45 (Leu2-Cδ), 19.63 (Val3-Cγ), 19.00 (Val3-Cγ). 
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Z-Lys(Boc)-Leu-[5Tz]-Val-Phe[5Tz]Phe-OBzl (45).  
Boc-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl 
(54 mg; 71 µmol) is dissolved in DCM/(4 M HCl 
in dioxane) 1:1 (3 mL) and stirred 2 h at rt. After 
evaporation of the solvent, the crude ammonium 
salt is used without further purification. Z-
Lys(Boc)-OH (54 mg; 0.14 mmol; 2.0 eq), Oxyma 
(20 mg; 0.14 mmol; 2.0 eq) and COMU (61 mg; 
0.14 mmol; 2.0 eq) are dissolved in DCM (1 mL; dry), after addition of sym-collidine (19 µL; 
0.14 mmol; 2.0 eq) the reaction mixture is stirred 10 min for preactivation. The crude 
ammonium salt is dissolved in DCM (1 mL; dry) and the activated acid mixture is added 
dropwise, followed by TMP (19 µL; 0.14 mmol; 2.0 eq). The reaction mixture is left to stir 
overnight. The solvent is removed under vacuum and the crude product purified by 
preparative HPLC. Yield: 41 mg (40 µmol); 56%. Analytical RP-HPLC: tR= 6.96 min 
(method 1, 254 nm). HR-MS (ESI): m/z= 1047.54319 [M+Na]+ (calc. 1047.5432). 
The Peptidotriazolamer was fully characterized after cyclisation and cleavage of the 
protecting groups. 
 
Cyclo-[Lys-Leu[5Tz]Val-Phe[5Tz]Phe] (42c). 
Cbz-Lys(Boc)-Leu[5Tz]Val-Phe[5Tz]Phe-OBzl (45) 
(29 mg; 28 µmol) is dissolved in MeOH (1 mL), after 
addition of Pd/C (6 mg; 20 wt%) and TES (45 µL; 
0.28 mmol; 10 eq), the solution is stirred for 20 min at rt. 
After full conversion of the starting material, the Pd/C is 
filtered off through a short plug of silica, which is 
washed with MeOH (3x), the filtrate is concentrated 
under vacuum to give H-Lys(Boc)-Leu[5Tz]Val-Phe[5Tz]Phe-OH as a colourless oil. 
Analytical RP-HPLC: tR= 5.11 min (method 1, 254 nm). 
The crude product is dissolved in DMF / DCM 1:1 (28 mL; 1 mM; dry) and sym-collidine 
(37 µL; 0.28 mmol; 10 eq) is added, followed by PyBOP (29 mg; 56 µmol; 2.0 eq), the reaction 
is left to stir overnight at rt. After full conversion of the linear precursor, H2O (10 mL) is 
added and the solvent is removed under vacuum to give cyclo-[Lys(Boc)-Leu[5Tz]Val-
Phe[5Tz]Phe] (46) as crude product.  
Analytical RP-HPLC: tR= 6.14 min (method 1 ,254 nm). 
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The residual material is dissolved in TFA/H2O/TIS (95:2.5:2.5) (3 mL) and stirred for 2 h at 
rt, the TFA is removed by co-evaporation with toluene, the crude product purified by 
preparative HPLC. Yield: 11 mg (14 µmol), TFA-salt; 50% over three steps. 
Analytical RP-HPLC: tR= 4.78 min (method 1, 254 nm). 
HR-MS (ESI): m/z= 683.4162 [M+H]+ (683.41401). 
1H-NMR (600 MHz, DMSO): δ [ppm]= 7.90 (d, 3J= 7.5 Hz, 3H, Leu2-NH), 7.90 (s, 1H, Tz1-
H), 7.69 (m, 1H, Lys1-NH), 7.68 (s, 1H, Tz2-H), 7.28-7.18 (m, 5H, Ph-H), 7.05-7.02 (m, 2H, 
Ph-H), 7.01 (d, 3J= 9.3 Hz, 1H, Phe4-NH), 6.87-6.85 (m, 2H, Ph-H), 6.68 (m, 1H, Ph-H), 5.23 
(dd, 3J= 11.9, 3.6 Hz, 1H, Phe5-Hα), 4.78 (ddd, 3J = 9.7, 9.3, 5.4 Hz, 1H, Phe4-Hα), 4.64 (m, 
1H, Leu2-Hα), 4.60 (d, J = 6.1 Hz, 1H, Val3-Hα), 4.31 (m, 1H, Lys1-Hα), 3.71 (dd, 2J= 13.8, 3J= 
3.6 Hz, 1H, Phe5-Hβ), 3.23 (dd, 2J= 13.8, 3J= 12.0 Hz, 1H, Phe5-Hβ), 2.99 (dd, 2J= 14.0, 3J= 9.7 
Hz, 1H, Phe4-Hβ) 2.80-2.75 (m, Lys1-Hε), 2.63 (dd, 2J= 14.0, 3J= 5.4 Hz, 1H, Phe4-Hβ), 2.48 
(qqd, 3J= 6.9, 6.8, 6.1 Hz, 1H, Val3-Hβ), 1.83 (m, 1H, Leu2-Hβ), 1.75 (m, 1H, Leu2-Hβ), 1.58-
1.48 (m, 4H, Lys1-Hβ, Lys1-Hδ, Leu2-Hγ), 1.36 (m, 1H, Lys1-Hβ), 1.32-1.20 (m, 2H, Lys1-Hγ), 
0.90 (d, 3J= 6.6 Hz, 3H, Leu2-Hδ), 0.86 (d, 3J= 6.6 Hz, 3H, Leu2-Hδ), 0.49 (d, 3J= 6.9 Hz, 3H, 
Val3-Hγ), 0.47 (d, 3J= 6.8 Hz, 3H, Val3-Hγ). 
13C-NMR (151 MHz, DMSO-d6): δ [ppm]= 170.43 (Lys1-C), 166.99 (Phe5-C), 166.44 (Val3-
C), 140.10 (Tz2-C), 139.55 (Tz1-C), 137.03 (CAr), 136.96 (CAr), 132.73 (Tz1-CH), 132.42 (Tz2-
CH), 129.41 (2C, CHAr), 128.92 (2C, CHAr), 128.86 (2C, CHAr), 128.74 (2C, CHAr), 127.30 
(CHAr), 126.94 (CHAr), 65.89 (Val3-Cα), 63.15 (Phe5-Cα), 54.55 (Lys1-Cα), 43.29 (Phe4-Cα), 
41.84 (Leu2-Cα), 41.54 (Leu2-Cβ), 39.09 (Lys1-Cε), 38.67 (Phe4-Cβ), 38.53 (Phe5-Cβ), 31.49 
(Val3-Cβ), 31.04 (Lys1-Cβ), 26.79 (Lys1-Cδ), 25.11 (Leu2-Cγ), 22.87 (Leu2-Cδ), 22.52 (Lys1-
Cγ), 22.49 (Leu2-Cδ), 19.23 (Val-Cγ), 18.27 (Val-Cγ). 
 
H-KLVFF-OH (42d). 
Fmoc-Phe-OH (100 mg; 258 µmol) is loaded onto 2-CTC resin (1.3 eq; 335 µmol; 220 mg; 
1.52 mmol/g loading) according to GP9. The loading was determined as 0.43 mmol/g 
(148 µmol; 57%). The peptide was then assembled by standard SPPS and purified by 
preparative HPLC. Yield: 114 mg (129 µmol), TFA-salt; 87%.  
Chemical formula: C35H52N6O6 (MW= 652.84 gmol-1).  
Analytic RP-HPLC: tR= 6.07 min (method 3, 254 nm). 
HR-MS (ESI): m/z= 653.4044 [M+H]+ (calc. 653.40211). 
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H-KLVFF-NH2 (42e). 
Fmoc-Phe-OH (40 mg; 103 µmol) is loaded onto rink amide resin (206 mg; 103 µmol; 1.0 eq) 
according to GP9. The loading was determined as 0.42 mmol/g (87 µmol; 84%). The peptide 
was then assembled by standard SPPS and purified by preparative HPLC.  
Yield: 55 mg (63 µmol), TFA-salt; 72%.  
Chemical formula: C35H53N7O5 (MW= 651.85 gmol-1).  
Analytic RP-HPLC: tR= 3.77 min (method 1, 254 nm). 
HR-MS (ESI): m/z= 652.4170 [M+H]+ (calc. 652.41809). 
 
H-klvff-NH2 (42f). 
Fmoc-Phe-OH (40 mg; 103 µmol) is loaded onto rink amide resin (206 mg; 103 µmol; 1.0 eq) 
according to GP9. The loading was determined as 0.42 mmol/g (87 µmol; 84%). The peptide 
was then assembled by standard SPPS and purified by preparative HPLC.  
Yield: 55 mg (63 µmol), TFA-salt; 37%. 
Chemical formula: C35H53N7O5 (M: 651.85 gmol-1). 
Analytic RP-HPLC: tR= 3.76 min (method 1, 254 nm). 
HR-MS (ESI): m/z= 652.4155 [M+H]+ (calc. 652.41809). 
 
Ac-Lys-Leu[4Tz]Val-Phe[4Tz]Phe-NH2 (42g). 
Fmoc-Phe[4Tz]Phe-OH (20 mg; 36 µmol) is 
loaded onto rink amide resin (83 mg; 
0.42 mmol; 1.1 eq) according to GP9. The 
loading was determined as 0.27 mmol/g 
(22 µmol; 61%). The peptide was then 
assembled by standard SPPS and purified by 
preparative HPLC. Yield: 12 mg (14 µmol) TFA-salt; 63%. Analytic RP-HPLC: 
tR= 4.35 min (method 1, 254 nm). HR-MS (ESI): m/z= 742.4541 [M+H]+ (calc. 742.45112). 
1HNMR (600 MHz; DMSO-d6): δ [ppm] = 9.04 (d, 3J= 8.5 Hz, 1H, Phe4-NH), 8.23 (d, 
3J= 8.7 Hz, 1H, Leu2-NH), 8.14 (s, 1H,Tz2-H), 7.98 (d, 3J= 8.3 Hz, 1H, Lys1-NH), 7.92 (s, 1H, 
CONH2), 7.79 (s, 1H, Tz1-H), 7.66 (s, 3H, Lys1-NH), 7.46 (s, 1H, CONH2), 7.24-6.94 (m, 10H, 
Ph-H), 5.52 (dd, 3J= 10.2, 5.4 Hz, 1H, Phe5-Hα), 5.16 (ddd, 3J= 8.5, 7.8, 6.8 Hz, 1H, Phe4-Hα), 
5.04 (td, 3J= 8.6, 6.7 Hz, 1H, Leu2-Hα), 4.91 (d, 3J= 10.1 Hz, 1H, Val3-Hα), 4.24 (td, 3J= 8.3, 
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5.5 Hz, 1H, Lys1-Hα), 3.38 (dd, 2J= 14.2, 3J= 5.4 Hz, 1H, Phe5-Hβ), 3.30 (dd, 2J= 14.2, 3J= 10.3 
Hz, 1H, Phe5-Hβ), 3.12 (dd, 2J= 13.6, 3J= 6.8 Hz, 1H, Phe4-Hβ), 2.99 (dd, 2J= 13.6, 3J= 7.8 Hz, 
1H, Phe4-Hβ), 2.75-2.69 (m, 2H, Lys1-Hε), 2.27-2.21 (m, 1H, Val3-Hβ), 1.84 (s, 3H, H3C-CO), 
1.69-1.64 (m, 2H, Leu2-Hβ), 1.61-1.52 (m, 2H, Leu2-Hγ, Lys1-Hβ), 1.50-1.43 (3H, Lys1-Hβ, 
Lys1-Hδ), 1.29-1.17 (m, 2H, Lys1-Hγ), 0.90 (d, 3J= 6.6 Hz, 3H, Leu-Hδ), 0.88 (d, 3J= 6.6 Hz, 
3H, Leu-Hδ), 0.77 (d, 3J= 6.7 Hz, 3H, Val3-Hγ), 0.56 (d, 3J= 6.7 Hz, 3H, Val3-Hγ). 
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 171.44 (Lys1-C), 169.58 (2C; Ac-CO, Phe5-
C), 167.12 (Val3-C), 149.61 (Tz1-C), 147.31 (Tz2-C), 137.95 (CAr), 136.72 (CAr), 129.46 (2C, 
CHAr), 129.29 (2C, CHAr), 128.69 (2C, CHAr), 128.35 (2C, CHAr), 127.17 (CHAr), 126.51 
(CHAr), 122.10 (Tz2-CH), 120.63 (Tz1-CH), 68.91 (Val3-Cα), 64.33 (Phe5-Cα), 52.68 (Lys1-
Cα), 47.27 (Phe4-Cα), 44.17 (Leu2-Cβ), 43.78 (Leu2-Cα), 40.52 (Phe4-Cβ), 39.16 (Lys1-Cε), 
38.28 (Phe5-Cβ), 32.06 (Lys1-Cβ), 31.91 (Val3-Cβ), 27.18 (Lys1-Cδ), 24.65 (Leu2-Cγ), 23.32 
(Leu-Cδ), 22.99 (H3C-CO), 22.73 (Lys1-Cγ), 22.34 (Leu2-Cδ), 19.18 (Val3-Cγ), 18.84 (Val3-Cγ). 
 
H-klvff-OH (42h). 
Fmoc-D-Phe-OH (60 mg; 0.15 mmol) is loaded onto 2-CTC resin (1.6 eq; 0.24 mmol; 160 mg; 
1.52 mmol/g loading) according to GP9. The loading was determined as 0.47 mmol/g 
(75 µmol; 50%). The peptide was then assembled by standard SPPS and purified by 
preparative HPLC. Yield: 45 mg (51 µmol), TFA-salt; 68%.  
Chemical formula: C35H52N6O6 (M: 652.84 gmol-1). 
Analytic RP-HPLC: tR= 3.92 min (method 1, 254 nm). 
HR-MS (ESI): m/z= 653.4012 [M+H]+ (calc. 653.40211). 
 
Ac-Lys-Leu[5Tz]Val-Phe[5Tz]Phe-NH2 (42i). 
Fmoc-Phe[5Tz]Phe-OH (50 mg; 89.5 µmol) is 
loaded onto rink amide resin (179 mg; 89.5 µmol; 
1.0 eq) according to GP9. The loading was 
determined as 0.42 mmol/g (75 µmol; 84%). The 
peptide was then assembled by standard SPPS 
according to general procedure and purified by 
preparative HPLC. Yield: 24 mg (28 µmol), TFA-
salt; 37%. Analytic RP-HPLC: tR= 4.63 (method 1, 254 nm). 
HR-MS (ESI): m/z= 742.4529 [M+H]+ (calc. 742.45112).  
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1HNMR (600 MHz; DMSO-d6): δ [ppm]= 8.80 (m, 1H, Phe4-NH), 8.45 (m, 1H, Leu2-NH), 
7.96 (d, 3J= 8.0 Hz, 1H, Lys1-NH), 7.66 (s, 1H, Tz2-H), 7.63 (s, 1H, Tz1-H), 7.19-6.69 (m, 10H, 
Ph-H), 5.46 (dd, 3J= 11.1, 4.6 Hz, 1H, Phe5-Hα), 5.19 (m, 1H, Leu2-Hα), 4.87 (m, 1H, Phe4-
Hα), 4.81 (d, 3J= 10.7 Hz, 1H, Val3-Hα), 4.15 (td, 3J= 8.5, 5.3 Hz, 1H, Lys1-Hα), 3.52 (dd, 2J= 
13.9, 3J= 4.6 Hz, 1H, Phe5-Hβ), 3.31 (dd, 2J= 13.9, 3J= 11.1 Hz, 1H, Phe5-Hβ), 2.75 (dd, 2J= 
13.7, 3J= 10.2 Hz, 1H, Phe4-Hβ), 2.69-2.61 (m, 3H, Val3-Hβ, Lys1-Hε), 2.28 (dd, 2J= 13.8, 3J= 
4.2 Hz, 1H, Phe4-Hβ), 1.83 (s, 3H, Ac-CH3), 1.57-1.52 (m, 2H, Leu2-Hβ, Leu2-Hγ), 1.45–1.32 
(m, 4H, Lys1-Hβ, Lys1-Hδ), 1.25-1.06 (m, 2H, Lys1-Hγ), 0.90 (m, 1H, Leu2-Hβ), 0.83 (d, 3J= 
6.9 Hz, 3H, Leu2-Hδ) 0.82 (d, 3J= 6.7 Hz, 3H, Leu2-Hδ), 0.77 (d, 3J= 6.6 Hz, 3H, Val3-Hγ) 0.41 
(d, 3J= 6.6 Hz, 3H, Val3-Hγ). 
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 169.80 (Ac-C), 168.90 (Phe5-C), 166.64 
(Val3-C), 141.29 (Tz1-C), 140.12 (Tz2-C), 137.36 (CAr), 137.08 (CAr), 132.29 (Tz2-CH), 132.17 
(Tz1-CH), 129.35 (2C, CHAr), 129.25 (2C, CHAr), 128.72 (2C, CHAr), 128.44 (CHAr), 127.13 
(CHAr), 126.62 (CHAr), 68.24 (Val3-Cα), 63.18 (Phe5-Cα), 52.52 (Lys1-Cα), 44.71 (Phe4-Cα), 
44.09 (Leu2-Cβ), 41.54 (Leu2-Cα), 39.69 (Phe4-Cβ), 39.12 (Lys1-Cε), 37.88 (Phe5-Cβ), 31.57 
(Lys1-Cβ), 29.43 (Val3-Cβ), 27.02 (Lys1-Cδ), 24.80 (Leu2-Cγ), 23.62 (Leu2-Cδ), 22.89 (CH3-
CO), 22.75 (Lys1-Cγ), 21.73 (Leu2-Cδ), 19.73 (Val3-Cγ), 18.99 (Val3-Cγ). 
 
H-D-chGly-[4Tz]-D-Tyr-D-chGly-[4Tz]-D-chGly-D-(NMe)Leu-NH2 (42j). 
Fmoc-D-Leu-OH (27 mg; 75 µmol; 1.5 eq) was 
loaded onto the rink amide resin (100 mg resin; 
~0.5 mmol.g-1) according to GP9. The loading 
was determined as 0.65 mmol.g-1 (65 µmol). The 
N-methylation was performed as described by 
Chatterjee et al.145 The remaining coupling steps 
were completed on solid phase, employing 
Fmoc-D-chGly-[4Tz]-D-Tyr(tBu)-OH (18h) (1.5 eq; 98 µmol; 61 mg) and Fmoc-D-chGly-
[4Tz]-D-chGly-OH (1.5 eq; 98 µmol; 53 mg) (18i). The crude peptide was precipitated from 
Et2O and purified by preparative HPLC. Yield: 8 mg (9 µmol); 14%.  
Analytical-HPLC: tR= 2.80 min (method 2, 254 nm).   
HR-MS (ESI): m/z= 773.5172 [M+H]+ (calc. 773.51847). 
1H-NMR (600 MHz, DMSO): δ [ppm]= 8.96 (d, 3J= 9.1 Hz, 1H, chGly3-NH), 8.32 (d, 
3J= 5.7 Hz, 3H, chGly1-NH3), 8.26 (s, 1H, Tz1-H), 7.91 (s, 1H, Tz2-H), 7.32 (s, 1H, Leu5-NH), 
7.06 (s, 1H, Leu5-NH), 6.89 (d, 3J= 8.3 Hz, 2H, Tyr2-Hδ), 6.54 (d, 3J= 8.4 Hz, 2H, Tyr2-Hε), 
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5.73 (dd, 3J= 10.3, 5.3 Hz, 1H, Tyr2-Hα), 5.55 (d, 3J= 10.1 Hz, 1H, chGly4-Hα), 4.98 (dd, 
3J= 11.3, 4.9 Hz, 1H, Leu5-Hα), 4.84 (dd, 3J= 9.0, 7.2 Hz, 1H, chGly3-Hα), 4.22 (m, 1H, chGly-
Hα), 3.16 (dd, 2J= 14.5, 3J= 5.2 Hz, 1H, Tyr2-Hβ), 3.11 (dd, 2J= 14.6, 3J= 10.4 Hz, 1H, Tyr2-
Hβ), 2.98 (s, 3H, N-CH3), 2.26 (m, 1H, chGly4-Hβ), 1.83-1.68 (m, 6H, CH2, chGly1-Hβ, 
chGly3-Hβ), 1.67-1.53 (m, 10H, CH2, Leu5-Hβ, Leu5-Hγ), 1.46 (ddd, 2J= 14.4, 3J=9.9, 4.9 Hz, 
1H, Leu5-Hβ), 1.38-0.74 (m, 18H, CH2), 0.72 (d, 3J= 6.6 Hz, 3H, Leu5-Hδ), 0.62 (d, 3J= 6.5 Hz, 
3H, Leu5-Hδ).  
13C{1H}-NMR (151 MHz, DMSO-d6): δ [ppm]= 172.66 (Leu5-C), 168.51 (chGly4-C), 167.47 
(Tyr2-C), 156.61 (Tyr2-Cζ), 147.00 (Tz2-C), 142.71 (Tz1-C), 130.22 (2C, Tyr2-Cδ), 126.15 
(Tyr2-Cγ), 123.51 (Tz1-CH), 121.42 (Tz2-CH), 115.42 (2C, Tyr2-Cε), 64.46 (Tyr2-Cα), 63.83 
(chGly4-Cα), 54.53 (Leu5-Cα), 51.98 (chGly1-Cα), 50.60 (chGly3-Cα), 42.05 (chGly3-Cβ), 
40.92 (chGly1-Cβ), 40.40 (chGly4-Cβ), 37.43 (Leu5-Cβ), 37.41 (Tyr1-Cβ), 31.54 (N-CH3), 29.57 
(CH2), 29.29 (CH2), 29.05 (CH2), 28.66 (CH2), 28.27 (CH2), 27.83 (2C, CH2), 26.26 (CH2), 26.17 
(CH2), 25.93 (2C, CH2), 25.69 (2C, CH2), 25.57 (CH2), 25.53 (CH2), 24.96 (Leu5-Cγ), 23.52 
(Leu5-Cδ), 21.34 (Leu5-Cδ). 
 
Cyclo-[Arg-Gly[5Tz]Asp-D-Phe[5Tz]Val] (48a). 
Fmoc-Arg(Pmc)-OH (79 mg; 0.12 mmol) is loaded onto 
2-CTC resin (100 mg; 0.15 mmol; 1.3 eq; 1.52 mmol/g 
loading) according to GP9. The loading was determined 
as 0.58 mmol/g (0.058 mmol; 48%). The peptide was then 
assembled by standard SPPS and used without further 
purification after cleavage (20% HFIP in DCM).  
Yield: 52 mg (0.054 mmol), 93% crude.  
Analytical RP-HPLC: tR= 5.14 min (method 1, 220 nm). 
25 mg (26 µmol) of the linear sequence are dissolved in 26 mL DMF/DCM 1:1, after the 
addition of sym-collidine (34 µL; 0.26 mmol; 10 eq) and PyBOP (20 mg; 39 µmol; 1.5 eq) the 
reaction mixture is left to stir overnight. The solvent is removed under vacuum and the 
crude peptide dissolved in TFA/TIS/H2O (90/5/5) and stirred 2 h at rt. The crude product is 
concentrated under vacuum and purified by preparative HPLC.  
Yield: 8.0 mg (12 µmol) TFA-salt, 46% over two steps. Analytical RP-HPLC: tR= 3.60 
(method 1, 220 nm). HR-MS (ESI): m/z= 623.3133 [M+H]+ (calc. 623.31609). 
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Cyclo-[Arg-Gly-Asp-D-Phe[5Tz]Val] (48b). 
Fmoc-Arg(Pmc)-OH (79 mg; 0.12 mmol) is loaded onto 
2-CTC resin (100 mg; 0.15 mmol; 1.3 eq; 1.52 mmol/g 
loading) according to GP9. The loading was 
determined as 0.68 mmol/g (0.068 mmol; 57%). The 
peptide was then assembled by standard SPPS and used 
without further purification after cleavage (20% HFIP 
in DCM). Yield: 57 mg (0.061 mmol), 89% crude. 
Analytical RP-HPLC: tR= 5.16 min (method 1, 220 nm).  
33 mg (31 µmol) of the linear sequence are dissolved in 31 mL DMF/DCM 1:1, after the 
addition of sym-collidine (41 µL; 0.31 mmol; 10 eq) and PyBOP (24 mg; 47 µmol; 1.5 eq) the 
reaction mixture is left to stir overnight. The solvent is removed under vacuum and the 
crude peptide dissolved in TFA/thioanisole/EDT/anisole (90:5:3:2) (2mL) and stirred 2 h at 
rt. The crude product is precipitated from cold Et2O (20 mL) and purified by preparative 
HPLC. Yield: 8.0 mg (11 µmol) TFA-salt, 35% over two steps.  Analytical RP-HPLC: tR= 
3.42 min (method 1, 220 nm). HR-MS (ESI): m/z= 599.3054 [M+H]+ (calc. 599.30485). 
 
Cyclo-[Arg-Gly-Asp-D-Phe[5Tz]Lys(N3)] (48c). 
Fmoc-Arg(Pmc)-OH (79 mg; 0.12 mmol) is loaded onto 
2-CTC resin (100 mg; 0.15 mmol; 1.3 eq; 1.52 mmol/g 
loading) according to GP9. The loading was 
determined as 0.84 mmol/g (0.085 mmol; 70%). The 
peptide was then assembled by standard SPPS and used 
without further purification after cleavage 
(DCM/MeOH/AcOH 8:1:1). Yield: 89 mg (0.054 mmol), 
AcOH salt, quantitative. Analytical RP-HPLC: tR= 5.33 min (method 1, 220 nm).  
40 mg (38 µmol) of the linear sequence are dissolved in 38 mL DMF/DCM 1:1, after the 
addition of sym-collidine (56 µL; 0.42 mmol; 10 eq) and PyBOP (30 mg; 57 µmol; 1.5 eq) the 
reaction mixture is left to stir overnight. The solvent is removed under vacuum and the 
crude peptide dissolved in TFA/thioanisole/EDT/anisole (90:5:3:2) (2mL) and stirred 2 h at 
rt. The crude product is precipitated from cold Et2O (20 mL) and purified by preparative 
HPLC. Yield: 3.9 mg (5.1 µmol) TFA-salt, 13% over two steps.  
Analytical RP-HPLC: tR= 3.98 (method 1, 220 nm).  
HR-MS (ESI): m/z= 654.3223 [M+H]+ (calc. 654.32190). 
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Fmoc-D-Phe[5Tz]Lys(N3)-OH (53). 
Fmoc-D-Phe[5Tz]Lys-OH (52): Prepared according to GP6 
starting from 9t (0.40 g; 0.52 mmol).  
Yield: 0.21 g (0.40 mmol); 77%. 
Fmoc-D-Phe[5Tz]Lys(N3)-OH (53): Tf2O (0.12 µL; 
0.74 mmol; 2.0 eq) and sodium azide (58 mg; 0.89 mmol; 2.4 eq) 
are suspended in ACN (1 mL) and stirred for 1 h at rt. Fmoc-D-
Phe[5Tz]Lys-OH (197 mg; 0.37 mmol) is dissolved in ACN/MeOH 1:1 (1 mL) and added to 
the reaction mixture above followed by TEA (154 µL; 1.11 mmol; 3.0 eq) and CuSO4x5H2O 
(1 mg; 4 µmol; 1mol%), the reaction mixture is then left to stir over night. The solvent is 
removed under vacuum and the product purified by column chromatography (PE/EtOAc 
2:1 including 1% TFA). Yield: 122 mg (0.22 mmol); 59%. Rf (PE/EtOAc 1:1 including 1% 
TFA)= 0.14. MS (ESI): m/z= 566.3 [M+H]+, 588.2 [M+Na]+.  
1H-NMR (500 MHz; DMSO-d6): δ [ppm]= 13.46 (s, 1H, CO2H), 8.07 (d, 3J= 8.8 Hz, 1H, NH), 
7.90-7.85 (m, 2H, HAr), 7.78 (s, 1H, Tz-H), 7.58-7.54 (m, 2H, HAr), 7.44-7.38 (m, 2H, HAr), 
7.33-7.24 (m, 6H, Ph-H, HAr), 7.20 (m, 1H, Ph-H), 5.34 (dd, 3J= 9.8, 4.9 Hz, 1H, Lys-Hα), 4.94 
(ddd, 3J= 9.4, 8.8, 5.2 Hz, 1H, Phe-Hα), 4.24-4.08 (m, 3H, CH-CH2-O, CH-CH2O), 3.18-3.05 
(m, 4H, Phe-Hβ, Lys-Hε), 2.38-2.19 (m, 2H, Lys-Hβ), 1.52-1.36 (m, 2H, Lys-Hδ), 2.24 (m, 1H, 
Lys-Hγ), 1.07 (m, 1H, Lys-Hγ).  
13C{1H}-NMR (151 MHz, DMSO) δ[ppm]= 170.38 (Lys-C), 156.10 (OCON), 144.08 (CAr), 
143.99 (CAr), 141.12 (CAr), 141.10 (CAr), 140.71 (Tz-C), 137.86 (CAr), 131.80 (Tz-CH), 129.65 
(2C; CHAr), 128.63 (2C; CHAr), 128.09 (2C; CHAr), 127.47 (CHAr), 127.45 (CHAr), 126.97 
(CHAr), 125.53 (CHAr), 125.47 (CHAr), 120.56 (2C; CHAr), 66.15 (CHCH2O), 59.98 (Lys-Cα), 
50.75 (Lys-Cε), 46.99 (CHCH2O), 46.51 (Phe-Cα), 39.56 (Phe-Cβ), 30.23 (Lys-Cβ), 28.09 (Lys-
Cδ), 23.03 (Lys-Cγ). 
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7.3. X-ray crystal structure analysis 
 
Boc-Val[5Tz]Ala-OBzl (9c) 
 
  
Table 8. Crystal data and structure refinement for Boc-Val[5Tz]Ala-OBzl. 
Empirical formula C21H30N4O4 (MW = 402.49 g*mol-1) 
Crystal system, Space group orthorhombic, P212121 
Uni cell dimensions a = 9.48169(7) Å; b = 10.83269(11) Å; c = 21.24183(16) Å 
 α = 90°; β = 90 °; γ = 90° 
Volume/Å3 2181.79(3) 
Z 4 
ρcalcmg/mm3 1.225 
μ/mm-1 0.700 
F(000) 864.0 
2Θ range for data collection 8.324 to 144.202° 
Reflections collected 34117 
Independent reflections 4299[R(int) = 0.0281] 
Data/restraints/parameters 4299/0/273 
Final R indexes [I>=2σ (I)] R1 = 0.0226, wR2 = 0.0569 
Final R indexes [all data] R1 = 0.0236, wR2 = 0.0577 
Largest diff. peak/hole / e Å-3 0.20/-0.15 
Flack parameter -0.01(4) 
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Table 9. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atom x y z U(eq) 
O1 3002.7(11) 5102.1(10) 1606.7(5) 23.5(2) 
O2 4773.2(10) 3710.9(9) 1407.6(4) 20.8(2) 
O3 239.7(11) 3658.2(9) 1845.2(5) 24.5(2) 
O4 -44.5(10) 5638.7(9) 2155.1(4) 22.0(2) 
N1 3567.2(12) 4465.9(11) 616.1(5) 19.0(2) 
N2 -70.3(12) 4316.3(10) 608.1(5) 17.8(2) 
N3 -947.8(12) 3361.0(11) 493.8(6) 21.7(3) 
N4 -311.3(13) 2645.2(12) 85.7(6) 22.4(3) 
C1 1638.7(17) 6051.1(16) -726.8(7) 30.0(4) 
C2 4068.9(16) 6413.1(15) -296.6(8) 27.5(3) 
C3 2860.6(15) 5494.5(13) -357.2(6) 20.3(3) 
C4 2389.9(14) 5066.4(13) 302.6(6) 16.7(3) 
C5 1148.2(14) 4202.6(13) 275.9(6) 17.4(3) 
C6 966.1(15) 3131.5(13) -58.3(6) 20.4(3) 
C7 3704.1(14) 4476.1(12) 1248.1(6) 18.2(3) 
C8 5027.6(15) 3354.0(12) 2067.4(6) 20.1(3) 
C9 6265.3(16) 2464.0(14) 2003.9(7) 23.9(3) 
C10 5437.0(18) 4473.6(15) 2455.3(7) 29.9(3) 
C11 3734.9(17) 2697.1(15) 2324.3(8) 28.7(3) 
C12 -449.8(14) 5220.1(13) 1089.9(6) 19.6(3) 
C13 -2017.6(15) 5542.8(14) 1062.4(7) 25.3(3) 
C14 -31.1(14) 4719.4(13) 1736.3(6) 19.5(3) 
C15 498.2(15) 5353.7(14) 2784.0(7) 23.5(3) 
C16 -628.4(14) 4893.9(13) 3223.9(6) 19.8(3) 
C17 -1232.6(16) 5701.7(15) 3653.9(7) 25.5(3) 
C18 -2256.4(18) 5288.6(16) 4072.1(7) 31.9(4) 
C19 -2682.7(16) 4067.0(17) 4057.5(8) 32.4(4) 
C20 -2088.5(17) 3254.7(15) 3630.2(7) 28.5(3) 
C21 -1058.0(15) 3661.2(14) 3215.3(7) 23.2(3) 
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Boc-D-Leu[5Tz]Val-OBzl (9d) 
 
Table 10. Crystal data and structure refinement for Boc-D-Leu[5Tz]Val-OBzl. 
Empirical formula C24H36N4O4 (MW = 444.57 g*mol-1) 
Crystal system, Space group monoclinic, P21 
Unit cell dimensions a = 9.81156(5) Å; b = 11.41705(6) Å; c = 23.04824(13) Å 
 α = 90 °; β = 90.6203(5) °; γ = 90 ° 
Volume/Å3 2581.69(2) 
Z 4 
ρcalcmg/mm3 1.144 
μ/mm-1 0.634 
F(000) 960.0 
2Θ range for data collection 7.672 to 144.25° 
Reflections collected 71693 
Independent reflections 10148[R(int) = 0.0272] 
Data/restraints/parameters 10148/3/610 
Final R indexes [I>=2σ (I)] R1 = 0.0268, wR2 = 0.0686 
Final R indexes [all data] R1 = 0.0272, wR2 = 0.0690 
Largest diff. peak/hole / e Å-3 0.24/-0.19 
Flack parameter 0.00(3) 
 
 
  
7. Experimental section 
 
 
- 158 - 
 
 
 
Table 11. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Atom x y z U(eq) 
O1 4348.0(12) 941.8(10) 3030.5(5) 28.2(3) 
O2 6358.3(14) -12.9(12) 3032.6(6) 39.0(3) 
O3 5984.0(12) 5602.1(11) 3693.5(5) 28.5(2) 
O4 4789.9(13) 4347.6(11) 3112.0(5) 30.0(3) 
N1 5276.0(14) 1561.6(12) 4131.7(6) 23.5(3) 
N2 5536.4(15) 583.5(13) 4440.3(6) 28.5(3) 
N3 4683.1(16) 575.0(14) 4873.8(6) 32.5(3) 
N4 4771.3(14) 4201.5(12) 4095.5(6) 22.6(3) 
C1 2522.9(18) -434.2(15) 3129.7(8) 29.4(4) 
C2 1173(2) -268.3(16) 2975.3(9) 37.8(4) 
C3 135(2) -635.7(19) 3337.6(11) 47.4(5) 
C4 454(2) -1164(2) 3855.8(11) 53.2(6) 
C5 1807(3) -1333(2) 4019.1(10) 55.4(6) 
C6 2842(2) -972(2) 3654.2(9) 41.3(4) 
C7 3640(2) -24.7(16) 2740.5(7) 32.0(4) 
C8 5648.6(17) 779.8(14) 3185.2(7) 24.8(3) 
C9 6073.9(16) 1758.3(14) 3603.5(7) 23.1(3) 
C10 7608.1(18) 1790.4(15) 3728.5(8) 28.7(3) 
C11 8363.1(19) 2127.2(18) 3175.9(8) 35.2(4) 
C12 7947(2) 2646.6(18) 4217.4(9) 36.9(4) 
C13 3885.2(19) 1544.8(16) 4841.0(7) 31.0(4) 
C14 4246.3(17) 2190.8(14) 4364.7(7) 24.2(3) 
C15 3700.0(16) 3322.1(14) 4118.0(7) 23.2(3) 
C16 2490.5(17) 3762.3(15) 4476.6(7) 27.2(3) 
C17 1888.7(18) 4936.4(16) 4278.9(8) 30.3(4) 
C18 1362(2) 4902(2) 3655.2(8) 40.2(4) 
C19 751(2) 5307.7(18) 4689.7(9) 38.5(4) 
C20 5144.4(16) 4699.1(14) 3589.7(7) 22.6(3) 
C21 6566.1(19) 6265.4(16) 3203.4(8) 33.5(4) 
C22 7502(2) 5487(2) 2855.8(9) 42.8(5) 
C23 7375(3) 7207(2) 3516.1(12) 56.6(6) 
C24 5440(2) 6802.0(19) 2834.4(10) 43.2(5) 
7. Experimental section 
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Boc-Leu[5Tz]Val-OBzl (9e) 
 
Table 12. Crystal data and structure refinement for Boc-Leu[5Tz]Val-OBzl. 
Empirical formula C24H36N4O4 (MW = 444.57 g*mol-1) 
Crystal system, Space group orthorhombic, P212121 
Uni cell dimensions a = 10.7988(2) Å; b = 11.15120(19) Å; c = 20.5911(3) Å 
 α = 90°; β = 90°; γ = 90° 
Volume/Å3 2479.58(8) 
Z 4 
ρcalcmg/mm3 1.191 
μ/mm-1 0.660 
F(000) 960.0 
2Θ range for data collection 8.588 to 133.93° 
Reflections collected 24888 
Independent reflections 4303[R(int) = 0.0585] 
Data/restraints/parameters 4303/0/300 
Final R indexes [I>=2σ (I)] R1 = 0.0369, wR2 = 0.0939 
Final R indexes [all data] R1 = 0.0440, wR2 = 0.1018 
Largest diff. peak/hole / e Å-3 0.16/-0.21 
Flack parameter 0.03(13) 
 
7. Experimental section 
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Table 13. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atom x y z U(eq) 
O1 5343.8(19) 6195.2(16) 5468.2(9) 31.0(5) 
O2 6662.7(17) 4621.5(18) 5627.8(9) 29.9(5) 
O3 2640(2) 4463.7(18) 7197.1(9) 35.2(5) 
O4 3805.0(19) 3439.5(16) 6481.7(9) 29.5(5) 
N1 4990(2) 4352(2) 5025.7(10) 23.2(5) 
N2 2310(2) 4383.9(19) 5562.5(10) 24.3(5) 
N3 1284(2) 3744(2) 5700.4(11) 28.4(5) 
N4 1034(2) 3094(2) 5185.0(11) 28.5(5) 
C1 5380(4) 3905(4) 2987.4(15) 49.1(9) 
C2 4713(3) 5967(3) 3322.8(16) 42.6(8) 
C3 5067(3) 4726(3) 3559.3(13) 32.8(7) 
C4 4030(3) 4164(2) 3958.3(13) 27.2(6) 
C5 3895(3) 4656(2) 4652.6(12) 23.5(6) 
C6 2741(3) 4142(2) 4955.9(12) 23.3(6) 
C7 1902(3) 3323(2) 4725.8(13) 27.7(6) 
C8 5631(3) 5153(2) 5381.5(13) 24.9(6) 
C9 7312(3) 5157(3) 6188.7(13) 30.2(6) 
C10 7950(3) 6319(3) 6006.0(17) 47.3(9) 
C11 6406(3) 5333(3) 6746.1(14) 36.8(7) 
C12 8255(3) 4203(3) 6358.8(16) 43.3(8) 
C13 2818(3) 5152(2) 6078.7(12) 25.2(6) 
C14 2006(3) 6245(3) 6222.8(13) 30.0(7) 
C15 1766(3) 6925(3) 5592.6(15) 40.8(8) 
C16 2678(3) 7052(3) 6710.4(14) 35.1(7) 
C17 3048(3) 4331(2) 6660.6(12) 26.6(6) 
C18 4009(3) 2485(2) 6950.0(14) 33.7(7) 
C19 4304(3) 1362(2) 6580.9(13) 29.4(6) 
C20 5284(3) 634(3) 6766.8(13) 31.8(7) 
C21 5508(3) -430(3) 6444.1(14) 35.2(7) 
C22 4770(3) -776(3) 5925.1(14) 38.0(7) 
C23 3802(3) -46(3) 5735.9(15) 41.3(8) 
C24 3568(3) 1016(3) 6058.9(14) 33.8(7) 
7. Experimental section 
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Boc-D-Val[5Tz]Ala-OBzl (9f) 
 
Table 14. Crystal data and structure refinement for Boc-D-Val[5Tz]Ala-OBzl. 
Empirical formula C21H30N4O4 (MW = 402.49 g*mol-1) 
Crystal system, Space group monoclinic, P21 
Unit cell dimensions a = 10.1473(3) Å; b= 21.6416(5) Å; c = 10.3140(3) Å 
 α = 90°; β = 91.319(3)°; γ = 90° 
Volume/Å3 2264.39(11) 
Z 4 
ρcalcmg/mm3 1.181 
μ/mm-1 0.674 
F(000) 864.0 
2Θ range for data collection 8.576 to 143.984° 
Reflections collected 33116 
Independent reflections 8856[R(int) = 0.0474] 
Data/restraints/parameters 8856/1/535 
Final R indexes [I>=2σ (I)] R1 = 0.0396, wR2 = 0.0995 
Final R indexes [all data] R1 = 0.0416, wR2 = 0.1017 
Largest diff. peak/hole / e Å-3 0.33/-0.25 
Flack parameter -0.01(9) 
 
  
7. Experimental section 
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Table 15. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Atom x y z U(eq) 
O1 993.8(18) 6293.4(8) 4093.8(17) 25.5(4) 
O2 2175.8(19) 6268.6(9) 6008.2(18) 29.4(4) 
O3 2512.7(19) 5545.4(9) 11592.8(17) 27.4(4) 
O4 1536.0(18) 4753.3(8) 10525.2(16) 24.7(4) 
N1 974(2) 5443.7(10) 5286(2) 23.6(4) 
N2 -1177(2) 5864.7(10) 8719(2) 26.3(4) 
N3 -78(2) 5896.6(10) 9403(2) 23.9(4) 
N4 867(2) 5628.4(9) 8697.4(19) 20.4(4) 
C1 1452(3) 6907.0(12) 3699(3) 25.7(5) 
C2 2925(3) 6891.3(13) 3482(3) 30.1(6) 
C3 1067(4) 7390.4(15) 4697(3) 39.2(7) 
C4 699(3) 7011.7(13) 2434(3) 31.6(6) 
C5 1443(2) 6026.3(12) 5200(2) 22.7(5) 
C6 1130(2) 5102.6(11) 6498(2) 21.0(5) 
C7 640(2) 4434.3(12) 6300(2) 23.9(5) 
C8 1466(3) 4100.9(13) 5303(3) 30.2(6) 
C9 690(3) 4076.9(12) 7577(2) 26.7(5) 
C10 373(2) 5424.2(11) 7544(2) 21.0(5) 
C11 -935(3) 5576.6(13) 7578(2) 25.4(5) 
C12 2204(2) 5595.7(11) 9257(2) 20.8(5) 
C13 2865(3) 6224.3(12) 9293(2) 25.5(5) 
C14 2118(2) 5306.1(11) 10607(2) 21.8(5) 
C15 1368(3) 4445.2(12) 11760(2) 27.7(5) 
C16 694(3) 3836.7(12) 11513(2) 26.3(5) 
C17 1241(3) 3401.9(13) 10692(3) 31.7(6) 
C18 642(4) 2831.1(14) 10506(3) 40.0(7) 
C19 -500(4) 2688.4(15) 11158(3) 42.6(7) 
C20 -1051(3) 3119.4(16) 11971(3) 39.7(7) 
C21 -462(3) 3694.3(14) 12149(3) 32.4(6) 
7. Experimental section 
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Boc-Ala[5Tz]Ala-OBzl (9g) 
 
Table 16. Crystal data and structure refinement for Boc-Ala[5Tz]Ala-OBzl. 
Empirical formula  C19H26N4O4 (MW = 374.44 g*mol-1) 
Crystal system, Space group  orthorhombic, P212121 
Unit cell dimensions  a = 5.69773(6) Å; b = 9.79814(10) Å; c = 35.5160(4) Å  
  α = 90°; β = 90°; γ = 90° 
Volume/Å3  1982.76(4) 
Z  4 
ρcalcmg/mm3  1.254 
μ/mm-1  0.733 
F(000)  800.0 
2Θ range for data collection  4.976 to 143.986° 
Reflections collected  33947 
Independent reflections  3868[R(int) = 0.0394] 
Data/restraints/parameters  3868/0/349 
Final R indexes [I>=2σ (I)]  R1 = 0.0243, wR2 = 0.0596 
Final R indexes [all data]  R1 = 0.0252, wR2 = 0.0603 
Largest diff. peak/hole / e Å-
3 
 
0.15/-0.13 
Flack parameter  -0.03(6) 
 
 
 
7. Experimental section 
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Table 17. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Atom x y z U(eq) 
O1 4410(2) 7097.6(11) 6443.0(3) 20.4(2) 
O2 6549(2) 5295.4(11) 6217.6(3) 20.0(2) 
O3 2286(2) 3043.0(13) 6552.2(3) 26.8(3) 
O4 4036(2) 1942.1(11) 6073.6(3) 20.0(2) 
N1 7015(2) 6137.0(13) 6812.8(3) 16.4(3) 
N2 5011(3) 2808.5(13) 7568.4(3) 20.1(3) 
N3 4887(2) 2149.2(13) 7248.1(3) 19.5(3) 
N4 6174(2) 2857.9(13) 6996.4(3) 16.6(3) 
C1 3220(3) 7418.2(15) 6087.7(4) 17.9(3) 
C2 1385(3) 8442.9(17) 6215.6(5) 23.0(3) 
C3 4970(3) 8067.2(16) 5818.4(4) 21.2(3) 
C4 2046(3) 6168.5(18) 5915.5(5) 23.8(3) 
C5 6035(3) 6096.8(15) 6467.9(4) 16.5(3) 
C6 8550(3) 5049.4(15) 6949.4(4) 16.0(3) 
C7 10447(3) 5652.7(18) 7203.3(5) 23.1(3) 
C8 7134(3) 3988.7(14) 7155.4(4) 15.5(3) 
C9 6377(3) 3931.7(15) 7521.1(4) 18.3(3) 
C10 6350(3) 2340.6(16) 6613.0(4) 17.4(3) 
C11 7253(3) 866.9(17) 6613.3(5) 22.9(3) 
C12 3979(3) 2498.9(15) 6419.6(4) 18.5(3) 
C13 1859(3) 2096.3(18) 5863.4(4) 22.7(3) 
C14 2084(3) 1348.7(15) 5495.5(4) 18.6(3) 
C15 4049(3) 1506.2(16) 5268.1(4) 21.2(3) 
C16 4178(3) 834.6(18) 4924.3(5) 23.8(3) 
C17 2330(3) 23.1(18) 4802.2(5) 26.5(4) 
C18 372(3) -138.1(18) 5028.3(5) 25.8(3) 
C19 251(3) 522.5(17) 5373.9(4) 21.8(3) 
7. Experimental section 
 
 
- 165 - 
 
 
Boc-chGly[5Tz]Phe-OBzl (9h) 
 
  
Table 18. Crystal data and structure refinement for Boc-chGly[5Tz]Phe-OBzl. 
Empirical formula C30H38N4O4 (MW = 518.66 g*mol-1) 
Crystal system, Space group orthorhombic, P212121 
Unit cell dimensions a = 10.32629(19) Å; b = 12.5469(2) Å; c = 25.1185(4) Å 
 α = 90°; β = 90°; γ = 90° 
Volume/Å3 3254.41(9) 
Z 4 
ρcalcmg/mm3 1.181 
μ/mm-1 0.640 
F(000) 1248.0 
2Θ range for data collection 7.876 to 144° 
Reflections collected 58573 
Independent reflections 6400[R(int) = 0.0487] 
Data/restraints/parameters 6400/0/392 
Final R indexes [I>=2σ (I)] R1 = 0.0303, wR2 = 0.0753 
Final R indexes [all data] R1 = 0.0324, wR2 = 0.0770 
Largest diff. peak/hole / e Å-3 0.20/-0.17 
Flack parameter -0.10(6) 
 
  
7. Experimental section 
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Table 19. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Atom x y z U(eq) 
O1 1678.5(12) 4074.4(9) 761.8(5) 23.9(3) 
O2 2759.6(13) 3767.4(10) 1538.1(5) 24.5(3) 
O3 6750.7(14) 5787.7(10) 1299.4(5) 28.8(3) 
O4 5150.7(13) 5191.6(9) 766.9(5) 26.7(3) 
N1 3141.5(14) 2795.8(11) 787.8(6) 21.8(3) 
N2 7250.6(16) 2595.3(12) 341.9(6) 26.7(3) 
N3 7259.7(16) 3339.8(12) 709.6(6) 24.6(3) 
N4 6162.7(15) 3222.2(11) 995.0(6) 20.5(3) 
C1 920.1(18) 4983.7(14) 970.4(7) 24.0(4) 
C2 154(2) 4655.8(16) 1459.7(8) 32.3(4) 
C3 0(2) 5217.5(16) 512.8(8) 32.5(4) 
C4 1811(2) 5919.1(15) 1074.6(8) 30.8(4) 
C5 2546.0(17) 3566.1(12) 1068.8(7) 20.9(3) 
C6 4116.7(17) 2103.0(13) 1023.6(6) 20.6(3) 
C7 3841.0(17) 911.7(13) 918.4(6) 21.6(3) 
C8 4762.2(19) 229.6(13) 1253.1(7) 25.7(4) 
C9 4543(2) -963.7(14) 1165.9(8) 30.6(4) 
C10 3142(2) -1263.4(15) 1274.3(9) 35.6(5) 
C11 2219(2) -589.3(15) 939.1(9) 33.3(4) 
C12 2439.6(19) 603.5(14) 1033.1(8) 26.8(4) 
C13 5434.3(17) 2401.8(13) 811.3(7) 20.7(3) 
C14 6149.4(19) 2015.7(14) 394.6(7) 25.5(4) 
C15 5891.7(17) 4001.8(13) 1414.7(6) 20.8(3) 
C16 6774.5(18) 3860.1(14) 1896.3(7) 23.2(3) 
C17 6590.1(18) 2775.8(14) 2146.8(7) 23.9(3) 
C18 7456.3(19) 1954.8(15) 2050.2(7) 28.9(4) 
C19 7262(2) 952.0(16) 2277.8(8) 34.7(4) 
C20 6204(2) 773.2(17) 2598.1(8) 38.3(5) 
C21 5323(2) 1579.1(18) 2692.3(8) 36.9(5) 
C22 5514(2) 2580.1(16) 2466.5(7) 28.6(4) 
C23 6009.7(18) 5104.7(13) 1160.7(7) 22.2(3) 
C24 5210(2) 6164.9(14) 459.4(7) 29.7(4) 
C25 4384.1(19) 6031.8(14) -28.6(7) 26.8(4) 
C26 4226(2) 5050.3(15) -275.8(8) 29.5(4) 
C27 3538(2) 4977.7(16) -748.8(8) 33.6(4) 
C28 3012(2) 5882.6(18) -981.5(8) 33.7(4) 
C29 3146(2) 6858.5(17) -730.1(8) 36.9(5) 
C30 3821(2) 6927.8(16) -255.3(8) 34.0(4) 
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Boc-Val[5Tz]Ala-Leu[5Tz]Val-OBzl (10) 
 
 
Table 20. Crystal data and structure refinement for Boc-Val[5Tz]Ala-Leu[5Tz]Val-OBzl. 
 
 
 
 
Empirical formula C33H50N8O5 (MW = 638.81 gm*mol-1) 
Crystal system, Space group orthorhombic, P212121 
Unit cell dimensions a = 9.1090(4) Å; b = 15.0895(10) Å; c = 25.6559(16) Å 
 α = 90°; β = 90°; γ = 90° 
Volume/Å3 3526.4(4) 
Z 4 
ρcalcmg/mm3 1.203 
μ/mm-1 0.670 
F(000) 1380.0 
2Θ range for data collection 6.796 to 143.952° 
Reflections collected 68785 
Independent reflections 6937[R(int) = 0.0323] 
Data/restraints/parameters 6937/0/433 
Final R indexes [I>=2σ (I)] R1 = 0.0242, wR2 = 0.0611 
Final R indexes [all data] R1 = 0.0250, wR2 = 0.0617 
Largest diff. peak/hole / e Å-3 0.13/-0.19 
Flack parameter -0.01(3) 
7. Experimental section 
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Table 21. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
 
  
Atom x y z U(eq) 
O1 4817.4(11) 5646.1(6) 6418.0(4) 18.9(2) 
O2 2481.0(11) 5139.6(6) 6299.6(4) 21.4(2) 
O3 -2378.9(11) 3753.6(7) 6275.7(4) 24.3(2) 
O4 219.9(12) 4364.4(7) 5250.1(4) 23.4(2) 
O5 1310.0(11) 5693.4(7) 5148.4(4) 22.0(2) 
N1 4439.8(13) 4248.7(8) 6169.6(5) 17.2(2) 
N2 2093.9(14) 2835.0(8) 7361.1(5) 22.8(3) 
N3 876.9(13) 2817.9(8) 7089.7(4) 20.0(2) 
N4 1225.3(12) 3049.8(7) 6593.3(4) 14.8(2) 
N5 -427.6(13) 4595.5(7) 6518.3(4) 15.5(2) 
N6 86.4(14) 7533.1(8) 6213.0(5) 21.6(2) 
N7 -196.3(14) 7124.8(8) 5774.0(5) 21.0(2) 
N8 -697.2(13) 6306.3(8) 5895.3(4) 17.1(2) 
C1 4323.8(16) 6552.8(9) 6566.2(6) 19.2(3) 
C2 3397.9(17) 6509.7(10) 7059.1(6) 25.6(3) 
C3 3540.6(16) 6983.9(10) 6108.7(6) 23.2(3) 
C4 5763.4(17) 7023.4(10) 6679.1(6) 25.0(3) 
C5 3812.8(15) 5028.5(9) 6299.5(5) 16.8(3) 
C6 3481.3(14) 3495.3(9) 6060.0(5) 15.6(3) 
C7 4367.2(16) 2726.7(9) 5823.0(5) 19.0(3) 
C8 5113.5(19) 3008.0(11) 5315.8(6) 28.6(3) 
C9 3358.6(17) 1935.1(10) 5727.8(6) 25.6(3) 
C10 2685.0(15) 3221.1(8) 6549.1(5) 15.7(3) 
C11 3215.7(16) 3077.9(10) 7042.4(5) 20.6(3) 
C12 26.5(14) 3095.4(8) 6210.9(5) 16.2(3) 
C13 -758.3(16) 2210.4(9) 6168.2(6) 23.6(3) 
C14 -1051.7(15) 3849.4(9) 6346.1(5) 16.3(3) 
C15 -1261.2(15) 5367.7(9) 6693.8(5) 16.1(3) 
C16 -1125.7(16) 5481.1(9) 7288.0(5) 20.0(3) 
C17 -1667.4(18) 4700.5(11) 7614.3(6) 25.3(3) 
C18 -1381(2) 4887.4(14) 8190.4(6) 39.3(4) 
C19 -3289(2) 4506.4(14) 7529.2(7) 38.8(4) 
C20 -727.1(15) 6188.5(9) 6422.1(5) 16.1(3) 
C21 -226.9(15) 6979.9(9) 6615.9(6) 19.4(3) 
C22 -1111.1(16) 5686.3(9) 5481.3(5) 18.7(3) 
C23 -1864.8(17) 6168.7(10) 5021.4(5) 23.5(3) 
C24 -2211(2) 5511.8(12) 4585.7(6) 34.8(4) 
C25 -3265.4(19) 6625.3(12) 5206.7(6) 30.7(4) 
C26 216.7(16) 5161.9(9) 5289.4(5) 18.8(3) 
C27 2588.9(16) 5265.6(10) 4911.5(6) 24.3(3) 
C28 2378.2(15) 5190.1(10) 4332.2(6) 20.7(3) 
C29 1709.0(18) 4454.8(10) 4108.9(6) 25.2(3) 
C30 1476.0(19) 4420.5(11) 3574.3(6) 29.1(3) 
C31 1918.5(18) 5116.9(11) 3260.1(6) 27.9(3) 
C32 2603(2) 5845.5(10) 3478.6(6) 29.7(3) 
C33 2829.6(18) 5880.9(10) 4013.5(6) 26.9(3) 
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